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ABSTRACT
A major challenge for effective gene therapy is systemic delivery of viruses carrying
therapeutic genes into affected tissue. The immunogenic nature of human adenoviruses (Ads)
limits their use for intratumoral (IT) injection in gene therapy. Ads transfection is further
hampered by the fluctuating presence of Coxsackie and Adenovirus Receptor (CAR) and
integrins on the cells’ surface. To circumvent these limitations we developed a novel approach
wherein Ads are encapsulated inside the shell of lyophilized, lipid-encapsulated, perfluorocarbon
microbubbles (MBs)/ultrasound (US) contrast agents, which act as delivery vehicles for a sitespecific gene transfer system.
We performed infection studies with Ad.GFP (Green Fluorescent Protein), Ad.mda-7
(melanoma differentiation associated gene 7) and CTV.mda-7 on human DU145 and mouse
prostate cancer cells as well as observed enhanced GFP expression when Ad.GFP was delivered
by MBs and US. Our results show that US breaks open the MB/Ads complexes by undergoing
cavitation at the sonoporated site, which allows Ads to transfer their transgene only to the
sonoporated region. Cavitation collapse of the MBs creates small shockwaves that increase cell
permeability by forming temporary micropores on the cell surface bypassing the receptormediated dependence of Ads for transfection. Fetal bovine serum (FBS) containing complement
did not allow the unprotected Ads to infect the cells; however, MBs complexed with Ad.GFP did
infect DU145 and TRAMP-C2 cells in a FBS rich media.
We studied MB assisted gene delivery of reporter (GFP) and therapeutic genes (p53, Rb,
Rb2 (p130) and Mda-7/IL-24) into prostate cancer (PC) xenografted in immune-compromised
athymic mice. The results demonstrated that MBs protect the host from unspecific viral immune
response thus protecting the viral payload and allowing for intravenous (IV) injection rather than

xviii

IT injection. Additionally, Ad gene transfer was enhanced at the targeted/sonoporated mice
tumor xenografts. This research demonstrated mda-7’s efficacy in reducing primary (treated) and
untreated tumors that simulated the presence of metastasis in athymic mice xenograft models
bearing human PC cells. Bystander anti-tumor activity of mda-7, a secreted cytokine was noted
for non-targeted tumors.
Earlier in vitro studies on the combination of radiation and gene therapy (Ad.p53, Ad.Rb,
and Ad.p130) demonstrated an increase in the percentage of cell death for DU145 cells. We also
studied UTMD (ultrasound targeted microbubble destruction) gene therapy in combination with
external beam radiation for radiation resistant PC. The results demonstrated an enhanced
therapeutic benefit of tumor suppressor genes in radiation resistant PC. We also demonstrated an
increase in the expression of tumor suppressor genes at the tumor site due to MBs and US.
These findings highlight the potential therapeutic benefit of this novel image guided gene
transfer technology alone or in combination with external beam radiation for prostate cancer
patients with therapy resistant disease.

xix

CHAPTER I: PROSTATE CANCER AND TREATMENT STRATEGIES
Prostate cancer
Prostate cancer (PC) is the most common malignancy in men and the second leading
cause of cancer related deaths in the United States [1]. According to the American Cancer
Society (ACS), PC represents 25% of newly diagnosed cancers every year [2]. There are more
than 1,100,000 new cases of PC and 300,000 related deaths worldwide each year. In the United
States about 240,000 new cases of PC are reported annually with a mortality rate >15% due to
widespread implementation of prostate-specific antigen (PSA) testing and effective treatment of
early stage PC disease [3-5].
The disease is primarily diagnosed in men above the age of 40, with a median age above
60 years [3]. The risk of incidence increases as one grows older. PC biology is heterogeneous as
it ranges from indolent type where tumors progress slowly or not at all for several years to others
that may progress more rapidly and be fatal after a few years. PC arises from different stresses
such as chronic inflammation, oxidative stress, immune surveillance loss, and somatic
alterations, which lead to genetic changes that transform the normal epithelium into preneoplastic lesions to invasive carcinoma. Therapeutic options vary depending on the severity of
the condition, age of the patient, staging, Gleason score and serum PSA level [6].
Organ confined disease staged T1/T2 with Gleason score ≤7 that lacks aggressive
features [7] is suitable for radical prostatectomy (RP) and radiation therapy (RT) with external
beam irradiation therapy (EBRT) or brachytherapy [8, 9]. This treatment option has shown 5 to
10 year survival rate with significant morbidity, erectile dysfunction in 30-70% of cases and
stress incontinence in up to 10% of the patients [6, 10]. In recent years, minimally invasive
therapies have been developed for patients with localized prostate cancer such as three-
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dimensional conformal radiotherapy (3D-CRT), brachytherapy, intensity-modulated external
beam radiotherapy (IMRT), cryosurgical ablation of the prostate and laparoscopic radical
prostatectomy. These treatment strategies are for patients who are either not eligible for surgery
or who do not want to risk the potential side-effects of surgery [6, 11-14].
Cancer with a Gleason score ≥8 which exhibits aggressive features and found outside the
prostate [7] and spread to other organs such as bladder, rectum and lymph nodes results in poor
survival rate compared to localized PC. Approximately 30-35% is initially diagnosed as
metastatic while 25% of patients develop metastases during follow up. Metastases are commonly
found on the bone with an X-ray showing osteoblastic lesions or a bone scan as hot spots with
areas of increased activity [15]. In such cases, RP followed by RT with hormone therapy (HT)
can prolong survival but with negative quality of life [3]. HT with anti-androgens is the standard
therapy for stage T4 PC that reduces serum levels of testosterone to castration levels, which
eventually becomes non-responsive to androgen ablation. When these therapies fail and the
cancer reoccurs there is a median survival of 2.5 years [15, 16]. Current therapy options for
patients with hormone-refractory prostate cancer (HRPC) include RT and cytotoxic
chemotherapeutic agents, such as mitoxantrone, estramustine and taxanes [15, 17]. These
approaches only have a palliative benefit and show no consistent impact on survival [15]. No
effective therapy exists for patients with metastases thus mandating the development of novel,
more efficacious and innovative treatment approaches [18].
Different approaches have been tested with varying results. For example, gene therapy
has been used to combat and cure a wide range of pathologies including locally advanced cancer
but the major limiting factor has been the development of an effective delivery system.
Metabolism of genetic materials by serum esterases prohibits intravenous administration.
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Additionally, genes are macromolecules and their size greatly hinders passage across the
capillary fenestrations of blood vessels without assistance. We and others have demonstrated
viral vectors to be efficient delivery systems resulting in high levels of transgene expression.
However, the antigenic nature of viruses leads to their rapid inactivation by the immune system.
Additionally, the viruses are non-specific. This requires direct target organ injection with or
without image guidance or operative bed injection. Current gene therapy technology is still in its
infancy but the promise of molecular medicine is so immense that further research is needed.

Treatment Strategies:
Radiation Therapy
Ionizing radiation is primarily used to treat cancers by targeting critical cell components
resulting in DNA damage directly by high radiation or indirectly by the action of free radicals
formed as a result of ionization of water molecules by low radiation [19, 20]. The resulting DNA
damage can result in double stranded breaks (DSB) that are difficult to repair and most toxic to
the cancer cells [19]. Normal cells have intact mechanisms that repair the majority of DNA
damage thus protecting the normal cells from harm. If the mechanism cannot repair the DNA,
radiation induces apoptosis by either stimulating death receptors such as DR4 (death receptor 4)
or CD95 (Fas) at the cell surface or halts cell cycle progression at distinct phases [19, 21]. The
effect is most pronounced during M (mitosis) and G2 (Gap-2) phases of the cell cycle [22, 23].
Failure to undergo apoptosis may contribute to resistance of cancer cells to the therapeutic
modalities.
Low dose rates of radiation can also be toxic as the oxygen reacts with the free radicals
(reactive oxygen species (ROS)) formed during the ionization of water producing more toxic
byproducts that make the cell sensitive to ionization radiation [23]. Solid tumors contain regions
3

with low blood supply resulting in reduced oxygen concentration (hypoxia) thus making these
regions more resistant to ionization radiation [21]. Even though improvements in radiotherapy
regimens are available the efficacy is still disappointing with regards to solid tumors.
Radiation can be delivered internally through radioactive seed implants called
brachytherapy. Implants can be precisely placed into a body cavity, into the tissue, into the lungs
and into blood vessels. The radiation sources deliver high doses of radiation to the specific tumor
while the radiation dose drops off within the adjacent normal tissue [19]. Zelefsky et al. [12]
reported the 8-year relapse free survival rate of 74% and 61% for low and intermediate risk
groups respectively using Phoenix ASTRO (American Society for Therapeutic Radiology and
Oncology) criteria for a multi-institutional study following brachytherapy [6].
The most common form of RT is delivered externally through a beam called EBRT. In
most PC cases, RT is accompanied with RP or androgen deprivation therapy (ADT) [24].
Adjuvant RT has shown to benefit men with adverse pathologic features with Gleason scores ≥ 7
at least in minimizing biochemical recurrence risk [25]. Thompson et al. from the Southwest
Oncology Group (SWOG) showed an overall survival with adjuvant RT with 10 year estimates
of 74% vs. 66% for patients with 60Gy to 64Gy and a metastasis free survival at 71% vs. 61% in
adjuvant RT vs. no RT cohorts [25, 26]. Ten year survival rate following RT for well
differentiated, moderately well differentiated and poorly differentiated PC is about 90%, 75%
and 50% [27]. Along with the benefits seen with RT, complications such as rectal complications,
urethral strictures and total urinary incontinence are common [25].
RT can be delivered in a fractionated dose of 1.8 - 2.0 Gy (Gray, unit of radiation) per
day for 7-8 weeks (5 days per week) or until a total of 60 - 80Gy is delivered [28]. Pollark et al.,
showed that dosage has a direct impact on treatment effectiveness in a Phase III trial where they
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compared 70Gy/2Gy versus 78Gy/2Gy, showing a significant difference (64% vs. 70%
respectively) in the 6-year biochemical relapse free survival rate (bRFS) [29]. Similar results
have been published in Phase III trial by Dearnaley et al., when comparing 64Gy/2Gy with
74Gy/2Gy in a 10-year bRFS [30]. Additionally, treatment strategy that employs less frequent
and larger fractions, termed hypofractionated radiation, may be more efficacious. Moderate (<5
Gy/day) hypofractionated RT has shown similar efficacy with an improved side effect profile
while extreme (≥5 Gy/day) hypofractionated RT is currently being evaluated but showing
promising efficacy [28]. As dose is increased the risk of side effect increases as well.
Advances in imaging have raised the therapeutic ratio (the index between cytotoxic
effects and normal tissue complications) and minimized damage to local tissue resulting in a
decrease in the side effects seen due to RT. Advances in imaging has led to vast improvements in
RT such as 3DCRT or IMRT and four dimensional RT (4D-RT) which splits the beam into
several lower intensity beams sparing damage to surrounding normal tissue. With these advances
more patients are being treated with doses exceeding 72Gy [31].
In this study we treated human DU145 PC tumors with EBRT from a clinical linear
particle accelerator (LINAC) model 21EX and model 6EX that produced 8Gy X-rays for the
cancer treatment. These particle accelerators at the Tri-State Regional Cancer Center in Ashland,
Kentucky offer bremsstrahlung x-ray energy of 6 MV, which was used in these investigations as
well as a rapid dose delivery to the targeted tumor at a rate of 6 Gy/MU [32].
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High Intensity Focused Ultrasound
High Intensity Focused Ultrasound (HIFU) is used as a treatment for localized PC. It is a
non-invasive and non-ionizing technique that induces coagulation, necrosis, cavitation and heat
shock through intense US energy that thermally ablates a portion of the tissue situated at the
focal point. US energy is delivered with a high-powered transducer, which is placed in the
rectum to generate US waves that travel through the walls of the rectum and deposit energy to a
focal zone in the prostate gland. There is no need for a surgical exposure or insertion of
instruments into the lesion [6, 33].
The high powered US causes a rise in temperature up to 70 - 80ᴼC [34]. This elevation
of tissue temperature leads to melting of the lipid membranes and protein denaturation (>43ᴼC)
that results in irreversible tissue damage called coagulative necrosis [34, 35]. Similar tissue
damage caused by a cavitation phenomenon can be achieved with bubble implosion and
mechanical tissue disruption as a result of the interaction between US and MBs of water in the
sonicated tissue enhancing tissue ablation [35].
In the past 15 years there have been 30,000 prostate HIFU treatments, mainly in Europe
[35]. In most clinical trials [6, 35, 36], patients had a localized PC (stage T1/T2) with Gleason
scores ranging from 2 to 10 and received HIFU because the patients were either unsuitable for or
unwilling to undergo RP. Uchida et al. [6] reported that after HIFU the biochemical disease free
5 years rate was at 84%, 64% and 45% in low, intermediate and high-risk PC groups using
Phoenix criteria. Pfeiffer et al. [36] also assessed the negative biopsy rates after HIFU at 84.2%,
63.6% and 67.5% for the low, intermediate and high-risk PC groups. Similarly after HIFU, 5year biochemical free survival rates was reported to be 84.8%, 64.9% and 54.9% for
aforementioned PC risk groups. Lastly, they also mentioned 5-year disease free survival rates as
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81.7%, 53.2% and 51.2% for the respective PC risk groups [36].
HIFU has advantages over current treatment modalities as it is non-invasive and nonionizing allowing for repeated treatments of the affected tissue as well as the ability to affect a
distant tissue [35, 37]. The disadvantages include the inability of US to travel through air
preventing treatment within lung or lumen of most hollow organs within the body and long (13hrs) exposure times depending on the size of the tumors [35]. Most common complications
associated with HIFU are urinary retention, urinary tract infections, urinary incontinence and
erectile dysfunction [35]. Presently, HIFU has some limitations and long-term clinical studies are
needed to evaluate cancer specific and overall survival. Refinement of the HIFU and transducer
technology will improve its therapeutic benefit making it an attractive treatment modality.
Currently, the cavitation phenomenon of microbubbles (MB) is being explored in relation
to different US intensities as a potential drug delivery vehicle. The underlying mechanism is yet
to be fully understood but there is growing evidence that suggest MB cavitation can elicit
biological and mechanical changes that allow for the temporary uptake of drugs. Our lab has
further explored this area of drug delivery with the intent to translate this technology from bench
to bedside.

Gene Therapy
Gene therapy is a therapeutic drug delivery and vaccination method that can be used to
treat a large array of genetic and non-genetic diseases. It uses genetic materials such as DNA and
RNA to rewrite or reverse the pathological conditions that account for the transformation of
normal cells to a malignant or diseased phenotype. There have been significant improvements in
the treatment of a variety of different malignancies including PC.
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Different strategies include the use of non-viral and viral vehicles that are suitable for
integrating the genetic material into the host cell. There are distinct advantages and
disadvantages for each delivery vehicle. Non-viral vehicles are suitable for their simplicity,
packaging capacity, potential for large scale production and inducing fewer immunological
responses. These vehicles have poor transfection and transduction efficiency to elicit a
therapeutic benefit. Viral vehicles on the other hand can be engineered and finely tuned while
retaining the capacity to deliver genetic material at a high transfection and transduction
efficiency. However, our immunological system has evolved to counterattack against these viral
pathogens by forming neutralizing antibodies that hamper its therapeutic potential.
Gene transfer can be done in vivo or ex-vivo. In vivo gene transfer is performed in the
host via an intratumoral (IT) injection. It is cost effective and tailored to a class of patients rather
than an individual. But the gene transfer efficiency is poor due to the mode of delivery and the
stimulation of the hosts’ immune system. Ex-vivo gene transfer is performed on surgically
harvested cells that are genetically engineered and re-introduced back into the host [15]. Exvivo gene transfer is typically done on clonal expansive cells such as dendritic cells,
macrophages, monocytes, etc. for vaccination based gene therapy.
There have been several gene therapy clinical trials, which have shown potential towards
treating prostate cancer. These therapies include vaccine therapy that uses various cytokines such
as interleukin 2 (IL2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), suicide
cytotoxic therapy such as HSV-thymidine kinase or certain toxins, transfection of suppressor
genes such as p53 or retinoblastoma (Rb), oncolytic viruses such as CV787 or CN-706 that have
been designed specifically to replicate preferentially in prostate cancer cells and anti-sense
therapy such as bcl-2 and C-myc to block oncogenes [15, 38-40]. In this study we have
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performed gene therapy with melanoma differentiated associated gene 7 or interleukin 24 (mda7/IL-24), p53, retinoblastoma (Rb), retinoblastoma like protein 2 (p130) on PC models.

Adenoviruses
Adenoviridae are icosahedral non-enveloped viruses with a 30 to 40kb linear double
stranded-DNA genome [41]. Ads have been isolated from a number of different species with
over 100 reported serotypes [42]. Human adenoviruses (HAdVs) consist of more than 55
serotypes that are divided according to haemagglutination and genome sequences into seven
species, HAdV-A, B, C, D, E, F and G. Members of species C, serotypes 2 and 5 Ads, are
commonly used as vectors for gene therapy [42-44].

Figure 1. Life cycle of adenoviruses. Replication-defective adenoviral vectors express the
proteins encoded on their DNA but do not enter the lytic phase. (Adapted from Vorburger and
Hunt, The Oncologist, 2002 [42].)
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The life cycle of an adenovirus can be divided into several stages (Fig. 1). During the
infection stage, virus surface proteins, such as hexon proteins, penton base proteins, and fiber
proteins attach to cellular receptors such as the coxsackie adenovirus receptor (CAR), integrins
αVβ1/2/3, membrane cofactor protein (CD46), desmoglein-2 (DSG2), coagulation factor IX and
X (FIX/FX), heparan sulfate proteoglycan (HSPG), etc. [45]. After entry into the nucleus, genes
from the early region 1 (E1a and E1b) are quickly transcribed (Fig. 1); these affect cellular
proteins that modulate several cellular processes, such as preventing apoptosis or inducing cell
cycle entry [46]. Four non-contiguous regions of the genome are expressed (E1 to E4) during the
early phases of viral replication. These regions serve as master transcriptional regulators that
start the process of viral gene expression leading unto genome replication. During genome
replication, the major late genes (L1 to L5) drive the viral replication and code for proteins that
make up components of the viral capsid or are involved in assembly of the capsid. Other viral
elements (cis or trans genes) are responsible for the origin of replication or the packaging signal
that condenses the DNA but these must be carried out by the virus itself [42].
The trans genes can be complemented or replaced by foreign or therapeutic DNA. At
least three such regions of the viral genome can accept insertions or substitutions of DNA: a
region in E1, E3, and between E4 and the end of the genome. The E1 deletion renders the
recombinant virus replication-defective, and thus provides an important safety feature [47]. The
first-generations of non-replicating ads are derived from E1/E3 deleted wild type (wt) Ads [41].
Newer generations of Ads have deleted or inactivated entire coding regions (E2, E3 or E4
regions) to increase DNA capacity and to alleviate antiviral host adaptive immunity [41].
However, to achieve a significant antitumor response Ads needs to be administered multiple
times, which can still provoke an immune response that mediates viral clearance [44, 48].
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Ad vectors have several advantages: first, they rapidly infect a broad range of human
cells; second, they yield high levels of gene transfer; third, they have low pathogenicity in
humans, fourth, they can accommodate relatively large (~7.5 kilobase (kb)) segments of DNA;
fifth, they can transduce non-proliferating (quiescent) cells; sixth, the viral genome does not
undergo rearrangement; seventh, they allow for the transmission of their genes into the host
nucleus but do not insert them into the host chromosome; eighth they are easy to manipulate and
finely retuned because the technology of Ad production at high titers is well established and the
Ad structure, genome and replication cycle is well characterized [42, 48, 49]. Ads are the most
commonly used vector in clinical trials (∼471 clinical trials or ∼23% of all clinical trials initiated
until January 2015) and approximately 75% of the 471 clinical trials have been initiated to treat
PC (51 clinical trials) [45, 50].

Conditionally Replication-competent Adenoviruses (CRCAs)
Replicating Ads or oncolytic Ads have the ability to infect a small portion of the tumor
and kill the tumor cells at the end of their lytic cycle. Their resulting progeny are now capable of
infecting the neighboring tumor cells ensuring a significant increase in the efficacy of gene
delivery coupled with cytolytic activity (Fig. 2). The replication competence of Ads can be made
conditional on the biology of the cells being infected. These replicating viruses are called
conditionally replicating Ads.
CRCAs can be made by modifying the adenoviral proteins to enable the virus to replicate
only in cells that bear the cancer related phenotypes [51]. For example, Ads deficient in E1B
(ONYX-015) contain a deletion of 827 base pairs (bp) in the E1B region that allows the virus to
replicate only in tumor cells lacking functional p53 [52]. In normal adenovirus, E1B codes for a
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55kDa protein that binds and inhibits p53 in normal cells which in turn blocks viral replication.
The ONYX-015 infected normal cell would exhibit p53 mediated growth arrest or apoptosis.
Thus functional ONYX-015 is restricted to p53 deficient cells, resulting in tumor selective
destruction [51].
CRCAs can also be made by placing key viral proteins under the regulatory control of
cell-specific gene promoters that restrict the viral lytic cycle to only the target cells [51]. For
example, Ad named CN706 contains a human PSA promoter gene that is cloned upstream of the
E1A viral gene which starts the early viral replication phase. In this study, we used cancer
terminator viruses (CTVs) that contained progression elevated gene-3 (PEG-3) promoter. This
promoter drives the expression of E1A and E1B genes thus ensuring cancer specific replication.
The CTV also contains cytomegalovirus (CMV) promoter that regulates the expression of
melanoma differentiated associated gene 7 or interleukin 24 (mda-7/IL-24) [53].

Figure 2. Schematic diagram of the cancer-selective killing efficacy of oncolytic Ads. Oncolytic
Ads specifically kill tumor cells at the end of their lytic cycle, while sparing normal cells.
12

Replicated viral progeny then spread throughout a tumor, infect, and lyse surrounding cancer
cells, ultimately leading to improved antitumor efficacy over non-replicating Ads. Moreover, the
amplification and propagation of therapeutic genes using replicating viruses in infected
neighboring cancer cells highlights the potential of replicating virus-based therapy. (Adapted
from Choi, et al. Advanced Drug Delivery Reviews, 2012 [54].)

Barriers to Virotherapy
Gene therapy makes efficient use of targeting viruses for cancer therapy, but several
barriers exist that limit the delivery of viruses from reaching and spreading throughout the tumor.
These barriers forces an increase in dosage of the viral particles thus increasing the possibility of
adverse events [55].

Figure 3. Barriers to systemic delivery of oncolytic viruses. There are three main areas that must
be addressed to enable systemic delivery of virus particles, namely (i) avoiding neutralization by
components of the blood stream including complement, FactorX, leukocytes, erythrocytes and
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antibodies, (ii) minimizing unwanted infection of irrelevant cells, notably hepatocytes, which are
usually present in vast excess, and avoiding premature scavenging by phagocytes, such as
hepatic Kupffer cells, (iii) maximizing extravasation within tumor vasculature and penetration to
infect all viable tumor cells whilst avoiding other components of the interstitium. Polymer coated
viruses present one promising approach to address these barriers, although several other
technologies are also under development. Abbreviations: ECM: extracellularmatrix, IgA:
ImmunoglobulinA, IgG: ImmunoglobulinG, IgM: ImmunoglobulinM, FX: FactorX. (Adapted
from Tedcastle, et al. Drug Discovery Today, 2012 [56].)

Current clinical trials in gene therapy are limited to intratumoral injections. This delivery
method has the advantage of delivering large payloads to the tumor site and minimizing
interactions with other cells but the viral spread is often limited to the needle track due to
pressure gradients, binding to extracellular matrix (ECM) components, and limited convection
[57, 58]. For massive tumor regression, infection must spread to cover a large volume of the
tumor mass. Poorly organized leaky vasculature (Fig. 3) increases the interstitial fluid pressure
(IFP) resulting in the loss of convection throughout the tumor making macromolecular transport
dependent on passive diffusion [55, 59]. However, in a solid tumor, the complicated structure of
the ECM (Fig. 3), which is composed of proteoglycans formed by both neoplastic and normal
stroma, acts as a physical barrier against the penetration of the viruses [54]. Thus passive
diffusion is limited due to the composition and organization of the tumor microenvironment. In
addition, both specific (e.g., neutralizing Abs or cytotoxic T cells) and nonspecific (e.g.,
phagocytes or anti-viral cytokines) immune response mechanisms may also limit spread of viral
particles [57].
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The other major hurdle is to successfully use systemic virotherapy to deliver viral
particles into tumor nodules [56]. Virus arriving at the tumor site must extravasate into the
tumor. Extravasation is dependent on the adequate blood supply, tissue perfusion and tumoral
enhanced permeability and retention (EPR) for transvascular transport. Tumor vasculature is
chaotic in terms of microvessel length, diameter, spatial distribution, blood flow velocity and
direction causing heterogeneous blood perfusion throughout the tumor [55]. The tumor
vasculature causes regions of low-oxygenation leading to hypoxic tumor environments that
become inaccessible to the virus. These regions are important as they house tumor stem cell
niches and treatment resistant cells that trigger relapses in patients [55, 60, 61]. On the contrary,
leaky tumor-associated vasculature can sometimes enable limited extravasation of virus particles
through passive diffusion [56]. The passive diffusion is mediated by EPR but it is not consistent
because of the differences in pore size and the abrupt changes in blood perfusion [55, 62, 63],
thus extravasation into the tumor site is a limiting factor of systemic delivery. Lastly, once
injected into the vasculature, the viruses undergo various interactions with the immune system,
thereby reducing viral efficiency.
Ads are regarded as pathogens by the body and are attacked by the host immune system.
They mostly induce the innate arm of the immune system resulting in the inactivation of the Ads,
the inflammation of the transduced tissue due to T- and B-cell targeting the transduced tissue[64]
and efficient clearance of Ads by the immune cells [41]. In fact, within 24 hours after IV
administration, 90% of the Ad vector is eliminated from the mouse liver [65]. Systemic delivery
of Ads into the bloodstream also exposes the virus to plasma proteins and blood cells (Fig. 3)
[58]. The resulting interactions include the neutralization and/or opsonization by antibodies and
complement (C3a)[66], phagocytosis by neutrophils and macrophages, sequestration on
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erythrocytes as well as others [56, 58]. The innate immune response also involves the induction
of cytokines by the viral capsid proteins and interactions with leukocytes, epithelial and
endothelial cells resulting in signal transduction via MAP (Mitogen-activated protein kinases)
and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [41] as well as
through Toll-like receptors and lectins in the plasma membrane and endosomes [44]. The
adaptive arm of the immune response is seen in patients with pre-existing immunity. This
immunity leads to a high prevalence of virus neutralization antibodies against Ads, preventing
the vector from transducing cells efficiently and lowering the overall effect [67]. Lastly, nonspecific uptake by other tissues such as the lung, Kupffer cells in the liver, spleen and tissue
resident macrophages all contribute to the rapid clearance of Ads. Thus these immune reactions
severely limit the benefit of systemic delivery, intratumoral delivery, repeated administration and
administration of high-titer Ads.
.
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ABSTRACT
The field of ultrasound has expanded since the discovery of ultrasound contrast agents
(UCAs) from diagnostics to therapeutic use. UCAs are known as microbubbles (MBs), which
can be chemically and physically manipulated to improve their therapeutic potential. MBs can be
tailored to bind to specific diseased tissues and act as carriers of different chemo-drugs and
genetic materials. These engineered MBs can behave differently to ultrasound intensities
resulting in different cavitation methods. Though the underlying mechanism is yet to be fully
understood, there is evidence to suggest that mechanical pore formation of cellular membranes
allows for the temporary uptake of drugs. The cavitation of MBs can induce temporary and
reversible enhancement in the permeability of both individual cells as well as the endothelium
including the blood brain barrier. There are too many side-effects and immune responses to
current cancer and diseased treatments. MBs protect the immunogenic drugs from eliciting a
detrimental response when delivered through the vasculature. They also help reduce the drug
dosage by improving drug targeting and drug response. Thus, MBs can be used as vehicles for
localized drug delivery and gene therapy allowing us to further develop the potential of curing
cancer and other diseases.

Keywords: Microbubbles, ultrasound, ultrasound contrast agent, chemotherapy, adenovirus,
Polyethylene glycol, perfluropentane, phospholipid, sonoporation, cavitation, Blood Brain
Barrier (BBB), Gene Therapy, Chemotherapy, DNA, RNA, Protein, siRNA, miRNA, Drug
delivery.
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INTRODUCTION
Historical Overview
Ultrasound (US) is the most widely used diagnostic imaging modality. This modality
provides a safe, non-invasive, and portable real-time imaging at a low cost [68]. US sound waves
have a frequency between 20 Hz to 20 kHz that is inaudible to the human ear [69]. Typically, in
ultrasonography the diagnostic frequency ranges from 1-10 MHz [70]. To produce a US image a
transducer that broadcasts the US wave pulses is placed on the skin or inside the body. These
waves are reflected by the interfaces between different tissues or structures in the body. The
imaging software system converts these reflected waves into electrical pulses and digitizes them
[68]. Imaging is possible because the speed of sound in the tissue (~1500m/s) is known [71].
Biological tissues (except lung or bone) mainly consist of water, which has low compressibility,
and sound waves propagate without significant scattering or reflection [71]. Thus the backscatter
energy from tissue contains less or no harmonics [72]. Blood, a liquid phase material, has low
compressibility and scatters US poorly, but the infusion of ultrasound contrast agents (UCAs) or
microbubbles (MBs) can increase the scattering and reflection of the ultrasonic waves [68].
Thus, harmonics can be used to differentiate between blood flow with UCAs and the surrounding
tissue [72].
The discovery of microbubble (MB) agents came from an accidental observation by Dr.
Charles Joiner, a cardiologist in the late 1960s. Dr. Joiner performed an M-mode echocardiogram
by injecting a patient with indocyanine green through the left ventricle to measure cardiac
output. He observed a transient increase in the US signal from the ventricle after each injection
[73, 74]. It was later shown that small bubbles forming at the catheter tip caused the increase in
the signal, but subsequent research into duplicating the results was not successful [74]. In 1968,
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Gramiak and colleagues observed a cloud of echoes after the injection of agitated saline in the
aortic root [73]. They showed that the backscatter of the US for the blood pool can be increased
by adding the gas bubbles that exist in agitated saline [72, 73]. Agitated saline is still used for the
detection of right to left shunts in the heart [75]. These bubbles were large and unstable and had
a short half-life and did not persist in the blood for long periods of time which limited their use
[72]. Only right heart imaging was achieved because the first generation of UCAs that entrapped
air and carbon dioxide in agitated saline and hydrogen peroxide could not pass through the
pulmonary circulation [76].
Mixing some of the patient’s blood with saline was found to markedly increase and
prolong the stability of the bubbles [74]. Dr. Feinstein [77] found that albumin was the blood
component improving MB stability [74]. Later on Feinstein developed the sonication method
that produced more stable MBs, whose size could be controlled [78]. In 1994, Albunex
(Molecular Biosystems, San Diego, CA) became the first commercially available contrast agent
approved for human use in the United States. Albunex has a coating made of human serum
albumin [72]. Coating of MBs resulted in the stabilization of MBs with different substances such
as phospholipid, albumin, or polymers. Coated MBs formed the second generation UCAs that
had a mean diameter less than 8 μm, which guarantees that the UCA could pass through the
pulmonary circulation and reach various organs. MBs survived longer in the blood stream due to
their lower solubility in water and had a strong harmonic response [76].
The making of more stable, more effective UCAs revolutionized the pharmaceutical
industry. The second commercially available contrast agent, Levovist, became available in
Europe and Japan in 1996. Levovist like its forerunner Echovist [74] (Bayer Schering Pharma
AG, Berlin, Germany) consists of galactose microcrystals whose surfaces provide absorption
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sites on which air bubbles form when suspended in water [72]. Echovist performed poorly in the
right heart because its intravenous (IV) injected MBs were not stable and failed to cross the lung
capillaries [74]. Levovist MBs were further stabilized with a trace amount of palmitic acid [72],
thus making it stable in the blood for 1-4 min, which increased the US signal by ~20 dB [74].
Levovist MBs formed in the blood flow while EchoGen® (Abbot Laboratories, Chicago, IL,
USA) achieved MB formation through a totally different mechanism. EchoGen® consists
essentially of a perfluoro-compound (perfluoropentane), which is liquid at room temperature but
becomes a gas at body temperature. EchoGen® is prepared as an aqueous emulsion with
surfactants that change to gas on injection, with the formation of MBs as small as 2–8 microns
[74].
Since 1997, contrast agents (CAs) are further stabilized by replacing the air core with
high-molecular-weight inert gases such as perfluorocarbons, which have a lower solubility and
diffusivity in aqueous liquids compared with air [72]. Clinically proven agents based on this
principle include SonoVue (SF6 gas), Definity/Luminity (C3F8), Imagent (C6H14), Sonazoid
(C4F10) (these materials possess a lipid stabilizer shell), and Optison (C3F8 has a shell of
denatured human serum albumin) [71]. These became the third generation of UCAs.
The history of UCA development has been long and difficult. Luck and astute
observations helped develop and make US imaging the most cost effective technology available
in the world. UCAs have opened up new opportunities in molecular imaging [71], drug delivery
systems, high focused US (HIFU) surgery [79], and atherosclerosis [80].
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Ultrasound Contrast Agents or Microbubbles
Ultrasound contrast agents are also known as microbubbles (MBs). MBs enhance the
quantification of perfusion and blood flow [81]. MBs are very echogenic and they resonate like a
musical instrument [74]. The physical and chemical design of contrast agents (CAs) are
manipulated such that synthetic surfactant, tuning of size, composition, degradability, surface
properties and bio-functionality make them very echogenic [81]. Typically, MBs are comprised
of surfactant shell made from proteins, lipid and biodegradable polymers with an inner gas core,
either of air or inert gases (Fig. 4). MBs have an average diameter of ~2 to 3µm, and the
combined mass of the shell and gas core (Fig. 4) of each MB does not exceed a pictogram [71].

Figure 4. Schematic representation of a coated microbubble.
The particle size of MBs for intravenous injection plays a significant role and needs to be
carefully controlled. MBs must be small enough to cross the capillary bed (7.5 micron). Indeed,
large bubbles are unable to pass through the capillaries, whereas small bubbles are considerably
less effective scatterers [81]. It is now accepted that the size must be in the range of 1-7µm,
preferably around 3µm, with as narrow size distribution as possible. The critical resonance
frequency required to destroy the bubble depends on the diameter [74]. The rigidity of the shell
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determined by the thickness of the surfactant would also determine its resonating potency and its
echogenicity. It has been determined that US reflectivity is proportional to the fourth power of a
particle diameter, but also directly proportional to the concentration of the particles themselves.
The resonance frequency of MBs 1–7µm in diameter lies within the 2–15 MHz range, which is
the US frequency used for clinical diagnosis [74].
Echogenic liposomes and various nanoparticle (NP) dispersions are being evaluated as
CAs. Most liposomes have a multi-lamellar structure with embedded air pockets that are
responsible for acoustic backscatter signal [82, 83]. Without an enclosed gas core the US signal
from these particles is low. NPs dispersions are mostly liquid perfluorocarbon-based emulsions
[84]. These NPs are also characterized as contrast agents for MRI, optical imaging, and drug
delivery. US imaging using these materials requires a high frequency (multi-MHz) or high
degree of target surface coverage with a CA [71, 85].
MBs do not diffuse across the endothelium and thus there is no interstitial enhancement.
Essentially, MBs act as blood pool markers, or markers of any other body space into which they
have been injected and their behavior is, in many respects, similar to that of labeled red blood
cells. Vascular enhancement usually lasts a few minutes and the MBs are then dissolved.
However, this model is complicated by evidence that some MBs are taken up by the
reticuloendothelial systems [74].
Single-bubble detection is possible in vitro in normal saline or blood with older imaging
equipment. However, echoes from normal tissue can be nonlinear with non-fundamental
frequency. To reduce these signals from tissues multi-pulse techniques such as phase inversion
and power modulation are applied [71]. However, to detect MB vibration current imaging
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systems use harmonic imaging, both in free-flow conditions [86] and when attached to a solid
target [71, 87]. MBs are known to emit US at different frequencies such as sub-harmonic, second
and third harmonic frequencies. This large discrepancy in the echoes between MBs and tissue
allows for enhanced imaging with quantification of perfusion, blood flow, tumor and tissue
vascularization [81], thus MBs are essential for diagnosing modality.
MBs are used not only for diagnostic applications but also for molecular imaging and
therapeutic applications [68, 88-90]. Molecular imaging targets the molecular changes associated
with diseases and improves the efficiency of in vivo imaging [72]. However, in this chapter we
will focus on its therapeutic applications in treating cancer. Initial applications of MBs depended
on the rate of bubble collapse and their bio-effects such as inducing cell damage, vascular injury
[91], and the lysis of thrombus [92]. Interestingly, oscillating MBs can increase membrane
permeability and open up tight junctions in endothelial cells [93-97], thus the therapeutic
potential of drug delivery and drug action is increased. Based on chemical and physical nature of
drugs, some MBs are known to have drugs encapsulated in liposomes, polymeric micelles,
hollow particles and emulsion droplets with the aim to reduce non-specific drug resistance and
side-effects associated with traditional cancer therapies [81].
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Types of Microbubbles
MBs can be divided into several categories depending on their physical and chemical
properties which are crucial in the design of a contrast agent for US guided drug delivery [81].
There are a few characteristics that are important when designing an MB. First, the intensity of
the backscatter or echo caused by the MB is determined by Rayleigh scattering regime [81, 98].
The intensity depends on the surface properties or shell material, gas content and colloidal
properties of MBs [81, 99]. Shell and gas components (Fig. 4) should be biodegradable, i.e.
readily metabolized and/or excreted with minimal side-effects [81]. Additionally, MBs shouldn’t
aggregate into large clusters which could result in non-specific and undesired adhesion to cells
[99]. MBs should be effective at low doses [81]; for instance, the typical US Food and Drug
Administration (FDA) approved dose of MBs for a patient is approximately 109-1010 MBs given
for a 1-2 mL bolus intravenous injection [99]. Additionally, pre-formed drug loaded MBs or
MBs alone should be sterilizable and stable with a shelf-life of two years [81, 99]. Other
requirements include backscattering proficiency, fragility and cavitation properties of MBs [81].
US or acoustic pressure required to cause cavitation is measured as mechanical index (MI), a
relative quotient computed as a peak negative acoustic pressure divided by the square root of the
frequency [71]. MBs behave differently at various acoustic pressures, for example, at MI >0.2
MBs behave in a nonlinear manner that allows some systems to detect smaller MBs [71]. At
higher pressures (MI >0.4 and up to 1-1.9, depending on the frequency), MBs are completely
destroyed [86]. Acoustic pressure depends on the diameter of the shell and its material, for
example, thin lipid monolayered bubbles are flexible and vibrate in response to low-pressure US
(e.g., MI = 0.06) [71], whereas, thick-shelled polymer bubbles don’t crack unless at critical
pressure, or vibrate resulting in low acoustic echo response [100].
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Agitated Gas Microbubbles (First Generation)
First generation MBs were prepared at patient bedside with two syringes connected via a
stopcock valve that contained air and saline [101]. When liquid and gas are rapidly transferred
from one medium to another the resulting high shear flow causes air bubbles to form of varying
sizes [71]. These bubbles produced by agitation are called agitated-saline and are both large and
unstable [71, 72]. The surface tension between the gas core and surrounding liquid causes the gas
to diffuse into the surrounding liquid decreasing the size of the bubble [71]. MB requires a
stabilizer shell to prolong its circulation time. The rate can be calculated using the equation by
Epstein and Plesset [102] and Chen et al. [103] that an air bubble with a diameter of 5μm in airsaturated water disappears in approximately 125 ms and an air bubble with a diameter of 3 μm
disappears in approximately 32 ms at room temperature and ambient pressure [72].
There are several limitations in using these bubbles such as the size of bubble, circulation
time and gas core. These bubbles are effectively removed by the lungs [72]. Additionally, these
bubbles have a size greater than 10μm and are unable to traverse the pulmonary circulation [68].
MBs larger than 6-8µm are trapped in the lung capillaries and bubbles smaller than 1µm are less
stable and less ultrasound responsive [81]. These bubbles need to be administered by
intracoronary or aortic root injection to visualize the left cardiac chambers [72]. Additionally,
because it takes at least 12 sec for a contrast agent to pass from a peripheral vein (i.e., the site of
injection) to the end-organ [104], to be useful these bubbles need to persist for several minutes
[72]. In 1984, Feinstein et al. introduced the use of sonication to create MBs that were stable and
small enough to transit through the pulmonary microcirculation from right to left heart [77].
Since the introduction of saline MBs, other agitated contrast agents (hydrogen peroxide,
dextrose, indocyanine green dye, iodinated contrast) have been used [68].
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Coated Microbubbles filled with Air (Second Generation)
The biggest dilemma facing scientists was the circulation time of bubbles. It was found
empirically that a small admixture of the patient’s blood to the saline improves the stability and
effectiveness of the agitated saline as a contrast agent [105]. Surfactants from the blood form a
coating around the gas core and promote the lifetime of the MB by greatly reducing the surface
tension at the interface [72]. The first stable MB marketed was Albunex (Table 1). Albunex had
a short shelf-life after intravenous injection (tens of seconds) [71].
An encapsulating shell is necessary to sustain the gas cavity and to reduce both the
diffusion of gas leaving the core and the surface tension [81]. The encapsulating shell increases
the shelf-life (days to months) of the bubbles. The albumin coating forms an elastic solid shell
around the gas core and is relatively stiff. Coating enhances the bubble’s stability by supporting a
strain to counter the effect of the surface tension [72]. The transpulmonary passage of contrast
particles became possible only after the addition of a MB shell, i.e., a surfactant (lipid, protein,
e.g. denatured albumin or polymer, e.g. poly-butyl-cyanoacrylate [69]) coat, which stabilized the
bubbles so that they did not attach to the extensive surface of lung endothelium capillaries [71,
106]. Bubble size is a critical parameter that must be controlled in the range of 1-7µm preferably
around 3µm [81]. At that point, intravenous administration of contrast became a feasible option
for delivering contrast to left heart chambers [106], with some contrast reaching the myocardium
vasculature. To circulate freely and avoid entrapment in the microvasculature, MB particles need
to be smaller than red blood cells (typically <4.5µm in mean diameter) [71].
The compressibility of gaseous particles is many orders of magnitude higher than that of
liquids and solids. As a result, the scattering efficiency from gaseous particles is many orders of
magnitude higher than that from other objects. According to Rayleigh Scattering the intensity of
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MB increases as the fourth power of frequency [81]. For such small MBs, the surface-to-volume
ratio is high, and air can easily escape and dissolve in the surrounding medium (as a result,
ultrasound contrast is lost). Therefore, transpulmonary air-filled MBs with these first-generation
shells did not circulate long after intravenous injection (tens of seconds) [71]. Air consists mostly
of nitrogen that is able to move easily out of the thin-shelled bubbles, especially in cases of
oxygen inhalation that had reduced blood levels of dissolved nitrogen [107, 108]. In
physiological conditions, the blood is saturated with air under atmospheric pressure, whereas the
air pressure inside the bubbles is larger than atmospheric pressure due to Laplace pressure. When
air-filled MBs are infused intravenously they dissolve spontaneously [99]. Surfactants such as
lipid (~3nm thick), protein (15-150nm thick) or polymeric shell (200-500nm thick) eliminates
the driving force for dissolution of MBs in saturated media as the elastic response of the interface
arrests the shrinkage of the gas core [99, 109]. To improve MBs’ stability, currently used
strategy is to fill them with a sparingly water soluble gas (perfluorocarbons act as osmotic agent)
instead of air [110].
At present Levovist (Table 1) is the most widely studied MB contrast agent and the only
one commercially available in several countries. Levovist (Table 1), like its forerunner Echovist
(Table 1) (also by Schering), is made of galactose microcrystals generating air in the vial [74].
Adding water to the galactose powder forms a suspension in which air MBs adhere to the fine
irregularities of the surface of the microcrystals remaining in the solid state, which dissolve after
injection, releasing the gas MBs into the blood. Levovist and Sonovue (Table 1) have half-lives
of 78 seconds and 5 minutes, respectively [81].
MBs are manufactured by two general techniques: self-assembly stabilization of
dispersed gas particles, and double-emulsion preparation with core extraction. The first
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technique is for lipid or protein-based bubbles. Gases (air or fluorinated gas with low solubility)
are dispersed in the aqueous medium that contains a lipid or surfactant micellar mixture or a
protein that is denatured by sonication. Those components are deposited on the gas-liquid
interface and stabilize the MB. Some preparations are stable on storage in the aqueous phase for
many months. Alternatively, MBs can be rapidly frozen and lyophilized for extended storage in
dry state. The addition of water results in a reformation of the MB aqueous dispersion
immediately before use [72].
Table 1: Comparison of Commercially Available Contrast Agents
Agent
Bubble Size mean Gas
Shell Composition
(range)
4.5µm (1-10µm)
Air
Albumin
Albunex
2-3µm (2-8µm)
Air
Galactose/ palmitic acid
Levovist
Air
D-galactose
Echovist
2-5µm (1-30µm)
Dodecafluoropentane Stabilized surfactant
EchoGen
2-5µm (1-30µm)
Perfluoropentane
Anionically charged surfactant
Sonogen
4.7µm(1-10µm)
Octafluoropropane
Albumin N-acetyltrytophan,
Optison
Caprylic acid
1.5µm(1-10µm)
Octafluoropropane
Lipids: DPPA, DPPC,
Definity
MPEG5000 DPPE
6µm
Perfluorohexane
Lipid: DMPC
Imagent
2.4-3.6 µm (3.4µm) Perfluorobutane
Phospholipids
Sonozoid
1-2 µm
Air
Cyanoacrylate (polymer)
Sonovist
2.5µm(1-10µm)
Sulfur hexafluoride
Lipids: Macrogol 4000, DSPC,
Sonovue
DPPG, Palmitric acid
Perfluorocarbon
Stabilized Lipid
Sonidel MB101 2.7 µm
2.9µm(1-8µm)
Air
Polymer
BG1135
2.5-3 µm
Perfluorobutane
Lipid
BR14
<10µm
Perfluorobutane
Phospholipids
BR38
4.0µm(3-5µm)
Nitrogen
Biodegradable polymer bilayer
PB 127
4.7 µm
Perfluorocarbon
Albumin
PESDA
2.5 µm
Variable
Lipid
Artenga
2µm
Perfluorocarbon
Poly-L-lactide co glycolide
AI-700
Nitrogen
Polylactide/Albumin
Cardiosphere/ 4µm
Bisphere
2.5 µm
Perfluorocarbon
Surface-modified Lipid
Targeson
Adapted from Liu, Y. et al. 2006 [69], Alzaraa, A. et al. 2012 [111] and Nomikou, N. and
McHale, A.P. 2010 [112])
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Coated Microbubbles filled with Inert Gases (Third Generation)
Since 1997, contrast agents have been further stabilized by replacing the air core with
high-molecular-weight inert gases or water soluble fluorinated gases [71] such as
perfluorocarbons [72] and sulfur hexafluoride [68] which have a lower solubility and diffusivity
in aqueous liquids compared with air [104]. Perflurocarbons act as osmotic agents and would
dilute the other gases inside the bubbles thereby also reducing their partial pressure [81, 113].
This effect counterbalances the Laplace pressure and blood pressure [81].
The gas core is generally surrounded by a protein (albumin), lipid, surfactant, or
biocompatible polymer surfactant with a diameter ranging from 2 to 500nm. This shell improves
stability against gas loss, dissolution, and MB coalescence, and produces a more standard size
distribution [68]. The gases such as perfluorocarbons are exhaled through the lungs. Examples of
this kind of agent are Optison (GE Healthcare, Chalfont St Giles, UK), which contains
octafluoropropane and an albumin shell; SonoVue (Bracco, Milan, Italy), which has a sulfur
hexafluoride core and a phospholipid coating [72]; Definity/Luminity (C3F8), Imagent (C6H14)
and Sonazoid (C4F10) which possess a lipid stabilizer shell [71] (Table 1).

Different types of Coated Microbubbles
Shell coating is critical for stabilizing MBs because the configuration and conformation
of the shell material determines its stiffness which increases its resistance to rupture by US as
well as its clearance efficiency by the reticuloendothelial system [68]. The shell can be stiff with
albumin, lysozyme and polymers or more flexible with lipid or phospholipid. Its thickness can
vary from 10 to 600nm [81]. Surface tension, shell viscoelasticity and permeability, surface
charge density, biodegradability, ligand density and payload capacity are properties that largely
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depend on the choice of the surface-active agent, i.e. lipid, protein or synthetic polymer. MBs’
surface properties and size play a crucial role in prolonging the circulation life of MBs as
phagocytic uptake depends on surface opsonization [114] and particle size. The larger sized MBs
are eliminated more rapidly. Dendritic cells and macrophages are assigned to the clearance of
MBs in the bloodstream [99]. The study of MBs’ biodistribution carried out by Tartis et al.[115]
using Positron emission tomography (PET) showed that MB shell material accumulates in the
spleen through size dependent filtration mechanisms. Immunogenicity, targeting efficiency,
availability, potential for imaging and drug release upon ultrasound irradiation are functional
properties consequently correlated with MBs’ structural features [99].

Figure 5. Schematic representation of different coated microbubbles. A) Polymer coated
microbubbles. B) Phospholipid coated microbubbles. C) Protein coated microbubbles.
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Interaction of Ultrasound and Microbubbles
Acoustic signals from MBs is dependent on the compressibility of the gas, bubble size,
shell thickness, shell viscosity, shell density, properties of the surrounding medium, US
frequency and power of the applied ultrasound [116, 117].
MBs owe their functionality to the gas core, which can compress and expand easily in
response to the acoustic pressure change (Fig. 8) [72]. This change can result in 100-fold volume
change and 4-5 fold diameter change [71]. Thus, when exposed to an ultrasound field, a gas
bubble will undergo volumetric oscillations in response to the varying pressure (Fig. 8) [74,
118]. The MB oscillations also results in a high backscattering of the ultrasound wave. The
amplitude of these oscillations will be much larger than those of a very weakly compressible
body such as a red blood cell [79]. Thus, despite their similarity in size, the MB will produce
much stronger US echoes [74, 118]. Moreover, the MBs can act as resonant systems with
resonant frequencies within the same range as medical ultrasound frequencies [72].
Eventually with increasing pressure from the US the MBs will undergo violent collapse,
releasing a shock wave and often fragmenting into smaller bubbles (Fig. 6, 7 & 8B) [119]. This
process is variously referred to as inertial, unstable, or transient cavitation (Fig. 8B). Transient
and unstable are both slightly misleading terms since a bubble can collapse repeatedly [120]
without fragmenting, but inertial cavitation means the collapse of a gas cavity with significant
amounts of energy being released (Fig. 8B) [72]. Broadband emissions are generated during
inertial cavitation where bubbles undergo large radial oscillations that are dominated by the
inertia of the surrounding liquid [121]. During compression of MB there is a rise in pressure and
temperature within the bubble, but during an inertial collapse the temperature may reach several
thousand degrees centigrade or more [122]. These extreme conditions are confined to the center
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of the bubble; however, the bubble will have expanded again before any significant heat transfer
can occur. Highly reactive chemical species may be produced such as free radicals and toxic
chemicals such as hydrogen peroxide (H2O2) [123] at relatively high intensities [124].

Figure 6. Optical frame images and streak image of ultrasound contrast agents. Optical frame
images and streak image corresponding to the oscillation and fragmentation of a contrast agent
microbubble, where fragmentation occurs during compression. The bubble has an initial
diameter of 3 μm, shown in A. The streak image in h shows the diameter of the bubble as a
function of time, and dashed lines indicate the times at which the two-dimensional frame images
in A–G were acquired relative to the streak image. (Adapted from Chomas et al. American
Institute of Physics, 2000 [125].)
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Figure 7. Schematic representation of lipid (left column) and polymer (right column)
microbubble interaction with ultrasound of increasing intensity (top to bottom). (Adapted from
Hernot and Klibanov, Advanced Drug Delivery Reviews, 2008 [68]).
In addition to a temperature rise, “streaming” currents may also be set up as ultrasound
propagates through a liquid as a result of momentum transfer [126]. A similar effect can occur on
a correspondingly smaller scale around MBs undergoing stable oscillations (Fig. 8A) [127]. If
the bubble is sufficiently close to a surface, such as a cell membrane, these circulating flows may
give rise to shearing stresses which have been hypothesized as the means by which uptake of
therapeutic components is enhanced [128]. Micro-streaming (Fig. 8A) will also contribute to
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circulating material in the target region, which is extremely important in the context of
therapeutic applications [129]. At higher amplitudes of oscillation, microstreaming can cause
significant damage to cells and produce mechanical erosion [79, 130, 131]. In addition when a
bubble rapidly collapses near a boundary, this collapse is asymmetrical. A high-speed liquid jet
may form projecting through the bubble towards the boundary. This phenomenon is known as
microjetting (Fig. 8C) [81]. Microstreaming and microjetting generate moderate shear stress on
inducing hyperpolarization of the cell membrane by modifying the electrophysiologic cell
activities and enhancing the cell’s permeability (Fig. 8) [132]. For drug-loaded MBs,
microjetting would be the ideal release mechanism (Fig. 8C), since it effectively produces small
holes within a cell membrane (sonoporation) which facilitates the drug uptake [133]. The rupture
size is large enough to allow the passage of non-deformable particles up to 0.5µm in diameter,
that depends on several parameters including the MB size, shell composition, acoustic pressure,
and intravascular pressure [81].
MBs and ultrasonic waves undergo a scattering interaction by absorbing the acoustic
energy [81]. MBs in a liquid are forced to oscillate with only a relatively small to moderate
increase and decrease of radius. The mechanical biological effect is estimated by certain
ultrasound parameters and is called mechanical index (MI). At low MI<0.1, MBs undergo
alternate equal expansion and contractions symmetrically and in a linear manner [81]. At a
slightly higher MI of 0.1 to 0.3, the bubble becomes somewhat resistant to compression than to
expansion which results in stable or non-inertial cavitation (Fig. 8A & B) and leads to non-linear
oscillations and backscatter at a variety of frequencies (harmonics, sub-harmonics and ultraharmonics) [68, 80]. When the bubbles are collapsing the kinetic energy of the bubble surpasses
its surface energy and fragments into a number of smaller bubbles. Fragmentation (Fig. 6, 7 &
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8B) has been exclusively observed with contrast agents with thin, elastic shells [134]. At even
higher acoustic pressures (MI 0.3–0.6), MBs undergo forced expansion and compression that
lead to its destruction by different methods such as outward diffusion of the gas during the
compression phase, diffusion via large shell defects, or complete fragmentation of the shell and
the gas core (Fig. 6, 7 & 8B)[125, 135]. MBs’ fragmentation can instead produce violent effects
which causes cell membrane permeability [136] and lysis [133](Fig. 8B). Acoustical experiments
are performed on a population of MBs, therefore they do not show how individual MBs respond
in an acoustic field. Experimental evidence is obtained with high-speed camera microscopy of
insonated bubbles [68]. These optical frame or streak images show the oscillating and
fragmentation changes of a 3μm MB (Fig. 6) [125].

Figure 8. Schematic representation of ultrasound causing microbubbles to behave in different
ways that leads to endothelial pore formation and increase vascular permeability. A) Stable
cavitation leads to expansion and contraction of microbubble that generates shear stress known
as microstreaming. B) Inertial cavitations lead to implosion of the microbubbles that allow for
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the release of the bubble contents or fragment into smaller microbubbles. C) Bubbles generate
microjets when the resonance diameter is larger than the blood vessels that damage the
endothelial lining.

Coated MBs undergo damping as dissipation of viscous energy. Damping reduces the
amplitude of the bubble oscillations and it widens the resonance curve of the bubble [72]. MB
shell material and stiffness also play a major role in determining the type of explosion or
implosion that may occur when exposed to acoustic energy. Lipid or protein MBs and polymer
MBs behave differently and depend on the amplitude of ultrasound to which they are exposed
[68, 134]. The regime of phospholipid coated MBs depends on bubble radius and the
concentration of phospholipid molecules. Phospholipid MBs exist in buckled, elastic and
ruptured regime. The bubble is compressed when the coating is condensed which leads to
buckling, and with the bubble coating in such a tensionless state, the resulting surface tension is
zero (Fig. 6D) [72]. When the bubble is expanded (Fig. 6B), the coating may be ruptured and the
gas core will be exposed to the surrounding liquid, changing the surface tension of the gas–liquid
interface. In the intermediate elastic regime, the coating is assumed to behave elastically where it
is relatively stiff. During the elastic regime, its resonance frequency is high and it will not easily
oscillate when driven below resonance [137]. An increasing acoustic pressure can modify the
concentration of lipid molecules on the bubble’s surface, forcing the bubble into the buckling
regime, which suddenly reduces its stiffness [72].
An oscillating phospholipid MB would most likely lead to stable or non-inertial
cavitation (Fig. 8A & B). For MBs with a thin shell such as Optison (albumin shelled MBs)
fragmentation is the major mechanism for bubble destruction [116]. Microjets (Fig. 8C) are also
generated during cavitation of thin-shelled MBs [91] which produce vessel wall ruptures in vivo
37

and extravasation of nanoparticles into the interstitial space. Polymeric shells are stiff and will
not oscillate actively at low US intensity (Fig. 7). The shell cracks as US pressure is increased
above the threshold value resulting in the escape of the encapsulated gas (Fig. 7) [68]. This type
of MB destruction is called sonic cracking (Fig. 7). However, thick shelled rigid albumin MBs
also undergo sonic cracking [116, 138]. For bubbles containing drugs in the gas phase (anesthetic
gases, nitric oxide, oxygen) [139, 140], sonic cracking is a suitable mechanism. Fragmentation
(Fig. 7), microjetting (Fig. 8) and sonic cracking (Fig. 7) can be effective mechanisms in drug
delivery and therefore their occurrence should be finely predicted and tuned [81, 141].
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Bio-Effects
US assisted drug delivery is a very complex process that relies on biochemical and
mechanical processes that occur during sonoporation which is defined as mechanical disruption
of the plasma membrane [80, 81] (Fig. 9).

Figure 9. Ultrasound interacts with the microbubble, causing oscillation and eventual
destruction, leading to the release of genetic material. The accompanying cavitation produces a
local shockwave that increases cellular permeability, allowing transcapillary passage of
macromolecules through small endothelial perforations. (Image courtesy of C.R. Merritt, MD,
Thomas Jefferson University Hospital, Philadelphia, PA.) (Adapted from Howard, Applied
Radiology, 2004, [142].)
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US energy can penetrate or “push” materials into skin, blood clots or other tissues [143]. Shear
stress can be generated on the membrane of an endothelial cell through the destruction of MBs
that causes high-energy microstreams and microjets which increases the permeability of blood
vessels promoting the extravasation (Fig. 10) of high molecular weight drugs [99]. This increase
in permeability is probably due to transient holes in the plasma membrane and possibly the
nuclear membrane [69]. Thus, acoustic cavitation is a pre-requisite in promoting the physical or
chemical release of drugs from carriers (MBs), or in promoting the transport of drugs into cells
(Fig. 10). US-induced passage of materials from the luminal to the adventitial side of vascular
tissue (Fig. 9 & 10) have been proposed in the literature such as paracellular widening of interendothelial clefts and tight junctions, free passage through injured endothelial lining and
transcytosis via fenestration and channel formation [94] (Fig. 11).

Figure 10. Enhanced drug and gene delivery achieved with the combination of particles and
ultrasound. Insonation of circulating microbubbles in the chorioallantoic membrane model
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results in small vascular defects, through which a fluorescent dye is transported, reproduced with
permission from (27). (a)–(f) are a sequence of images acquired from 1.00-MHz center
frequency insonation at a peak negative pressure of 1.3 MPa. (a) was acquired before insonation,
(b)–(f) were acquired 0.06, 0.12, 1.24, 2.24 and 3.24 seconds after insonation began,
respectively, demonstrating the transport of the fluorescent probe from the vasculature to the
tissue interstitium.(Adapted from Ferrara et al., American Chemical Research, 2009[144].)

Figure 11. Ultrasound mediated drug delivery through different means of transport.
Sonoporation allows for the mechanical disruption of the endothelial cell membrane.
Intracellular trasnsport allows for the uptake of microbubbles through endocytosis that transports
the microbubble through to the interstitium. Paracellular transport allows for the opening of the
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tight junctions or separation of bonds that hold the endothelial cells together which causes pore
formation in the blood vessel wall.
In vivo studies suggest that a MI of 0.4 has been shown to be detrimental to the plasma
membrane and microvasculature [145]. However, low intensity stable cavitation may not be
adequately effective in triggering the drug delivery [81]. Reported bio-effects in vivo include
hemolysis, damage to the microvasculature, opening of the blood brain barrier, effects on cardiac
rhythm and thrombolysis [146]. The vessel wall structure has also been found to influence the
degree of rupture [147]. The fore mentioned mechanisms have been proposed for the blood brain
barrier (BBB)[148], but are also supported by studies in other tissue beds, including renal [149],
prostate [150] and skeletal muscle [147] tissues.

Sonoporation
Sonoporation refers to the localized, mechanical disruption of plasma membrane (Fig.
11) [80]. Van Wamel et al., [151] using high speed imaging, showed transport of propidium
iodide (PI) against endothelial cells as a direct correlation between cell deformation and resulting
cell membrane permeability with in vitro studies. According to van Wamel et al. [93] poration is
a transition of hydrophobic to hydrophilic pores. This transition creates cylindrical pores when a
rotation of the polar heads brings a hydrophilic surface to the pore (Fig. 12). When US is applied,
the adhered MBs on the transmembrane generate a critical ‘shear’ force, which leads to
formation of pores once the membrane breakdown force is exceeded. Rapidly oscillating MBs
undergo rapid expansion and compression (Fig.12) due to changes in the volume of the gases
inside the bubble. The oscillating MBs generates fluid flow over the cell surface and is termed as
microstreaming (Fig.13), which is responsible for the disruption of cell membrane by tearing the
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lipid bilayer membrane open [130]. Cells can withstand compression better than elongation,
which may act as the main component that determines pore formation. Scanning electron
microscopy studies have already shown that membrane poration occurs after US and MBs
treatment [152]. Mehier-Humbert et al. [152] showed an efficient delivery of FITC-dextran (77164 KDa) or particles of 25nm. They showed cell membranes with a pore size distribution up to
75nm with ~60% of cells being positive for delivery of the particle. Pore formation allows for
direct transfer of molecules into the cytoplasm. Van Wamel et al. [151] have also shown that PI
does not enter a cell 1 min after the US exposure. These results support the general idea that the
pores reseal quickly upon termination of US. Mehier-Humbert et al. [152] showed that almost all
the routes of entry had closed 5 seconds after termination of US. The action of MBs on cells is a
mechanical one and can be as important as chemical stimuli in determining vascular fate or
pathological state. The most important biomedical application of the sonoporation technique is
that it allows the introduction of membrane-impermeable xenomolecules (synthetic molecules)
such as dyes, hormones, proteins, plasmids, etc. into living cells [93].

Figure 12. Proposed model of the oscillating microbubble enforced pore formation in the cell
membrane. The pushing and pulling behavior of the microbubble causes rupture of the cell
membrane creating a hydrophilic pore allowing trans-membrane flux of fluid and
macromolecules. (Adapted from van Wamel et al., Journal of Control Release 2006 [93]).
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Paracellular transport
Drugs can be delivered by paracellular transport between functional endothelial cells with
MBs. Transport by low-frequency US is strongly supported in the literature [153]. When a sound
wave is propagated through a liquid medium, steady currents (Fig. 13) are set up in the direction
of beam as a result of momentum transfer [126]. This acoustic streaming (Fig. 13) occurs around
MBs undergoing stable bubble oscillations (Fig. 13) within the US field growing in size via
rectified diffusion [154]. These eddying flows may, in turn, impose shear stresses on nearby
surfaces, such as cell membranes, and it is thought that this may promote the uptake of
therapeutic components [130, 155]. When a MB oscillates near a vessel wall (Fig. 13), its shell is
estimated to travel at speeds on the order of 250 m/s [156], either by directly perturbing nearby
structures or by causing local fluid convection [157]. The acoustic radiation forces cause bubbles
to move in the direction of the wave propagation by bringing them in contact with vessel
endothelium [158]. Radiation pressure may be involved in Focused US + MBs-based blood brain
barrier opening through activating the stretch-sensitive or mechanosensitive (MS) ion channels
in the vascular endothelium [159]. MS channels are now known to be implicated in many basic
cell functions [160]. During localized elongation of cell membranes the MS channels are
activated by the conformational changes [161, 162]. The resulting openings are reversible [163].
Endothelial cell morphology can vary significantly between normal and diseased organs.
The tissue microenvironment surrounding blood vessels seems to control the endothelial cell
phenotype in vivo [164]. Thus the blood vessels or microvasculature in the brain differs from
other organs. BBB is known to restrict the paracellular translocation of large hydrophilic
macromolecules and toxic compounds into the brain via specific membrane located transport
systems [165]. When MB oscillations occur in the cerebral microcirculation, the BBB is
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disrupted, causing drug extravasation due to breakdown of transmembrane tight junction proteins
that regulate the paracellular permeability of the endothelial cell layer [166].

Figure 13. Possible mechanisms for blood–brain barrier disruption via ultrasound +
microbubbles. Assuming that the effect is not due to bubble collapse (inertial cavitation),
possible effects include stimulation of the endothelial cells via radiation force on the bubbles,
bubble oscillation or from microstreaming of the fluid around the bubbles. (Adapted from
Vykhodtseva et al, Ultrasonics, 2008 [159].)

Transcytosis/Intracellular transport
MB cavitation can also provoke drug transport through a vascular endothelial cell.
Transcytosis or intracellular transport (Fig. 11), in the context of drug delivery, consists of the
drug being endocytosed at the luminal surface of the endothelial cell membrane [80].
Transcytosis can be achieved through either a receptor-mediated fashion [167] or by invagination
caused by cavitation with US [168]. Ghitescu et al. [167] showed specific adsorptive binding of
albumin complexes to plasmalemmal vesicles and clustering in uncoated pits. Plasmalemmal
vesicles allow endothelial cells to transport molecules, such as proteins, from the blood that are
too large to diffuse through cell junctions or fenestrae, and this transport takes place both by
vectorial transcytosis (vesicles) and by connective transcytosis (channels) (Fig. 11). Ghitescu et
al [167], also demonstrated that albumin can stimulate endocytosis and transcytosis (Fig.11) in
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mouse pulmonary and myocardial endothelium. Thus, albumin coated MBs could potentially
undergo endocytosis through similar process. Subsequent transportation through several
intracellular compartments and secretion from the cell at the basolateral aspect [169] results in
delivery to vascular tissue. MBs could undergo endocytosis via caveolar, an alternative pathway
for targeted drug delivery [170]. Endocytosis through caveolar is a receptor-mediated process via
receptor-targeted drug vesicles [80, 171].
According to Chen et al. [168], invagination occurs when bubbles collapsed near the
vessel wall that results in the vessel wall being pulled inward toward the lumen. Invagination
causes higher strain on the vessel wall than distention resulting in vessel rupture [168]. This
localized mechanical destruction of the endothelial membrane results in endocytosis and
subsequent transcytosis (Fig.12). Cavitating MBs near the cell membrane can create a pore for
increased membrane permeability to macromolecules, genes such as wt-p53 (plasmid vector)
[172] and extracellular ions such as Ca+2 [173], which is repaired by cellular mechanisms within
seconds [174]. Meijering et al. [95] demonstrated that endocytosis plays a key role in UMTD of
macromolecules sized between 4 and 500 kDa. Dextran molecules of 155 and 500 kDa were
mainly localized in vesicle-like structures after UTMD as a result of macropinocytosis, clathrinmediated and caveolin-mediated endocytosis. MBs also showed increased membrane
permeability to extracellular ions is upregulated by endocytosis due to the calcium flux into the
cell [95]. The types of MB oscillations required to observe these effects have also been
investigated. Inertially cavitating MBs near the cell membrane form 1 - 200 nm pores due to
localized tensions [175]. These pores are capable of resealing bifunctionally by either rapid
phospholipid rearrangement or gradual, exocytosis-mediated membrane tension changes, which
restore membrane integrity [173]. Thus, US enhanced endocytosis is an important pathway for
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targeting drug delivery by UTMD [80].

Enhanced Permeability and Retention Effect
UCAs are typically used to study the vasculature in animals and humans, thus employing
them to study the aberrant tumor vasculature due to angiogenesis is a natural transition.
Perfluoropentane filled silica nanoshells and microshells have been used to selectively image a
tumor in a mouse ovarian tumor model [176]. Tumor angiogenesis is characterized by branching
vessels with irregular diameters ranging from 10 to 200μm [177] and a lack of defining
structures such as arterioles, capillaries, or venules [178]. Tumors induce angiogenesis to
increase their nutrient and oxygen supply. The particular property of angiogenic vessels is their
rapid growth from established vessels renders them “leaky” and defective. According to
Pasqualini et al. [179] and Li [177], the tumor microvasculature has a vascular pore cutoff size
from as low as 380nm up to 780nm, and the endothelial cells are misaligned or have large
fenestrations. This phenomenon, which is generally referred to as the Enhanced Permeability and
Retention (EPR) effect, can achieve high local concentrations of nano-encapsulated drugs at a
tumor site (10- to 50- fold higher than in normal tissue) [99]. US exposure can enhance the size
of these leaky vascular pores allowing for micron sized bubbles to collect at the tumor site. At
the breast cancer (SK-BR-3) tumor site Zhao et al. [180], with phospholipid MBs, showed
membrane pore diameter of 1-2µm with US exposure of 30 sec, diameter of 2-3µm with US
exposure of 60 seconds and diameter of 3-5µm with US exposure greater than 60 seconds. Thus
the EPR effect seen in tumors can be extremely beneficial in treating cancer.
Submicron bubbles could show higher intracellular uptake than microsized bubbles,
allowing drug-release in different cellular compartments such as cytoplasm and nucleus [99].
The ability to synthesize nanobubbles has opened up further opportunities to deliver therapeutic
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agents which require targeted extravasation into the tissues as micrometer sized MBs are
typically too large to exit the vasculature. A prerequisite for this process is that the nanocarrier
stays in the blood long enough to slowly accumulate in the tissue of interest with affected and
leaky vasculature [99]. Nanometer sized bubbles can potentially exhibit an improved circulating
lifetime [178]. The radiation force generated by insonofication [181] with the medical
ultrasonography equipment can force the nanobubbles or MBs towards pores in these vessels and
induce penetration of nanobubbles or MBs through the pores. The penetration of MBs results in a
higher concentration of contrast in the tumor, a better visualization of the acoustic imaging and a
targeted delivery of drug payload. In addition, the drug containing nanobubbles can be made
slowly biodegradable, thus delivering their payload at a controlled rate [99]. These properties of
the micro- or nano- bubbles make them an efficient drug delivery system for treating cancer. The
most successful nano-bubble system consists of liquid paclitaxel loaded into perfluorocarbon
emulsions that become echogenic when accumulated at the site of interest such as ovarian, breast
and pancreatic cancer [182, 183].
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Uses of Microbubbles
Cavitation of MBs and its subsequent bio-effects on the vasculature and tissue cells
shows the potential of using MBs as delivery vehicles. The chemical, physical and structural
properties of the MBs also enhance the notion of using them to deliver therapeutic agents. Drugs
can be incorporated into the MBs in a number of different ways, including binding of the drug to
the MB shell and attachment of site-specific ligands. Drugs can also be imbedded in the
membrane or loaded internally with the therapeutic agents and gas (Fig. 14).

Figure 14. Manipulation of the microbubble shell for gene and/or drug delivery. (A) Drugs (red
diamonds) may be attached to the surrounding microbubble membrane. (B) Materials may be
imbedded in the membrane. (C) Bubbles may be loaded internally with the therapeutic agents
and gas. (D) Hydrophobic drugs may be incorporated into an oily emulsion that forms a film
around the bubble, which is then surrounded by a stabilizing membrane. (Adapted from Unger et
al., European Journal of Radiology, 2002 [184].)
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Subsequently, hydrophobic drugs may be incorporated into an oily emulsion that forms a film
around the bubble, which is then surrounded by a stabilizing membrane (Fig. 14).
Perfluorocarbon-filled MBs act as carriers of these agents until the site of interest is reached as
they are sufficiently stable for circulating in the vasculature as blood pool agents [185].
Ultrasound applied over the skin surface can then be used to burst the MBs at this site, causing
localized release of the drug [172, 186-188]. The use of US and MBs lowers the concentrations
and reduces the systemic side effects of hazardous drugs like cytotoxic agents thereby improving
the therapeutic index [185]. Thus, there is an increasing interest in developing noninvasive
delivery methods for gene therapy and chemotherapeutics.
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CHAPTER III : ULTRASOUND TARGETED MICROBUBBLE DELIVERY IN
PROSTATE CANCER CELLS
ABSTRACT
Background
The use of human adenoviruses (hu-Ads) in gene transfer studies is limited because of their
immunogenic nature. To circumvent this limitation we have developed a novel approach
constituted of hu-Ads encapsulated inside microbubbles (MBs). The melanoma-differentiationassociated-gene-7 or interleukin-24 (mda-7/IL-24) is a tumor suppressor with pro-apoptotic
activity against several cancers. However, to translate the site-specific gene transfer of Ad.mda-7
complexes by ultrasound-targeted microbubble destruction (UTMD) from the bench to the
bedside, studies involving the use of immune-deficient animal and immune-competent mice
models are required.

Hypothesis
It has been shown that transfer of genes to mouse cells using hu-Ads is dependent on the
expression of Coxsackie and Adenovirus Receptor (CAR) and certain integrins, which mediate
hu-Ad attachment and internalization. Our hypotheses are that the murine derived prostate cancer
cells will express CAR and/or a,ß integrins and will be transduced by hu-Ads. Microbubbles will
protect the viruses from inactivating substances such as complement. UTMD will enhance gene
transfer in both DU145 and murine PC cells regardless of complement rich FBS media.

Methods
We investigated the expression of CAR and a,ß integrins in murine and control human DU145
PC cells by flow cytometry analysis. We tested the infectivity of Ad.GFP (green fluorescent
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protein) and Ad.mda-7/IL-24 on both murine and DU145 prostate cancer cells. Viral burst assay
was carried out on murine and DU145 PC cells with the CTV.Mda-7 oncolytic adenovirus to
measure viral replication. We also tested the microbubble delivery of Ads with ultrasound in cell
culture. Western blot analysis confirmed mda-7 protein expression following Ad-transduction.
Annexin-V studies assessed the pro-apoptotic effect of the Ad.mda-7/IL-24.

Results
Our studies showed that cells express CAR receptor, a,ß integrins and that Ad.GFP and Ad.mda7/IL-24 transferred their transgene in the murine and human DU145 prostate carcinoma cells.
Murine PC cells were unable to replicate the CTV oncolytic virus. Additionally, mda-7/IL-24
significantly increased the apoptotic rate of the murine and DU145 transduced cells.
Microbubble delivery of Ads with ultrasound in cell culture enhances gene transfer into the cells
regardless of the complement rich FBS media.

Conclusion
Our study demonstrated the feasibility of using human DU145 prostate adenocarcinoma cells and
TRAMP-C2 cells derived from a murine model of prostate cancer to translate the ultrasoundmediated microbubble Adenovirus delivery system that we have developed.
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INTRODUCTION
For more than four decades, human adenoviruses have served as an excellent model
system to study molecular mechanisms controlling cell cycle progression and cell death. More
than 60 types of HAdV have currently been identified and divided into eight species, designated
A, B1, B2, C, D, E, F and G. Members of the different species use different receptors for virus–
host interactions and some are currently characterized as potential viral vectors in cancer gene
therapy. HAdV show strict host specificity. Murine cells lack some of the receptors needed for
HAdV infection such as the Coxsackie and Adenovirus Receptor (CAR), thus, murine cells are
generally refractory (non-permissive) for HAdV infection and replication, although a very low
level of HAdV infection and replication has been described in some mouse cells [189, 190].
Melanoma differentiation associated gene-7 also called interleukin-24 (mda-7/IL-24) is
well-known for its pro-apoptotic, anti-angiogenic, radio-sensitizing, immune-stimulatory
properties and bystander activity on distant tumors [53, 191-197]. Mda-7/IL-24 is a
multifunctional suppressor gene belonging to the IL-10 family of cytokines [198, 199]. When
delivered by HAdV vector, mda-7/IL-24 induces apoptosis selectively in almost all cancer cells
while leaving normal cells unharmed [195]. Mda-7/IL-24 can be expressed and secreted from
naïve normal and cancer cells thereby enhancing its apoptotic activity against primary and
metastatic cancer [194]. Thus, HAdV expressing mda-7 should provide both tumor selectivity
and adequate induction of newly synthesized mda-7/IL-24 [53].
Gene therapy by adenoviral vectors has shown promising results in treating locally
advanced cancers; however, due to their immunogenicity they trigger both adaptive and innate
immune responses. The antigenic nature of Ads leads to their rapid inactivation by neutralization
antibodies and clearance by the immune system. Ad vectors elicit an innate immune response
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through the myeloid differentiating factor 88 (MyD88)/Toll-like receptor (TLR)-9 resulting in
the production of type I interferons (IFNs), interleukin (IL)-6 and IL-12 inflammatory cytokines
[200, 201]. Additionally, unmodified viruses are generally non-specific in their action and this
limits their use to direct target tumor or organ injection [53]. To circumvent these limitations we
developed a novel approach wherein Ads are encapsulated inside the shell of acoustically active,
lyophilized, lipid-encapsulated, perfluorocarbon microbubbles (MBs) (ultrasound (US) contrast
agents), which act as delivery vehicles for a site-specific gene transfer system. MBs protect the
viral payload from detection and rapid degradation by the hosts’ immune system allowing for an
intravenous (IV) injection rather than intratumoral (IT) injection [53, 202]. US breaks open the
MB/Ads complexes by inducing cavitation, which allows Ads to transfer their transgene only to
the sonoporated region. Cavitation of the MBs creates small shockwaves that increase cell
permeability by forming temporary micropores on the cell surface bypassing the receptormediated dependence of HAdV. Our novel viral delivery technique mediated by MB and US
brings new hope to the frontier of gene therapy and its use in clinical settings.
In order to facilitate the translation of this technology into human application, we
envision testing an adenovirus carrying mda-7 (INGN 241) that is already in phase-I and -II
clinical trials in patients with multiple solid tumors (none of which is of prostate origin) in
treating PC cells [203]. In vivo studies involving the use of immune-deficient and immunecompetent PC mice models are required. Thus, we studied the capacity of human Ad.mda-7/IL24 to infect mouse PC cells (TRAMP-C2) derived from immune-competent mice and compared
it to human PC (DU145). We also studied the effect of Ad.mda-7/IL-24 to increase the apoptotic
rate of TRAMP-C2 and DU145 prostate cancer cells following mda-7 gene transfer. Lastly, we
tested US guided MB assisted gene delivery of reporter Ad.GFP in both murine and human PC.
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MATERIALS AND METHODS
Cell Lines and Cell Culture
The DU145 (human prostate adenocarcinoma), TRAMP-C2 (mice prostate
adenocarcinoma) and human kidney embryonic 293 cell lines were obtained from the American
Type Culture Collection (ATCC, Rockville, MD). DU145 cells were grown in RPMI 1640
(Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Waltham, MA), and 100 units/mL penicillin supplemented with 1 mg/mL streptomycin (both
from Hyclone, Waltham, MA). The 293 cells were grown with Dulbecco’s modified Eagle’s
medium (Hyclone, Waltham, MA) supplemented with 10% FBS (Hyclone, Waltham, MA).
TRAMP-C2 cells were grown with Dulbecco’s modified Eagle’s medium (Hyclone, Waltham,
MA) supplemented with 5% FBS (Hyclone, Waltham, MA), and 100 units/mL penicillin
supplemented with 1 mg/mL streptomycin (both from Hyclone, Waltham, MA). All cells were
grown at 37ᴼC, in a 5% CO2/95% atmosphere incubator.

Cytological Observations
The cells were examined under an inverted Olympus IX70 microscope (Olympus
America, Inc. Melville, NY). Fluorescence images were captured with Sensicam QE camera
(Cooke Co., Auburn Hills, MI) and managed with the SlideBook 3.0 software (Intelligent
Imaging Innovations Inc., Denver, CO).
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Adenoviral Production and Purification
Ad-GFP, which expresses the green fluorescence protein gene under the strong
cytomegalovirus (CMV) constitutive promoter was generated using the AdEasy system
(Carlsbad, CA); the conditionally replication competent cancer terminator virus CTV.Mda-7
(Ad.PEG-E1A-mda-7) [18, 204, 205] and Ad.mda-7 [206] were amplified and purified with the
BD Adeno-X virus purification kit (BD Biosciences, Mountain View, CA) following
manufacturer’s directions. Viral titers were determined by a plaque assay and the titer was
adjusted to 1.2x1012 plaque-forming units (pfu)/mL as described [206]. CTV.Mda-7 (Ad.PEGE1A-mda-7) and Ad.mda-7/IL-24 were provided by Dr. Paul Fisher (Virginia Commonwealth
University, Richmond VA). Each viral stock was propagated and purified from 293 cell cultures.
Cells were harvested 24-36 hours after infection, pelleted and re-suspended in heat-inactivated
media. 293 cells were lysed by a three-freeze/thaw cycle method. Cell debris was removed.
Viruses were purified by chromatography followed by dialysis. Viruses are aliquoted and stored
at -80°C. Viral titers were determined by a plaque assay. Ad transductions were performed using
10, 25, 50 MOI Ads, in RPMI-1640 media with 2% Fetaclone-III heat-inactivated FBS
(Hyclone, Thermo Scientific, Waltham, MA) and in with DMEM media with 2% Fetaclone-III
heat-inactivated FBS (Hyclone, Thermo Scientific, Waltham, MA). Cells were collected after
24- or 48-hours.

Viral Burst Assay
HEK 293 cells were used as control. HEK 293 cells, DU145 cells, TRAMP-C2 cells were
infected with replicative HAdV (CTV.Mda-7) at 100 pfu/mL and 1,000 pfu/mL. Filtered
transfection supernatants and viral particles present in the cells were collected at both 24 and 48
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hours post-transfection. Cells were harvested 24- and 48- hours after infection, pelleted and resuspended in heat-inactivated media. 293 cells were lysed by a three-freeze/thaw cycle method.
Cell debris was removed. Viruses are aliquoted and stored at -80ᴼC. The collective viral particles
were tittered and determined by a plaque assay.

Antibodies
The following primary antibodies were used in Western Blot studies: mouse monoclonal
anti-Mda-7/IL-24 k101 (GenHunter Corporation) (1:2,000 incubation for overnight), GFP
cat#632377 (1:500) (BD Bioscience) and β-actin cat#A3853 (1:1,500) (Sigma Aldrich) as a
control. The following are used in the flow cytometry studies: Rabbit Anti-Coxsackie
Adenovirus Receptor Polyclonal Antibody, Alexa Fluor® 488 Conjugated bs-2389R-A488,
Rabbit Anti-Integrin Alpha V + Beta 5 Polyclonal Antibody, Alexa Fluor® 647 Conjugated bs1356R-A647 and Rabbit Anti-Integrin Alpha V + Beta 3 (CD51+CD61) Polyclonal Antibody,
Alexa Fluor® 488 Conjugated bs-1310R-A488 from Bioss Inc.

Western Blot Analysis
DU145 and TRAMP-C2 cells were transduced with 10, 25, 50 multiplicity of infection
(MOI) of Ad.GFP and Ad.mda-7. Western blot analysis was conducted as previously described
[53]. Cells were lysed on ice for 1hr with lysis buffer. Fifty μg of total protein plus loading
buffer were loaded in each well for western blot analyses. SDS-PAGE was run using 8-12% bisacrylamide gel at room temperature. Samples were blotted onto a nitrocellulose membrane. To
detect proteins the membranes was blocked with 5%Milk-TBST overnight at 4ᴼC and reacted to
primary antibodies for 2hr at room temperature with constant motion on an orbital shaker. The
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membranes were washed with TBST to remove excess primary antibodies. Incubation for 45
minutes with appropriate secondary antibodies followed. Immunodetection was performed using
the enhanced chemiluminescence (ECL) system (Amersham, IL) according to the manufacturer’s
instructions. Western blot analyses with antibodies against the targeted proteins were performed
to validate successful viral transfection of the cells.

Flow Cytometry Assay
DU145 and TRAMP-C2 cells were checked for different surface Ad receptors such as
CAR (coxsackie adenovirus receptor) and integrins αVβ3/5. Each was compared against IgG
control. 10µL of Boss primary conjugated antibody was added for 30 mins at 4ᴼC, aashed
several times with 2mL 1X PBS and resuspended in 100µL of 1X PBS. Samples were analyzed
on BD Accuri C6 Flow Cytometery.
Adenoviral transduced DU145 and TRAMP-C2 cells were trypsinized and collected.
Cells were centrifuged at 5000 rpm, washed and suspended in 1% FCS-PBS. This step was
repeated three times. Samples were prepared and run by a BD Accuri C6 Flow Cytometer (BD
Bioscience, San Jose, CA). Single cells population was gated and an FL1 & FL4 area histogram
was drawn and formatted to show only the events inside the single cell region.

Annexin-V Assay
Apoptotic cells were analyzed with fluorescein isothiocyanate (FITC) conjugated to
Annexin-V antibody and Propidium Iodide (PI) from the Annexin-V/FITC Kit (Bender
MedSystems, Burlingame, CA) following manufacturer's instructions. Cells were trypsinized and
washed with PBS. Cells were centrifuged and re-suspended in binding buffer. The samples were
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analyzed with BD Accuri C6 Flow Cytometer (BD Bioscience, San Jose, CA). Annexin-V assay
experiment was repeated three times and was run as triplicate of technical repeats. Statistical
analysis was performed with GraphPad Prism 6 statistical software.

UTMD for Prostate Cancer Cells.
Human DU145 and murine TRAMP-C2 prostate cancer cells were grown in both Fetal
Bovine Serum (FBS) rich media and Heat-inactivated FBS media. Targeson (Targeson, Inc. San
Diego, CA) custom synthesis US contrast agent (perfluorocarbon microbubbles, encapsulated by
a lipid monolayer and polyethylene glycol stabilizer) were prepared following manufacturer’s
instructions [53]. Cells were infected with Ad.GFP with 10MOI or with Ad.GFP complexed with
microbubbles (Targeson) at 10MOI. US exposure was achieved with a Micro-Maxx SonoSite
(SonoSite, Bothell, WA) US machine equipped with the transducer L25 set at 0.7 Mechanical
Index (MI), 1.8 MPa for 1 min [53].

Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 6 statistical software.
Comparison of cell death by Annexin-V on adenoviral transduced groups was conducted using
an ANOVA test with post hoc test Tukey’s multiple comparison test. P-values of less than 0.05
were considered statistically significant.
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RESULTS
Cytological Observations after Adenoviral Gene Transfer
The murine TRAMP-C2 and human DU145 prostate cancer cells were transduced with
an Ad carrying the green fluorescence protein (GFP) (Ad.GFP) (Fig.15) with increasing doses of
10, 25 and 50 MOI (multiplicity of infection). TRAMP-C2 cells and DU145 cells infected with
various doses of Ad.GFP showed a dose dependent increase of fluorescence. However, DU145
cells showed a higher transduction of GFP in comparison to TRAMP-C2 cells at each
multiplicity of infection.

Figure 15. Fluorescence microscopy images of Ad.GFP (10, 25, 50 MOI) transduced TRAMPC2 and DU145 cells. We effectively infected TRAMP-C2 cells with Ad.GFP and observed a
dose-dependent expression of GFP, which was correlated to the increasing amount of Adenoviral
MOI used.

60

Quantification of the Ad.GFP Viral Uptake
Ad.GFP uptake was determined for murine TRAMP-C2 and human DU145 prostate
cancer cells by using FACS analysis after infecting the cells with 10, 25 and 50 MOI. A
discrepancy is observed for TRAMP-C2 cells when infected with 10MOI, showing only a 90%
uptake of Ad.GFP. A dose dependent increase in uptake of Ad.GFP is observed in TRAMP-C2
cells as the MOI is increased. DU145 cells on the contrary showed a 100% uptake regardless of
MOI (Fig. 16).

Figure 16. In vitro assessment of Ad.GFP uptake in murine and human carcinoma cell lines.
Cells were infected at 10, 25 and 50 particles/cells (ppc) of Ad.GFP and harvested at 24 hours
post-infection to determine the infectivity by FACS analysis.

Quantification of Ad Receptors Present on the Surface of the Cells
Surface Ad receptors were determined by Accuri C6 flow cytometry for the percentage of
expression of Coxsackie Adenovirus Receptor (CAR), integrin αVβ5 and αVβ3 that are known
to be responsible for the attachment of Ad5 to mammalian cells (Table 2). Both human DU145
and murine prostate cancer cells showed a similar expression profile for CAR and integrins
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αVβ3/5.
Table 2. Determination of the expression of surface Adenoviral receptors by flow cytometry.

Cells
DU145

αVβ5

CAR

αVβ3

90.08±1.71 95.98±0.17 28.58±1.13

TRAMP-C2 96.60±0.22

93.9±1.38

32.70±1.97

Verification of Protein Expression by Western Blots
The TRAMP-C2 cell line is generated from prostate tumors harvested from a 32-week
TRAMP mouse. We carried out infection studies with Ad5 carrying mda-7 or GFP at different
multiplicities of infection (MOI). Figure 17 shows dose dependent expression of GFP and mda-7
protein by western blot analysis (Fig. 17). The results show that we effectively transferred to
murine PC cells a transgene (GFP or mda-7) with Ad5 viruses.

Figure 17. Western blot analysis of TRAMP-C2 and DU145 cells infected with different MOIs
of Ad.GFP or Ad.mda-7/IL-24. Cell lysates were run on SDS-PAGE and reacted with
appropriate specific primary and secondary HRP-conjugated antibodies. Beta actin was used as
a loading control.
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Viral Burst Assay to Assess the Capacity of Replicative HAd5 to Produce Viral Particles
The control HEK 293 embryonic kidney cells and human DU145 prostate cancer cells
showed an increase in viral count at both 24 and 48 hours post infection of 100 pfu/mL and
1,000 pfu/mL replicative competent HAd5 (CTV). Thus, DU145 and HEK 293 are permissive
for the replication of HAd5 and would make good animal models for testing the replicative and
transfection ability of HAd5. However, TRAMP-C2 cells showed a decrease in viral count from
24 to 48 hours for both pfu of HAd5 indicating a lack of viral replication (Fig. 18). Thus
TRAMP-C2 cells are non-permissive for replication of HAd5 and would make a good animal
model only for the transfection ability of HAd5.

Figure 18. Subconfluent murine and human cell lines were infected with replicative competent
HAdV at 100 pfu/mL and 1,000 pfu/mL and harvested 24- and 48-hours later.

Annexin-V Staining for Cell Death
The apoptotic rate of the transduced cells was quantified by assessing Annexin-V
expression. The analyzed cells were allocated in a quadrant diagram according to their DNA
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content and the presence of Annexin-V on the extracellular cell membrane during apoptosis.
Statistical analysis was run on Annexin-V triplicates using Graphpad Prism 6 software for an
ANOVA on dead cells with a post hoc test of Tukey’s multiple comparison test (Fig. 19 and
Table 3). TRAMP-C2 and DU145 cells were undergoing apoptosis and necrosis, collectively
called as dead cells. Non-transduced cells were compared to Ad.mda-7/IL-24 transduced cells.
Mean and standard deviation from Annexin-V experiment was calculated for each adenoviral
treated group. There was an increase in the significance and percentage of cell death that was
concentration dependent compared to the control. A significant percentage of cell death for
TRAMP-C2 cells infected with 50MOI was observed in comparison to 10MOI of Ads (Fig. 19
and Table 3). Cell death observed for TRAMP-C2 cells infected with 10MOI and 25MOI did not
show any significant difference in comparison to DU145 cells infected with 10MOI. However,
overall DU145 cells showed more cell death with Ad.mda-7 at 25MOI and 50MOI in
comparison to TRAMP-C2 cells infected with the same MOI.

Figure 19. Annexin-V/PI staining of TRAMP-C2 and DU145 cells infected with Ad.mda-7/IL24. TRAMP-C2 cells were transduced with Ad.mda-7/IL-24 at 10, 25 & 50 multiplicity of
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infection (MOI) and harvested at 96 hours post infection and determined by FACS analysis. Bar
graph represents sum of apoptotic and necrotic cells.

Table 3. ANOVA (Analysis of Variance) significance table with a Post Hoc Tukey’s multiple
comparison test for Annexin-V assay between TRAMP-C2 and DU145 cells transduced with
Ad.mda-7/IL-24. * The mean difference is significant at the 0.05 level.
Comparison between groups
Significant?
Yes
TRAMP-C2:Control TRAMP-C2:10MOI
TRAMP-C2:Control

TRAMP-C2:25MOI

Yes

TRAMP-C2:Control

TRAMP-C2:50MOI

Yes

TRAMP-C2:Control

DU145:Control

No

TRAMP-C2:Control

DU145:10MOI

Yes

TRAMP-C2:Control

DU145:25MOI

Yes

TRAMP-C2:Control

DU145:50MOI

Yes

TRAMP-C2:10MOI

TRAMP-C2:25MOI

Yes

TRAMP-C2:10MOI

TRAMP-C2:50MOI

Yes

TRAMP-C2:10MOI

DU145:Control

Yes

TRAMP-C2:10MOI

DU145:10MOI

No

TRAMP-C2:10MOI

DU145:25MOI

Yes

TRAMP-C2:10MOI

DU145:50MOI

Yes

TRAMP-C2:25MOI

TRAMP-C2:50MOI

Yes

TRAMP-C2:25MOI

DU145:Control

Yes

TRAMP-C2:25MOI

DU145:10MOI

No

TRAMP-C2:25MOI

DU145:25MOI

Yes
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TRAMP-C2:25MOI

DU145:50MOI

Yes

TRAMP-C2:50MOI

DU145:Control

Yes

TRAMP-C2:50MOI

DU145:10MOI

Yes

TRAMP-C2:50MOI

DU145:25MOI

No

TRAMP-C2:50MOI

DU145:50MOI

Yes

DU145:Control

DU145:10MOI

Yes

DU145:Control

DU145:25MOI

Yes

DU145:Control

DU145:50MOI

Yes

DU145:10MOI

DU145:25MOI

Yes

DU145:10MOI

DU145:50MOI

Yes

DU145:25MOI

DU145:50MOI

Yes

UTMD for Prostate Cancer Cells.
Human DU145 and murine prostate cancer cells were infected either with Ad.GFP or
complexed Ad.GFP/MB at 10MOI and after 24hours images were taken with fluorescent
microscopy. US application increased the expression of GFP in comparison to the control or
Ad.GFP alone group for both DU145 and TRAMP-C2 cells (Fig. 20 and 22). US also allowed
for the transfection of Ad.GFP in complement rich FBS media for both DU145 and TRAMP-C2
cells (Fig. 20 and 22).
MBs also facilitated the transfection of Ad.GFP in both FBS rich and Heat Inactivatedcomplement depleted FBS media (Fig. 21 and 23). Transfection increased further when Ad.GFP
was complexed with a MB (Ad.GFP/MBs) and US was applied to both DU145 and TRAMP-C2
cells (Fig. 21 and 23). Similar GFP expression was observed for DU145 when complexed
Ad.GFP/MBs were incubated with FBS and US was applied regardless of media being used (Fig.
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21) because FBS contains a complement, which binds to the free Ads on the surface of the
bubble thereby inactivating the Ads. Similar observation was also recorded for TRAMP-C2 cells
(Fig. 23). Lastly, unclean complexed Ad.GFP/MBs showed similar GFP expression compared to
cleaned (FBS incubated) complexed Ad.GFP/MBs in complement rich FBS media (Regular
media). Highest transfection was observed for DU145 cells that received the unclean (FBS
untreated) Ad.GFP/MBs and US (Fig. 21).

Figure 20. DU145 cells infected with Ad.GFP at 10MOI and Ultrasound application.
*Flo:Florescence, HI:heat inactivated, US: Ultrasound, Regular media: contains fetal bovine
serum (FBS).
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Figure 21. DU145 Cells infected with Ad.GFP/MBs at 10MOI and Ultrasound application. In
second column MBs rehydrated with PBS was added separately with Ad.GFP at 10MOI. In the
third column Ad.GFP/MBs were complexed but not cleaned with FBS before adding it to the
cells. In the fourth column Ad.GFP/MBs were complexed and cleaned with FBS before adding it
to the cells. *Flo:Florescence, HI:heat inactivated, US:Ultrasound, Regular media: contains fetal
bovine serum (FBS).

Figure 22. TRAMP-C2 cells infected with Ad.GFP at 10MOI and Ultrasound application.
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*Flo:Florescence, HI:heat inactivated, US: Ultrasound, , Regular media: contains fetal bovine
serum (FBS).

Figure 23. TRAMP-C2 cells infected with Ad.GFP/MBs at 10MOI and Ultrasound application.
In second column MBs rehydrated with PBS was added separately with Ad.GFP at 10MOI. In
the third column Ad.GFP/MBs were complexed but not cleaned with FBS before adding it to the
cells. In the fourth column Ad.GFP/MBs were complexed and cleaned with FBS before adding it
to the cells. *Flo:Florescence, HI:heat inactivated, US: Ultrasound, Regular media: contains
fetal bovine serum (FBS).
.
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DISCUSSION
There are many obstacles to successful virotherapy that have become apparent from
clinical studies, including problems associated with the use of replicating human Ads that are
species-specific as the non-human (animal) model systems rarely predict the outcome seen in
humans. For example, human tumor xenografts in nude mice can provide a ‘permissive’
preclinical model for Ads but nude mice are by definition immune-compromised [190], thus the
immune responses due to Ads cannot be fully studied in this pre-clinical model. Additionally,
due to species specificity, Ads do not replicate in normal mouse tissues thereby preventing any
relevant off-target effects in such systems. Lastly, immune-compromised mice have a deficient
immune system thus making it difficult to observe the effects of immune modulatory viruses
[56], thus more suitable animal models need to be selected for the desired effect to be observed.
In this study, the ability of both replicating (CTV.mda-7) and non-replicating (Ad.GFP
and Ad.mda-7/IL-24) human Ad5 was tested by infecting human DU145 and murine prostate
cancer cells. The goal of this study was to tested if human DU145 PC cells that are radioresistant, androgen receptor ablated, p53 mutated cells and isolated from a brain metastasis
would make a good pre-clinical model for the use of microbubble assisted gene delivery with
US. This delivery system has several components that needed to be test to ensure successful
translation from bench to bedside. The infection studies on DU145 cells with Ad.GFP, Ad.mda-7
and CTV.mda-7 showed successful transduction with different MOI of replication permissive
HAd5 and demonstrated a therapeutic response to gene therapy with mda-7. Lastly, US greatly
enhanced the transgene expression of GFP when delivered with complexed Ad.GFP/MBs
regardless of the presence of FBS, thus ensuring a proper penetration of the encapsulated Ads
into the cell. FBS acted as a complement protein system inactivating the Ads from infecting
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DU145 cells. US and MBs cause temporary pore formation on the plasma membranes and
increase the permeability of the membrane to allow an increased Ad uptake. These factors make
DU145 xenograts an attractive immune-compromised animal model to test the delivery of
microbubble assisted gene delivery with US.
Similarly, TRAMP-C2 PC cells that are radio-resistant, possessing wild-type (wt) p53,
isolated from 32-week old C57BL6 immune-competent mice with poorly differentiated prostate
carcinoma were tested for the delivery of MB assisted gene therapy with US to verify if they
would make a good pre-clinical immune-competent model. Similar results to DU145 studies
were observed using TRAMP-C2 cells except that infection studies using TRAMP-C2 cells
showed a reduced GFP expression in comparison to the transfected DU145 cells. However, a
dose dependent increase in transgene expression was observed as the MOI were increased. The
transgene expression could not be explained by the Ads surface receptor expression in TRAMPC2 cells, as they are similar to DU145. Also, a reduced therapeutic response was observed for
Ad.mda-7 transfected cells in comparison to DU145 cells, however still statistically significant in
comparison to the control. Thus, murine immune-competent TRAMP-C2 prostate cells that can
be syngeneically implanted into immune-competent C57BL6 would make an attractive model to
study the immune-modulating, immune-responses due to the Ads and the therapeutic benefit of
microbubble assisted US guided gene transfer. Additionally, the TRAMP mouse model of
prostate cancer can be used to demonstrate the validity of UTMD mda-7 gene delivery approach
in immune competent animals.
Successful completion of the immune competent animal studies will open the possibility
to translate from the bench to the bedside the targeted mda-7 gene delivery method by
performing clinical studies on metastatic prostate cancer patients.
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CHAPTER IV: ERADICATION OF THERAPY-RESISTANT HUMAN PROSTATE
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ABSTRACT
Intratumoral injections of a replication-incompetent adenovirus (Ad) expressing
melanoma differentiation–associated gene-7/interleukin-24 (Ad.mda-7), a secreted cytokine
displaying cancer-selective, apoptosis-inducing properties, profoundly inhibits prostate cancer
(PC) growth in immune-incompetent animals. In contrast, Ad.mda-7 is ineffective in PCs
overexpressing antiapoptotic proteins such as Bcl-2 or Bcl-xL. However, intratumoral injections
of a conditionally replication-competent Ad (CRCA) in which expression of the adenoviral E1A
gene is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and
which simultaneously expresses mda-7/interleukin (IL)-24 in the E3 region of the Ad (Ad.PEGE1A-mda-7), a cancer terminator virus (CTV), is highly active in these cells. A major challenge
for gene therapy is systemic delivery of nucleic acids directly into an affected tissue. Ultrasound
(US) contrast agents (microbubbles—MBs) are viable candidates for gene delivery/therapy.
Here, we show that MB/Ad.mda-7 complexes targeted to DU145 cells using US dramatically
reduced tumor burden in xenografted nude mice. Additionally, US-guided MB/CTV delivery
completely eradicated not only targeted DU145/Bcl-xL-therapy-resistant tumors, but also
nontargeted distant tumors (established in the opposite flank), thereby implementing a cure.
These findings highlight potential therapeutic applications of this novel image-guided gene
therapy technology for advanced PC patients with metastatic disease.

Key Words: CTV; mda-7/IL-24; bystander anti-tumor activity; systemic targeted viral gene
delivery; apoptosis induction
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INTRODUCTION
Prostate cancer (PC) is the most common cancer and the second leading cause of cancerrelated deaths in men in the United States [1]. At present, no effective therapy is available for
metastatic PC [207]. Advanced PC is refractory to conventional anticancer treatments because of
frequent overexpression of antiapoptotic proteins Bcl-2 and/or Bcl-xL [208, 209]. The
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), is a secreted cytokine
having broad-spectrum, cancer-selective, apoptosis-inducing properties that profoundly inhibits
prostate cancer cell growth [210]. Adenovirus (Ad)-mediated delivery of mda-7/IL-24 (Ad.mda7) has shown dramatic anti-tumor effects in animal models and in clinical trials [195, 196, 211,
212]. However, forced overexpression of Bcl-2 or Bcl-xL renders prostate cancer cells resistant
to Ad.mda-7 [209]. In contrast, a conditionally replication-competent adenovirus (CRCA) (a
cancer terminator virus- CTV), which expresses mda-7/IL-24 (Ad.PEG-E1A-mda-7) can
abrogate acquired resistance of prostate cancer cells mediated through Bcl-2 and/or Bcl-xL
overexpresion causing growth arrest and apoptosis and selectively replicating in prostate cancer
xenografted cells in athymic nude mice. Moreover, the CTV completely eradicates not only
primary tumors but also distant tumors following repeated intratumoral injections into the
primary tumor site [18, 213].
A major challenge for effective gene therapy is the ability to specifically deliver nucleic
acids and potentially toxic gene products directly into diseased tissue. Progress in gene therapy
has been hampered by concerns over the safety and practicality of viral vectors, particularly for
intravenous delivery, and the inefficiency of currently available non-viral transfection techniques
[214]. Viruses are appealing delivery vectors because of their ability to efficiently transfer genes
with sustained and robust expression. Recombinant Ads are one of the most common gene
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transfer vectors utilized in human clinical trials, but systemic administration of this virus is
thwarted by host innate and adaptive antiviral immune responses which can limit and/or preclude
repetitive treatment regiments [215].
The quest for novel, safe and more efficient systemic gene delivery systems has recently
highlighted ultrasound (US) contrast agents (microbubbles) as a potential candidate for
enhancing delivery of molecules to target tissue [136, 216-218]. Currently used US contrast
agents (microbubbles) contain high-molecular weight gasses with less solubility and diffusivity,
which improves microbubble persistence and allows passage through the microcirculation.
Microbubbles (MB) can be injected in peripheral veins, because the more robust bubbles can recirculate through the systemic circulation numerous times, surviving for several minutes within
the bloodstream [218, 219]. The ideal MB diameter most likely is between 2.5 to 4 µm. MB is
small enough to prevent entrapment within the pulmonary capillary bed (ranging from 5 to 8 µm
in diameter), but big enough to entrap and protect viral vectors such as Ad from the environment.
We previously demonstrated the feasibility of site-specific gene delivery mediated by
diagnostic US using Ad-GFP encapsulated in commercially available US contrast agents in vitro
and in vivo [214]. An additional goal of our previous study was to determine if incubation of the
microbubbles with complement could improve specificity of viral transgene transduction to the
target tissue/organ allowing a simplified approach to encapsulation of the viral vectors with
commercially available contrast agents. In the current investigation we tested a US contrast agent
provided by Targeson, Inc (San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound
platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear array transducer. Targeson’s
agents are lipid-encapsulated perfluorocarbon microbubbles with a mean diameter of 2.5 µm that
can be used in a wide variety of animal models, and are compatible with virtually all ultrasound
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scanners. The gas-filled microspheres effectively lower the energy threshold for non-thermal
cavitation, thus allowing diagnostic transducers operating within the energy levels mandated by
the FDA to be used for drug/gene delivery. Ultrasound-targeted microbubble destruction
(UTMD) enables focal release of entrapped materials as well as the creation of small shock
waves that increase cellular permeability [220]. In addition, the microbubbles protect the viruses
from rapid degradation by the immune system, thus allowing for intravenous (IV) injection
rather than direct target organ delivery by catheter-based approaches or operative bed injection
[214, 218]. The IV injection is particularly important in cancer gene therapy of potentially
inaccessible tumors because the microbubbles may also limit the amount of inflammatory
response to the viruses and may allow repeated injections.
The ultimate goal of our research programs is to develop efficacious therapies for cancer.
A primary focus is to engineer effective and safe delivery systems for viruses, chemotherapeutic
agents and small molecule drugs. In the present study, we provide proof-of-principle for two
essential components of this process, a site-specific gene delivery approach mediated by
diagnostic US generated by a portable platform that works efficiently in vivo in combination with
Ads delivering a highly effective, broad-based cancer gene therapeutic mda-7/IL-24. Evidence is
provided that this combination has profound effects in animal models containing therapyresistant human prostate cancer cells.
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MATERIALS AND METHODS
Cell Lines, Cell Culture and Adenovirus Production
The DU145 (human prostate adenocarcinoma), cell line was obtained from the American
Type Culture Collection (ATCC, Rockville, MD) and the DU-Bcl-xL cell line, which
constitutively expresses elevated levels of Bcl-xL has been described previously [209]. The cell
lines were grown at 37 °C, in a 5% CO2/95% atmosphere, in Dulbecco’s modified Eagle’s
medium (Mediatech Inc., Herndon, VA) supplemented with 10% fetal bovine serum (FBS) from
Hyclone, Inc., (Logan, UT). Ad-GFP, which expresses the green fluorescence protein gene under
the strong cytomegalovirus (CMV) constitutive promoter was generated using the AdEasy
system (Carlsbad, CA); the conditionally replication competent cancer terminator virus CTV
(Ad.PEG-E1A-mda-7) [18, 204, 205] and Ad.mda-7 [206] were amplified and purified with the
BD Adeno-X virus purification kit (BD Biosciences, Mountain View, CA) following
manufacturer’s directions. Viral titers were determined by a plaque assay and the titer was
adjusted to 1.2x1012 plaque-forming units (pfu)/mL as described [206].

Preparation of Microbubbles and Ultrasound Platform
Targeson (Targeson, Inc. San Diego, CA) custom synthesis US contrast agent
(perfluorocarbon microbubbles, encapsulated by a lipid monolayer and polyethylene glycol
stabilizer) were prepared following manufacturer’s instructions. Microbubbles were reconstituted
in the presence or absence of 1 mL of 1.2x1012 pfu of Ads and unenclosed, surface associated
Ads were inactivated as previously described [214]. For in vivo experiments US exposure was
achieved with a Micro-Maxx SonoSite (SonoSite, Bothell, WA) US machine equipped with the
transducer L25 set at 0.7 Mechanical Index (MI), 1.8 MPa for 10 min.
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Antibodies and Western Blot Analysis
DU145 cells were transduced with 50 MOI of Ad.mda-7 or Ad-CMV as a control and 24
or 48-hr post transduction 50 µg of total cell extracts were subjected to Western blot analysis
using a mouse monoclonal anti-MDA-7/IL-24 (GenHunter, Inc, Nashville, TN) (1:2,000
incubation for 1 hr) or the mouse monoclonal anti-GAPDH sc-0411 (1:5,000 incubation for 1 hr)
(SantaCruz, Santa Cruz, CA), as control. Western blot analysis was also conducted on protein
extracts from microbubble/US assisted in vivo transfer of Ad-GFP or mda-7/IL-24 using
antibodies that specifically recognized GFP sc-53882 (SantaCruz, Santa Cruz, CA), MDA-7/IL24 (GenHunter, Nashville, TN), and β-actin sc-47778 (SantaCruz, Santa Cruz, CA). Briefly, 96
hr following targeted microbubble/US assisted in vivo transfer of Ad-GFP, mice were sacrificed
and fresh tumor (right and left flank), heart, lung, liver, and kidney tissues were harvested and
snap frozen in liquid nitrogen. Mice receiving mda-7/IL-24 gene-microbubble US guided therapy
were sacrificed at the endpoint of the study (5-6 wks after gene therapy injections). Tissues were
homogenized and equal amounts of proteins were run on a SDS-PAGE and transferred to a
nitrocellulose membrane. The membrane was then incubated with the monoclonal anti-GFP
1:2,000 for 1 hr at room temperature and then washed three times in TBS-T. Monoclonal antiMDA-7/IL-24 (GenHunter, Inc, Nashville, TN) was incubated 1:2,000 for 1 hr at room
temperature and then washed three times in TBST. Monoclonal anti β-actin (1:5,000) was
incubated 1 hr at room temperature and then washed three times in TBST. Appropriate
secondary HRP-conjugated antibodies 1:20,000 were incubated 45 min at room temperature and
washed three times with TBS-T. Signals were developed on an X-ray film after reaction with an
Electrogenerated Chemiluminescence (ECL) Supersignal kit (Pierce, Rockford, IL).
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Animal Study and Ultrasonic Bubble Destruction
Animal studies were performed in accordance with NIH recommendations and the
approval of the institutional animal research committee. Animal care and humane use and
treatment of mice were in strict compliance with (1) institutional guidelines, (2) the Guide for the
Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC, 1996),
and (3) the Association for Assessment and Accreditation of Laboratory Animal Care
International (Rockville, MD, 1997). All the animals used in these studies were 8- to 12-weekold female/male congenitally athymic BALB/c nude mice, homozygous for the nu/nu allele, bred
in our laboratory. The colony of the mice was developed from breeding stock obtained from
Charles Rivers Laboratories, Wilmington, MA. The mice were maintained in isolation in
autoclaved cages with polyester fiber filter covers, under germ-free conditions; all food, water,
and bedding were sterilized. A total of about 420 nude mice (n=10 each experimental point) were
implanted with the human prostate adenocarcinoma cell lines (DU145 or DU-Bcl-xL) as a
xenograft model (injecting 1.5 X 106 or 2.5 x 106 cancer cells on each flank of the animal). After
~30-days, mice were sedated in an IMPAQ6 anesthesia apparatus (VetEquip Inc, Pleasanton,
CA) that was saturated with 3-5% Isofluorane and 10-15% oxygen with the aid of a precision
vaporizer (VetEquip Inc, Pleasanton, CA) to deliver the appropriate amount of anesthetic and to
induce anesthesia. The mice were placed on a warmed mat with 37°C circulating water for the
entire procedure. A27-gauge needle with a heparin lock was placed within a lateral tail vein for
administration of contrast material. The nude mice received injections of 100 µL of
microbubbles with/without Ads through the tail vein for 5 wks/once a wk. The mice were split
into two control groups (one control group receiving 100 µL of microbubbles and US, and
another control group receiving both microbubbles/Ad-GFP and US) and eight active groups of
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10 mice each (all receiving microbubbles and Ad.mda-7 or CTV and US). Six additional control
groups were set up which received direct i.v. injections of 100µL of the Ads (Ad-GFP, Ad.mda7/IL-24, or CTV) in the presence or not of US. Grayscale US imaging was performed with a
SonoSite scanner (SonoSite, Bothell, WA) equipped with the transducer L25 set at 0.7
Mechanical Index (MI), 1.8 MPa for 10 min. Ultrasound images were recorded as digital clips.
In every experiment, 10 animals for each treatment or control group were used to study tumor
regression. Every experiment was repeated at least twice. Tumor volumes were determined by
measuring the tumors twice a wk with either a caliper or by ultrasound measurements of the
tumor axes. Tumor volumes were determined using the following formula: V = (π / 8) a Χ b2,
where V is the tumor volume, a is the maximum tumor diameter, and b is the diameter at 90° to
a [221]. The mice were humanely sacrificed by placing them in a CO2 gas jar placed in a
ventilated fume hood. The tumors (right and left flank), heart, lungs, kidneys, and liver were
harvested. Tissues to be sectioned were dry snap frozen or placed either in OCT (Sakura Finetek
USA, Inc., Torrance, CA), frozen in liquid nitrogen, and stored at -80°C or were preserved in
neutral buffered formalin at 4°C prior to embedding in paraffin for immunohistochemical
analysis.
Statistical Analysis
All statistical analyses were performed by using SAS version 9.1. Comparisons of tumor
volumes were done separately three times: before the treatment, two weeks after the treatment,
and at the end of the study. Statistical analyses for comparisons of different types of treatments
were done using one-way ANOVA followed by Tukey-Kramer multiple adjusted pair wise tests.
P-value < 0.05 was considered significant.
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RESULTS
Targeson Microbubbles and a SonoSite Portable Micro-Maxx Ultrasound (US) Platform
Efficiently Targets Ad-GFP Viruses to Tumors
We previously documented the feasibility of in vivo gene delivery mediated by diagnostic
US using Ad-GFP encapsulated in a series of commercially available US contrast agents [214].
In the current investigation, we tested a different US contrast agent available from Targeson, Inc
(San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound platform (SonoSite, Inc.,
Bothell, WA) equipped with a L25 linear array transducer. Targeson’s agents are lipidencapsulated perfluorocarbon microbubbles with a mean diameter of 2.5 µm that can be used in
a wide variety of animal models, and are compatible with virtually all ultrasound scanners [222].
Targeson agents are normally sold as already reconstituted contrast agents that are stable for
three months from arrival, and for this study we obtained a custom made freeze-dried Targeson
contrast agent (perfluorocarbon microbubbles, encapsulated by a lipid monolayer and
polyethylene glycol stabilizer) to be reconstituted with the viruses as previously described [214].
To confirm the ability of the lyophilized Targeson US contrast agent to deliver viruses
efficiently and specifically to defined sites in vivo, we performed a pilot study in which tumor
xenografts were established in both flanks of athymic nude mice by injecting each site with 2 x
106 DU145 human prostate carcinoma cells (Figure 24A). The DU145 tumor-bearing nude mice
(n=10) were then injected in their tail vein with 100 µL of US contrast agent that was
reconstituted with Ad-GFP or water as control. A portable SonoSite Micro-Maxx ultrasound
platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear array transducer set at 0.7
Mechanical Index (MI), 1.8 MPa for 10 min was used to sonoporate only the tumor implanted on

82

the right side (Figure 24A). Mice were sacrificed 96 hr after treatment and tumors (right and left
side), lung, heart, liver and kidney were harvested and snap frozen. Figure 24B shows the
specific delivery to the right tumor as evidenced by expression of the green fluorescence protein
(GFP) in an immunoblot in which total protein extracts were run on a 10% SDS-PAGE. As a
GFP control, we ran a GST-GFP fusion protein. Protein gel loading was normalized using βactin as a control. US-targeted microbubble destruction (UTMD) enables focal release of
entrapped materials as well as the creation of small shock waves that are visualized as an
enhancement of the image on the US scanner. Figure 24, panel C depicts the B-mode US
imaging of a sonoporated tumor before injection with the microbubble/Ad-GFP complex contrast
agent. Figure 24, panel D shows the B-mode ultrasound imaging of the same sonoporated tumor
following microbubble/Ad-GFP complex injection. The image enhancement of the targeted
tumor from cavitation of the microbubbles within the US field of view is clearly discernable
indicating that the US settings are efficient in targeting microbubble destruction.
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Figure 24. (a) Schematic representation of the microbubble delivery of Ad-GFP complexes and
ultrasound (US) release in a tumor target site of the mouse. (b) Western blot analysis of AdGFP/microbubble–transduced DU145 tumor xenografts. Immunoblot showing the expression
levels of green fluorescent protein (GFP) in DU145 cells following ultrasound-targeted
microbubble/Ad transduction of GFP at 96 hours. Only the tumor on the right flank was
sonoporated for 10 minutes resulting in the delivery and expression of GFP. The left tumor,
heart, lung, liver, and kidney were negative for GFP expression. Purified glutathione-S-
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transferase–GFP was used as a positive control. Protein gel loading was normalized using β-actin
as a control. (c) Ultrasound imaging and US contrast enhancement of in vivo transduced DU145
tumor xenografts. B-mode US imaging of a tumor before MB contrast agent injection. (d) Bmode US imaging of the same tumor depicted in c following injection of microbubbles/Ad-GFP
complexes. MBs cavitation within the targeted tumor dramatically enhances the tumor image
within the US field of view. Ad, adenovirus.

Microbubble Assisted Ad.mda-7 Gene Delivery Inhibits DU145 Human Prostate Cancer
Growth In Vivo
In vitro and in vivo Ad-mediated gene transfer of the human mda-7/IL-24 gene (Ad.mda7) potently suppresses the growth of human cancer cells with no apparent toxicity to normal cells
[195, 203, 206, 211, 212, 223-230]. Repeated intratumoral administration of Ad.mda-7 to tumor
xenografts of various histological origin results in growth suppression via induction of apoptosis
and anti-angiogenic mechanisms [195, 196, 209-212, 226, 228, 231]. Additionally, mda-7/IL-24
induces a profound “bystander” antitumor effect resulting in tumor growth suppression not only
in the treated tumors, but also in untreated distant tumors [18, 194, 195, 197, 205, 211-213, 223,
224, 226, 227, 232, 233]. Although these results have been encouraging, this approach is limited
since systemic delivery of Ad for treatment of disseminated cancer has not shown significant
efficacy.
We have employed a novel systemic delivery approach to target Ad release in a sitespecific manner that consists of Ad incorporated in microbubbles combined with diagnostic US
[214]. Proof-of-principle for this strategy comes from studies using Ad to systemically deliver
the GFP gene in a tissue specific manner [214]. Because mda-7/IL-24 has shown significant
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potential as a selective and effective anticancer agent in multiple animal model studies and in a
Phase I intratumoral gene therapy trial in patients with advanced solid cancers [195, 196, 203,
211, 212, 223, 224, 228], we tested the capacity of this approach to deliver Ad expressing this
novel cytokine in prostate adenocarcinoma nude mouse xenograft models. For these studies, we
used DU145 human prostate carcinoma cells and DU145 cells genetically engineered to express
elevated levels of Bcl-xL (DU-Bcl-xL) [209], which is a common event in advanced prostate
cancer and provokes resistance to multiple chemotherapeutic agents and to mda-7/IL-24 [207210]. The therapeutic arm of this work included two different viral constructs to deliver mda7/IL-24, Ad.mda-7, a nonreplicating Ad similar to the one used in Phase I clinical trials [206],
and the CTV, a conditionally replication competent Ad capable of expressing mda-7/IL-24 that
has been previously shown to completely eradicate not only primary breast, prostate and
melanoma tumors but also distant tumors by intratumoral injections in a nude mouse model [18,
197, 204, 205].
To test this new therapeutic approach for tumor delivery, DU145 or DU-Bcl-xL tumor
xenografts were established on both flanks of nude mice by injecting 2 x 106 cells in each side of
the animals. DU145 and DU-Bcl-xL tumor bearing nude mice (n=10 each group) were then
injected in their tail vein with 100 µL of US contrast agent that was reconstituted with Ad-GFP
or water as control. Additional DU145 and DU-Bcl-xL tumor control nude mice (n=10 each
group) were injected in the tail vein with 100 µL of Ad.mda-7 or the CTV (Ad.PEG-E1A-mda-7)
without US contrast agent. Alternatively, tumor-bearing animals were injected in their tail vein
with 100 µL of US contrast agent that was reconstituted with Ad.mda-7 or the CTV. A portable
SonoSite Micro-Maxx US platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear
array transducer set at 0.7 Mechanical Index (MI), 1.8 MPa for 10 min was used to sonoporate
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the tumor implanted on the right side. In this study, gene therapy treatments were started ten
weeks after the injection of the cell lines, when tumors reached an approximate volume of 150200 mm3. Mice were injected once a week for four weeks for a total of four treatments. Mice
were sacrificed two weeks after the end of the treatments to determine whether tumor
suppression was reversible or irreversible. At the end of the study tumors (right and left flank),
lung, heart, liver and kidney were harvested and snap frozen using liquid nitrogen.
US of Ad-GFP microbubble complexes in the right side tumor resulted in progressive
growth of the tumors on both flanks (Figures 25A and E). The results shown in Figure 25
represent the average tumor volumes measured in a minimum of 7 mice for each mda-7/IL-24
group and a minimum of 5 mice for each control GFP group. All the mice were injected in the
tail vein with the microbubble/Ad complexes and only the tumor on the right flank was
sonoporated. Interestingly, we observed that microbubble-mediated Ad.mda-7 gene therapy
inhibited the growth of DU145 prostate tumor xenografts during the treatment regimen (Figure
25B), while the CTV microbubble-mediated gene therapy resulted in a steady progressive tumor
regression that lasted an additional two weeks post-treatment (Figure 25C).
As predicted from previous studies [18, 209, 210], Ad.mda-7 was ineffective in causing a
therapeutic response in tumor xenografts on either flank developed from DU-Bcl-xL cells
(Figure 25F). In contrast, the conditionally replication competent CTV (Ad.PEG-Prom-mda-7)
elicited a sustained growth inhibition of the therapy resistant DU-Bcl-xL tumor xenografts
(Figure 25G). A Western blot analysis of total protein extracts from the harvested tumors showed
expression of MDA-7/IL-24 protein in both the tumor samples implanted on the right and left
flank (Figures 25D and H) validating the “bystander” effects of MDA-7/IL-24 previously
reported [18, 194, 197, 204, 233]. In the case of the CTV, this amplified expression of MDA-
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7/IL-24 in the non-injected left tumor may also reflect secondary viral infection by the CRCA
[18]. GAPDH expression was used to confirm equal loading of the gel. No tumor regression was
observed in mice bearing DU145 and DU-Bcl-xL control tumors when injected intravenously
with comparable doses of unprotected Ad.mda-7 and CTV viruses (Figures 27 and 28).
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Figure 25. Growth curves and western blot analysis of large DU145 and DU-Bcl-xL tumor
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xenografts treated with microbubble encapsulated Ad-GFP, Ad.mda-7, or cancer terminator virus
(CTV) (Ad.PEG-E1A-mda-7) and treated with ultrasound (US) in the right tumor. Subcutaneous
tumor xenografts from DU145 and DU-Bcl-xL were established in athymic nude mice in both
right and left flanks and only tumors on the right side were sonoporated following tail-vein
injection of the indicated microbubble/Ad complexes during a course of 4 weeks. Tumor
treatments were initiated when tumors reached a size of 250–350 mm3. Arrows point at tumors
and asterisks point at treatment times. (a) Measurement of green fluorescent protein (GFP)treated DU145 tumor volumes. The data represent mean ± SD with at least 5 mice in each group.
(b) Measurement of Ad.mda-7-treated DU145 tumor volumes. The data represent mean ± SD
with at least 7 mice in each group. (c) Measurement of CTV-treated DU145 tumor volumes. The
data represent mean ± SD with at least 7 mice in each group. (d) Western blot analysis of protein
extracts from representative DU145 tumor samples treated with Ad.mda-7 or CTV. The
immunoblot was reacted with anti-MDA-7/IL-24. Arrowheads point at the various glycosylated
forms of MDA-7/IL-24. Protein gel loading was normalized using anti-GAPDH as a control. (e)
Measurement of GFP-treated DU-Bcl-xL tumor volumes. The data represent mean ± SD with at
least 5 mice in each group. (f) Measurement of Ad.mda-7-treated DU-Bcl-xL tumor volumes.
The data represent mean ± SD with at least 7 mice in each group. (g) Measurement of CTVtreated DU-Bcl-xL tumor volumes. The data represent mean ± SD with at least 7 mice in each
group. (h) Western blot analysis of protein extracts from representative DU-Bcl-xL tumor
samples treated with Ad.mda-7 or CTV. The immunoblot was reacted with anti-MDA-7/IL-24.
Arrowheads point at the various glycosylated forms of MDA-7/IL-24. Protein gel loading was
normalized using anti-GAPDH as a control. Ad, adenovirus; GAPDH, glyceraldehyde 3phosphate dehydrogenase.
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Microbubble Assisted CTV Gene Delivery Eradicates Prostate Cancer growth In Vivo
In our study, the size of the tumor was measured twice a week by caliper as well as by Bmode ultrasound scanning. Figure 26A shows the ultrasound image and measurements of a
DU145 tumor before treatment with Ad.mda-7-microbubble complexes. Panels B and C
demonstrate the volume reduction in the same tumor after 2 and 4 weeks of treatments with
Ad.mda-7-microbubble complexes and US. Figure 26D shows the B-mode scan image and
measurements of a DU-Bcl-xL tumor before treatment with CTV-microbubble complexes.
Panels E and F emphasize the dramatic volume reduction in the same tumor after 2 and 4 wks of
treatments with CTV-microbubble complexes and US leading to the eradication of the tumor
xenograft. Additionally, no tumor regrowth in the primary or distant sites was evident CTVmicrobubble complex and US-treated DU-Bcl-xL animals after an additional three weeks posttreatment. To investigate if the tumor would reappear after a longer period of time following the
last treatment, three out of ten animals initially treated with CTV-microbubble complexes were
not sacrificed at the endpoint of the study and were maintained for an additional 3 months. The
mice were then sacrificed and dissected to look for potential tumor recurrence and/or eventual
tumor spread. We did not observe any local tumor reappearance or distant metastasis in the lungs
or liver in these mice that were treated with CTV-microbubble complexes and US indicating that
this therapeutic approach could be suitable to target conditionally replication-competent
adenoviruses (CRCA) to prostate tumors causing the eradication of localized as well as distant
metastatic tumors. Future studies testing this approach in immune competent tumor bearing and
transgenic animals would provide definitive support for exploring this strategy in the context of a
Phase I clinical trial.
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Figure 26. B-mode ultrasound (US) imaging of DU145 tumor xenografts treated with
microbubble/US-guided Ad.mda-7 and therapy resistant DU-Bcl-xL tumor xenografts treated
with microbubble/US-guided cancer terminator virus (CTV).
Subcutaneous tumor xenografts from DU145 and DU-Bcl-xL cells were established in athymic
nude mice in both right and left flanks and only tumors on the right side were sonoporated
following tail-vein injection of the indicated microbubble/Ad complexes during a course of 4
weeks. Tumor volumes were determined by measuring twice a week the tumors with either a
caliper or by US measurements of the tumor axes.
(a) Ultrasound image and measurement of a DU145 tumor before treatment with Ad.mda7/microbubble complexes and US.
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(b) US image and measurement of the same DU145 tumor 2 weeks following treatments with
Ad.mda-7/microbubble complexes and US.
(c) US image and measurement of the same DU145 tumor 4 weeks following treatments with
Ad.mda-7/microbubble complexes and US.
(d) US image and measurement of a DU-Bcl-xL tumor before treatment with CTV/microbubble
complexes and US.
(e) US image and measurement of the same DU-Bcl-xL tumor 2 weeks following treatments
with the CTV/microbubble complexes and US.
(f) US image and measurement of the same DU-Bcl-xL tumor 4 weeks following treatments with
CTV/microbubble complexes and US.
Complete eradication of the DU-Bcl-xL tumor occurs 4 weeks after initiating the therapeutic
treatment protocol. Ad, adenovirus; GFP, green fluorescent protein.
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Figure 27. Growth curves of control DU145 tumor xenografts injected i.v. using unprotected
Ad-GFP, Ad.mda‐7, or CTV (Ad.PEG-E1A-mda‐7) and treated or not with US. Subcutaneous
tumor xenografts from DU145 were established in athymic nude mice in both right and left
flanks and only tumors on the right side were sonoporated following tail vein injection of the
indicated Ads during a course of 4 wks. Tumor treatments were initiated when tumors reached a
size of 150 – 200 mm3. Asterisks point at treatment times.
A) Measurement of CTV-injected and sonoporated DU145 tumor volumes. The data represent
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mean ± s.d. with at least 5 mice in each group.
B) Measurement of CTV-injected, but not sonoporated DU145 tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
C) Measurement of Ad.mda-7-injected and sonoporated DU145 tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
D) Measurement of Ad.mda-7-injected, but not sonoporated DU145 tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
E) Measurement of Ad.GFP-injected and sonoporated DU145 tumor volumes. The data represent
mean ± s.d. with at least 5 mice in each group.
F) Measurement of Ad.GFP-injected, but not sonoporated DU145 tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
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Figure 28. Growth curves of control DU-Bcl-xL tumor xenografts injected i.v. using unprotected
Ad-GFP, Ad.mda‐7, or CTV (Ad.PEG-E1A-mda‐7) and treated or not with US. Subcutaneous
tumor xenografts from DU-Bcl-xL were established in athymic nude mice in both right and left
flanks and only tumors on the right side were sonoporated following tail vein injection of the
indicated Ads during a course of 4 wks. Tumor treatments were initiated when tumors reached a
size of 150 – 200 mm3. Asterisks point at treatment times.
A) Measurement of CTV-injected and sonoporated DU-Bcl-xL tumor volumes. The data
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represent mean ± s.d. with at least 5 mice in each group.
B) Measurement of CTV-injected, but not sonoporated DU-Bcl-xL tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
C) Measurement of Ad.mda-7-injected and sonoporated DU-Bcl-xL tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
D) Measurement of Ad.mda-7-injected, but not sonoporated DU-Bcl-xL tumor volumes. The
data represent mean ± s.d. with at least 5 mice in each group.
E) Measurement of Ad.GFP-injected and sonoporated DU-Bcl-xL tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
F) Measurement of Ad.GFP-injected, but not sonoporated DU-Bcl-xL tumor volumes. The data
represent mean ± s.d. with at least 5 mice in each group.
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DISCUSSION
Microbubbles have been used to protect viruses from rapid degradation by the immune
system, thus allowing intravenous injection rather than direct target organ delivery by catheterbased approaches or operative bed injection [234]. However, variable levels of non-targeted gene
expression have been noted in other organs such as the liver and lungs [234]. We have recently
shown that US imaging and US contrast agents can increase target specificity of Ads to tumors,
achieving transient transgene expression with strict image-guided site specificity by selecting
microbubbles which completely enclosed the Ads in their gas filled core [214]. In our prior
experience, US-mediated microbubble destruction improved the efficacy and reduced the nonspecific expression of gene therapy vectors providing a useful tool for manipulating gene
expression in the living animal.
Genetic therapies for prostate cancer represent promising strategies for the treatment of
this neoplasm. The prostate gland is accessible by US, and potential therapeutic genes can be
directed to this organ using portable diagnostic US platforms such as the SonoSite MicroMaxx
(SonoSite, Inc., Bothell, WA) after a simple intravenous injection. Importantly, because prostate
cancer is commonly a relatively slow-growing disease, it may be necessary to use repeated gene
therapy applications, with single or multiple genes, over the life span of the patient. In these
contexts, gene therapy protocols that delimit virus exposure to the immune system and can be
administered multiple times during a patient’s lifetime are appealing. This possibility will need
to be explored in the future using tumor-bearing immune competent animals. In the current work,
we explored the ability of US-mediated microbubble destruction to specifically deliver in
prostate adenocarcinoma xenografts the mda-7/IL-24 gene [235, 236], that has been successfully
employed in a Phase I clinical trial in patients with advanced solid tumors [195, 196, 203, 211,
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212, 223, 224, 228].
Potentially useful approaches for treating prostate and other cancers involve the use of a
replication incompetent adenovirus (Ad.mda-7) or a conditionally replication competent Ad
(Ad.PEG-E1A-mda-7; CTV) to administer the therapeutic cytokine mda-7/IL-24 to induce
targeted therapy of tumors [18, 195-197, 204, 205, 211, 212, 237]. Although very effective in
prostate cancer cell lines, no therapeutic benefit is observed with Ad.mda-7 in the context of
prostate cancer cells displaying elevated expression of Bcl-2 and/or Bcl-xL [18, 209]. In contrast,
administration of the CTV by direct intratumoral delivery in nude mice containing xenografted
Bcl-xL overexpressing DU145 cells implanted on both flanks of the animal results in tumor
eradication in both the primary injected tumor and the distant untreated tumor [18].
Conditionally replication competent Ads (CRCA), which induce oncolysis by cancer-specific
replication, have been evaluated in several prostate cancer clinical trials [238, 239]. Most
currently employed CRCA are based on the ONYX-015 backbone, which is dependent on the
p53 status of the cancer cells and have shown only minimal objective clinical responses, thus
limiting their universal applicability for the treatment of prostate or other cancers [240]. To this
end, the novel CTV CRCA that employs the progression elevated gene-3 (PEG-3) promoter that
functions in all types of cancer cells [18, 204, 205, 241, 242], irrespective of their p53 or
Rb/retinoblastoma gene status, with very limited to no activity in normal cells has been
constructed. In the cancer terminator virus (CTV), Ad replication through the E1A gene is driven
by the cancer-specific promoter of progression elevated gene-3 (PEG-3) [243], which results in
concomitant production of mda-7/IL-24 from the E3 region of the Ad. This CTV generates large
quantities of MDA-7/IL-24 as a function of Ad replication uniquely in cancer cells that not only
have cancer-selective apoptosis-inducing properties but also display a plethora of indirect
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antitumor ‘‘bystander’’ activities, including distant tumor growth suppression and apoptosis,
immune modulation and anti-angiogenesis [195, 196, 204, 211, 212, 223, 232, 233, 237].
A limiting factor in effective gene therapy when employing intravenous viral delivery
and when using CRCA is the effect of the immune system in neutralizing Ads [215]. In this
context, a means of shielding the initial viral delivery vector using microbubbles in principle
permits enhanced delivery of the viral payload to tumors when coupled with US [214]. In the
present study, we have employed this strategy using CTV-microbubble complexes coupled with
US to treat both DU145 and therapy resistant DU-Bcl-xL established tumor xenografts on both
flanks in nude mice. Systemic administration of the CTV-microbubble with US on the
established right-side tumor resulted in robust transgene expression and apoptosis induction with
complete eradication of both the injected right side primary and distant (opposite flank;
potentially representative of metastasis) human prostate cancers. However, no tumor regression
was observed instead in mice bearing DU145 and DU-Bcl-xL control tumors when injected
intravenously with unprotected Ad.mda-7 and CTV viruses (see Figures 27 and 28), indicating
that comparable doses of untargeted, unprotected viruses injected directly i.v. failed to elicit an
antitumoral response. An exciting finding was that this protocol resulted in the indication of an
enduring response in which no tumor regrowth occurred 3 months after cessation of the therapy
protocol in the treated or untreated tumor site and additionally these animals had no signs of
metastatic spread to the lungs or liver. Previous studies have indicated that the CTV when
injected intratumorally will enter into the circulation, replicate and generate MDA-7/IL-24
protein in the primary and distant tumors in the nude mouse, predicting induction of a potential
immune response [18, 204, 205, 237, 241]. Further studies are planned in the context of immune
competent animals, which would be an important step toward developing clinical trials with the
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CTV-microbubble approach and US.
Obvious questions are why mda-7/IL-24 serves as such an effective anti-tumor agent and
why the CTV is superior to Ad.mda-7 as a viral-based therapeutic for primary and disseminated
cancers. A noteworthy reason for the robustness of mda-7/IL-24 is the ability of this secreted
cytokine to elicit a potent ‘bystander’ anti-cancer effect [195]. Mda-7/IL-24 can directly induce
apoptosis when expressed inside cancer cells and can also induce growth suppression, apoptosis
and endogenous MDA-7/IL-24 protein expression and secretion when added as a purified protein
through interactions with the IL-20R1/IL-20R2 and IL-22R1/IL-20R2 cell surface receptors
[195, 211, 232, 233]. As a secreted cytokine, MDA-7/IL-24 also induces an array of potent
immunomodulatory proteins from immune cells, including IL-6, IFN-γ, tumor necrosis factor-α,
IL-1β, IL-12, and granulocyte macrophage colony-stimulating factor [232]. These cytokines
secreted by peripheral blood mononuclear cells can activate antigen-presenting cells to present
tumor antigens, thereby triggering an antitumor immune response [244]. These observations
have been recapitulated in a Phase I clinical trial involving intratumoral injection of Ad.mda-7
(INGN 241) in patients with advanced carcinomas and melanomas [203, 211, 228]. In principle,
the ‘bystander’ effects elicited by MDA-7/IL-24 are concentration dependent [233] and large
amounts of this cytokine generated by the CTV would be predicted to have an enhanced
therapeutic impact in the patient. Moreover, the immunomodulatory functions of mda-7/IL-24
would be particularly significant in a patient with an intact immune system where the generation
of robust amounts of mda-7/IL-24 by the CTV might result in an amplified immune response
against the cancer cells. The potent activity of the CTV compared to Ad.mda-7 suggests a need
for only limited administration of this CRCA [18, 204, 205, 237], which would work extremely
well in the context of microbubble-Ad complexes. In principle, the microbubble approach would

101

further minimize the activation of the immune system against the Ad that would normally
promote viral clearance. We presently confirm for the first time that microbubble-assisted
delivery of the CTV can serve as a valuable therapeutic tool to combat therapy resistant prostate
cancer. As previously emphasized, the CTV-microbubble injected US treated mice appeared to
be disease free 3 months after therapy cessation suggesting that a cure was established. We are
planning to conduct long-term animal studies to verify this provocative observation in both
immune incompetent and immune competent animals.
In summary, the present studies support the proposition that US-directed delivery of
CTV-microbubble complexes might provide a nontoxic and effective alternative or complement
to conventional adjuvant treatment modalities for patients with primary and metastatic prostate
cancer. Based on previous studies of combinatorial therapy preclinical-trials in cell culture and in
animal models, a combination of CTV-microbubble approach employing US with localized lowdose radiotherapy might promote an even more profound effect, potentially further enhancing
mice survival [212, 245]. We are currently studying the effects of chemotherapy and/or radiation
therapy combined with microbubble-enhanced delivery of the CTV on promoting a cure in a
preclinical setting of prostate cancer.
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ABSTRACT
Combining radiation therapy and direct intratumoral (IT) injection of adenoviral vectors
has been explored as a means to enhance the therapeutic potential of gene transfer. A major
challenge for gene transfer is systemic delivery of nucleic acids directly into an affected tissue.
Ultrasound (US) contrast agents (microbubbles) are viable candidates to enhance targeted
delivery of systemically administered genes.
Here we show that p53, pRB, and p130 gene transfer mediated by US cavitation of
microbubbles at the tumor site resulted in targeted gene transduction and increased reduction in
tumor growth compared to DU145 prostate cancer cell xenografts treated intratumorally with
adenovirus (Ad) or radiation alone. Microbubble-assisted/US-mediated Ad.p53 and Ad.RB
treated tumors showed significant reduction in tumor volume compared to Ad.p130 treated
tumors (p<0.05). Additionally, US mediated microbubble delivery of p53 and RB combined with
external beam radiation resulted in the most profound tumor reduction in DU145 xenografted
nude mice (p<0.05) compared to radiation alone. These findings highlight the potential
therapeutic applications of this novel image-guided gene transfer technology in combination with
external beam radiation for prostate cancer patients with therapy resistant disease.

Keywords: Retinoblastoma, RB, p130, p53, tumor suppressor gene, microbubbles, ultrasound,
systemic targeted viral gene delivery, radiation, external beam radiation, apoptosis induction,
prostate cancer.
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INTRODUCTION
Current gene transfer clinical trials for prostate carcinoma use adenoviral vectors as
efficient gene transducing agents but these viral vectors have been shown to elicit an immune
response [202]. Rapid inactivation of adenoviruses by anti-adenoviral and neutralizing antibodies
in the blood limits the use of adenoviral gene transfer to intraprostatic injections for site-specific
delivery. To circumvent this problem we previously demonstrated a unique intravenous sitespecific delivery system for gene transfer both in vivo and in vitro, using adenoviral (Ad)
mediated delivery of GFP [214] and melanoma differentiation associated gene-7/interleukin-24
(mda-7) encapsulated in commercially available ultrasound (US) contrast agents (microbubbles)
[53]. The microbubbles (MBs) are able to entrap and protect viral vectors from the immune
system and are small enough to flow freely in the pulmonary and liver capillary bed. MBs
undergo cavitation in the sonification zone, and release their contents. Cavitation also creates
shockwaves that increase cell permeability allowing for better uptake of the genetic material into
the targeted cell [53, 68, 214].
Radiation therapy (RT) is commonly used in cancer management, with 40% to 60% of all
cancer patients receiving radiation treatment [246]. RT stimulates death receptors at the cell
surface, generates reactive oxygen species and activates several cell cycle regulatory proteins
including p53 [247], pRB [248], and other proteins that trigger senescence, necrosis or apoptosis
[249]. Additionally, factors such as location, size, and inadequate vascular supply (hypoxia) play
a role in the lack of responsiveness of neoplasms to ionization radiation [250].
The human prostate cancer, DU145, displays genetic mutations in key cell cycle
regulatory proteins, p53 and pRB. DU145 expresses a mutant p53 protein (mt-p53) due to
mutations at codon 223 and 274 on both alleles [251], which is functionally inactive, stabilized,
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and temperature sensitive [252]. Therefore, because functional p53 is required for ionizing
radiation to activate p21cip/waf and to induce a G1-cell cycle arrest, DU145 cells are
radioresistant [251, 253]. In addition, pRB gene has a biallelic disruption in these cells; one allele
is deleted while the other produces a truncated product of the RB gene resulting in the loss of
another G1 cell cycle phase regulator required for apoptosis following irradiation [254]. Studies
by Sasaki, et al. [255] and Bowen, et al. [256] showed that DU145 cell death following ionizing
radiation is increased when p53 and pRb are restored.
Another cell cycle regulator, p130 is frequently altered in several human neoplasms
including prostatic carcinomas. Previously we observed that p130 was expressed at low levels in
more aggressive prostate tumors and hypothesized that the lack of p130 expression could be
involved in the progression of the disease [257]. Additionally, we have examined the role of
p130 in γ-radiation induced apoptosis by using a hamster tetracycline inducible glioblastoma cell
line HJC12, and demonstrated that the cell cycle regulator p130 promoted radiation induced
apoptosis by downregulation of the antiapoptotic BCl-2 gene and upregulation of pro-apoptotic
transcription factor p73 [258]. These data suggest that cell cycle regulatory proteins play a
significant role in the radio-sensitivity of prostate cancer cells.
In 1996, Stevens and colleagues demonstrated that ionizing radiation improves viral gene
transfer efficiency with greater integration of the transgene into the host cells [259]. In addition,
combined treatment with adenovirus p53 and radiation has been shown to enhance the proportion
of apoptotic cells by greatly increasing the number of cells arrested in the G1-phase of the cell
cycle [255]. We hypothesized that ultrasound guided targeted delivery of adenoviruses
containing the cell cycle genes p53, RB and p130 in combination with external beam radiation
can further enhance the incorporation of cell cycle transgenes in prostate cancer cells, resulting
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in greater ablation of prostate tumors than x-ray radiation alone.
In the current investigation we used an ultrasound contrast agent provided by Targeson,
Inc (San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound (US) platform (SonoSite,
Inc., Bothell, WA) equipped with an L25 linear array transducer. Targeson’s agents are lipidencapsulated perfluorocarbon microbubbles (MBs) with a mean diameter of 2.5 µm. The gasfilled microspheres effectively lower the energy threshold for non-thermal cavitation, thus
allowing diagnostic transducers operating within the energy levels mandated by the FDA to be
used for drug/gene delivery. Ultrasound-targeted microbubble destruction (UTMD) enables focal
release of entrapped materials as well as the creation of small shock waves that increase cellular
permeability [220]. In addition, the MBs protect viruses from recognition and rapid degradation
by the immune system, thus allowing for intravenous injection rather than direct target organ
delivery by catheter-based approaches or operative bed injection [214, 218]. MB protection of
the viruses may also limit the inflammatory response to the viruses, potentially allowing for
repeated injections of transgene containing MBs.
The ultimate goal of this research is to develop efficacious treatment modalities for
therapy resistant prostate cancer. In the present study, we provide proof-of-principle for a sitespecific gene delivery approach mediated by a standard, portable diagnostic US platform. This
system worked effectively in vivo to deliver Ads carrying cell cycle regulatory genes (p53, RB,
and p130). Evidence is offered that the combination of 8 Gy radiation therapy with US targeted
gene transfer of p53 and RB reduced the tumor size in an animal xenograft model of radiationresistant human prostate cancer cells.
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MATERIALS AND METHODS
Cell Lines, Cell Culture, and Adenoviral Production.
The DU145 (human prostate adenocarcinoma), cell line was obtained from the American
Type Culture Collection (ATCC, Rockville, MD). DU145 cells were grown in RPMI 1640
(Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (Hyclone, Waltham, MA),
and 100units/mL penicillin supplemented with 1 mg/mL streptomycin (both from Hyclone,
Waltham, MA). The human kidney embryonic 293 cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD) and grown with Dulbecco’s modified Eagle’s
medium (Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (Hyclone,
Waltham, MA). All cells were grown at 37ᴼC, in a 5% CO2/95% atmosphere incubator.
The recombinant adenoviruses with wild-type p53, RB, p130 used in this study were
serotype 5 adenovirus containing a cytomegalovirus (CMV) promoter. Non-coding empty
Adenoviruses carrying only the CMV promoter were used as vector control. Each viral stock was
propagated in and purified from 293 cell cultures. Cells were harvested 24-36 hours after
infection, pelleted, resuspended in heat inactivated media and lysed by three-freeze/thaw cycles.
Cell debris were removed and the viruses purified by chromatography followed by dialysis.
Viruses were aliquoted and stored at -80°C. Viral titers were determined by a plaque assay.
Ad.p53 viruses were generated using the AdEasy system (Carlsbad, CA), as previously described
[260-263]. The Ad.RB viruses were generously provided by Dr. Juan Fueyo (M.D. Anderson
Cancer Center, The University of Texas) and Ad.p130 viruses were purchased from Vector
BioLabs (Philadelphia, PA). All adenovirus transductions were performed using 50 MOI Ads for
in vitro studies, in RPMI-1640 media with 2% Fetaclone-III heat-inactivated FBS (Hyclone,
Thermo Scientific, Waltham, MA).
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Radiation
External beam radiation was provided using Varian Medical Systems, Inc. (Palo Alto,
CA) Model 21EX and Model 6EX linear accelerators (LINAC), each owned and operated by
Tri-State Regional Cancer Center in Ashland, KY. The machines were approved by the Inspector
General of the State of Kentucky for irradiations to biological specimens and animals as desired
by us. These particle accelerators offer a bremsstrahlung x-ray energy of 6 MV, which was used
in these investigations as well as a rapid dose delivery to the targeted tumor at a rate of 6Gy/MU.
Here, the number of monitor units (MU) is simply the internal timer of the LINAC. All dosages
were pre-calculated for in vitro and in vivo studies as previously described [264].
For the in vitro studies, 2 x 10^6 DU145 cells were seeded in 75cm^2 flasks and
irradiated at 10Gy or 20Gy, at room temperature. For one treatment of 10Gy, 965 MU were
given at 600 MU/min for a run time of 1 min 37 seconds. For one treatment of 20Gy, 1,930 MU
were given at 600 MU/min for 3 min 13 seconds. For a combination therapy, 2 x 10^6 DU145
cells were first radiated at 10Gy and 20Gy following by infection with Ad5CMV-p53 or
Ad5CMV-RB or Ad5CMV-p130 viruses at 50 multiplicity of infection (MOI) units. The
sensitivity to x-ray induced apoptosis was evaluated by phase contrast microscopy and flow
cytometric analysis. Cells were collected at 24, 48, 72 and 96 hours after radiation to carry out
Flow cytometric analysis and Western Blots.
For the in vivo studies, mice received irradiation in pie cages for a one-time dose of 8Gy
(800 MU given at 600 MU/min for 80 seconds). An approved protocol concerning the Physics
Policies and Procedures for handling of the mice and disposal of waste was used.
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Flow Cytometry Analysis
Irradiated, adenoviral (Ad.p53, Ad.RB and Ad.p130) transduced and combination treated
DU145 cells were harvested at 24, 48, 72 and 96 hours following treatments, to study the cell
cycle phase of each group. After three washings in 1mL of 1% fetal calf serum (FCS)-PBS the
cells were fixed in 70% ethanol and stored at -20ᴼC. Cells were centrifuged, washed and
resuspended in 1% FCS-PBS. The samples were then incubated at 37ᴼC with propidium iodide
(PI) and RNAse A for 30 min. The DNA content was analyzed by a BD Accuri C6 Flow
Cytometer (BD Bioscience, San Jose, CA). The proportions of G1, S, G2 phase cell cycle were
determined as previously reported [255].
Apoptosis analysis was done using the Annexin-V assay on the Flow Cytometer.
Apoptotic cells were analyzed with fluorescein isothiocyanate (FITC) conjugated to Annexin-V
antibody and Propidium Iodide (PI) from the Annexin-V/FITC Kit (Bender MedSystems,
Burlingame, CA) following manufacturer's instructions. The samples were analyzed with BD
Accuri C6 Flow Cytometer (BD Bioscience, San Jose, CA). The Annexin-V assay experiment
was repeated three times and was run as triplicate of technical repeats. Statistical analyses were
performed with IBM SPSS statistic software.

Antibodies and Western Blot Analysis
Western blot analyses with antibodies against the targeted proteins were performed to
validate successful viral transfection of the cells and of the in vivo tumors. DU145 cells were Xirradiated, transduced with 50 MOI of Ad.p53, Ad.RB, Ad.p130, or Ad.CMV (control) for 24,
48, 72 and 96 hrs post-irradiation/transduction. Cells were lysed on ice for 1 hr with lysis buffer.
Fifty μg of total protein plus loading buffer were loaded in each well for western blot analyses.
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SDS-PAGE was run using 8-12% bis-acrylamide gel at room temperature. Samples were blotted
onto a nitrocellulose membrane. To detect proteins, the membranes were blocked with 5%MilkTBST overnight at 4ᴼC and reacted with primary antibodies for 2 hr at room temperature with
constant motion on an orbital shaker. The membranes were washed with TBST to remove excess
primary antibodies. Incubation for 45 minutes with appropriate secondary antibodies followed.
Immunodetection was performed using the enhanced chemiluminescence (ECL) system
(Amersham, IL) according to the manufacturer’s instructions using x-ray films. The following
primary antibodies were used: mouse monoclonal antibodies against p53 (DO-1) cat#sc-126
(1:500), pRb cat#sc-102 (1:250) (Santa Cruz Biotechnology, Santa Cruz, CA), β-actin
cat#A3853 (1:1,500) (Sigma Aldrich) and rabbit polyclonal antibody against RBL2/p130 cat#sc317 (1:250).

Preparation of MBs and US Platform.
Targeson (Targeson) custom synthesis US contrast agent (perfluorocarbon MBs,
encapsulated by a lipid monolayer and polyethylene glycol) stabilizer were reconstituted as
previously described [53]. MBs were reconstituted in the presence or absence of 1 ml of 10^12
plaque-forming units of Ads [53]. Unenclosed, surface-associated Ads were inactivated using
incubation with FBS as previously described [53, 214]. For in vivo experiments US exposure was
achieved with a Micro-Maxx SonoSite (SonoSite) ultrasound machine equipped with the
transducer L25 set at 0.7 Mechanical Index, 1.8 MPa for 10 minutes as previously described [53,
214].
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Animal Study
Animal studies were performed in accordance with National Institutes of Health
recommendations and the approval of the institutional animal research committee. DU145,
human prostate carcinoma cells were xenografted to 8- to 12-week-old female or male athymic
BALB/c nude mice, homozygous mutant for the nu/nu allele, bred in our laboratory. The colony
of mice was developed from breeding stock obtained from Charles Rivers Laboratories,
Wilmington, MA. Mice were sedated in an IMPAQ6 anesthesia apparatus (VetEquip,
Pleasanton, CA) that was saturated with 3–5% isofluorane and 10–15% oxygen with the aid of a
precision vaporizer (VetEquip) to deliver the appropriate amount of anesthetic and to induce
anesthesia. Mice received subcutaneous injections along each of their dorsal flanks (both sides
per mouse), of 2 x 10^6 DU145 cells in 200µL of PBS using a 22-gauge needle. Tumors were
measured post-injection in their longest dimension and at 90ᴼ to their longest dimension using
vernier calipers. Once the tumors reached a volume of approximately 200mm^3 the mice were
divided into their various treatment groups. Tumor volumes were calculated using the formula
tumor volume = (long arm x short arm2)/2 [265].
Sonoporation: Gray scale-B-mode US imaging was performed with a SonoSite scanner
(SonoSite) equipped with the transducer L25 set at 0.7 Mechanical Index, 1.8 MPa for 10
minutes. US images were recorded as digital clips. Tumors on the right flank were sonoporated
immediately after the MB encapsulated viral vector intravenous injections using a 27-gauge
needle. Tumors on the contralateral flank (on the left flank) would serve as internal controls.
Radiation of 8Gy was given to the appropriate groups followed by four weeks of MB guided
delivery of Ad.p53, Ad.RB or Ad.p130.
Radiation: Radiation treatments were provided to groups of mice, generally 11 mice/pie-
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cage. Groupings were limited by the number of available slots in the Braintree Scientific, Inc.
(Braintree, MA) Model MPC pie cage. The LINAC was programmed to provide an 8Gy
radiation. Radiation was given to the appropriate groups followed by four weeks of adenoviral
treatments.
The DU145 tumor-bearing mice were directly injected in the tumor (IT) or through the
dorsal tail vein (IV). Each control group got an IT injection of 100µL of PBS MBs or 100µL of
un-encapsulated Ad.p53, Ad.RB or Ad.p130 viruses at a concentration of 10^9 pfu/µL.
Radiation of 8Gy alone constituted an additional control group. Experimental groups were
injected IV with 100 µL of MB encapsulated Ad.p53, Ad.RB or Ad.p130 at a concentration of
10^9 pfu/µL. Tumor growth inhibition rate was calculated using the formula (1-(treated
group/control group))*100%.
The animals were sacrificed by CO2 asphyxiation. Tumors, heart, lungs and liver were
harvested at the end of the treatment course. Tissues used for molecular biological analysis were
snap frozen in liquid nitrogen and stored at -80°C. Frozen tissues were homogenized and total
proteins were extracted. Western blot studies allowed determining if the enhanced gene
expression was specific to microbubble encapsulation and restricted to the US treated tumors
instead of other tissues. The combination of external beam radiation, ultrasound treatment and
systemic delivery of MB protected genetic material by viruses was examined for expression of
the transduced tumor suppressor genes.

In Vivo Bioluminescence Imaging
We imaged animals with the IVIS Lumina II (Caliper Life Sciences) at 24hrs and one
week after MB-assisted gene delivery, to quantify photons emitted by the control animals that
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received Ad.LUC. For each imaging session mice were injected intraperitoneally with Dluciferin (150 mg kg−1) under anesthesia using 1.5–2.5% isoflurane/oxygen mixture. Images
were acquired 10 min after injection of D-luciferin as follows. The anesthetized mice were
placed in a light-tight chamber, and images were generated over a 1-minute exposure using a
cryogenically cooled charge-coupling device camera IVIS Lumina II (Caliper Life Sciences) to
quantify photons spontaneously emitted by the animal. Images were pseudocolored using the
Xenogen (Caliper Life Sciences, Hopkinton, MA, USA) software and overlayed on a black-andwhite photograph of the animal generated with cabinet lighting. The visual output represents the
number of photons emitted s_1 cm_2 as a pseudocolor image where the maximum is red and the
minimum is purple. Image acquisition and BLI data analysis were done using Living Image
software (Caliper Life Sciences).

Statistical Analyses
All statistical analyses were performed using IBM SPSS software. Comparisons were
conducted using an ANOVA test with post hoc test of Dunnett’s T3. P values of less than 0.05
were considered statistically significant.
A comparison of tumor volumes was done for week 19 after the treatment at the end of
the study. Statistical analyses for comparisons of different types of treatments were done using
one-way analysis of variance using a post hoc test of Dunnett’s T3. P value <0.05 was
considered significant.
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RESULTS
Phase Contrast Microscopic Analysis: Irradiated DU145 Cells that were then Transduced
with p53, RB, and p130 Genes
We observed that after 96 hours, radio-resistant DU145 cells, which were x-ray irradiated
and then transduced with 50 MOIs of Ad.p53, Ad.RB, or Ad.p130 had a higher number of dead
cells than cells which did not receive the transgenes and that there was an increase in the number
of apoptotic cells as radiation dose was escalated from 10 to 20Gy (Fig. 29a). Microscopic
analysis revealed that following radiation induced DNA damage, cells adopted a large flattened
shape with distorted cell membranes and multiple nuclei typical of senescent cells. We also
observed that at 96 hours, the RB or p53 gene transfer and radiation therapy resulted in a higher
increase of cell death than p130 gene transfer (Fig. 29a). Non-irradiated and non-transduced
control cells exhibited similar percentages of cell death when compared to control non-coding
CMV-Adenoviruses transduced cells (data not shown).
Interestingly, cells x-ray irradiated and transduced with Ad.p53, Ad.RB or Ad.p130
showed an increase in cell death, compared to the control x-irradiated group from 24-72 hours
(Fig. 29b). Few dead DU145 cells were observed at 24-72 hours following x-ray irradiation
when compared to the non-transduced control (Fig. 29b). Radiation combined with adenoviral
transductions increased the number of dead cells regardless of the transduced genes (p53, RB &
p130) in a time and dose dependent manner (Fig. 29a and b). Taken together, these data suggest
that gene transfer of RB or p53 resulted in an improvement in the cell death of the radio-resistant
DU145 cells.
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Figure 29a. Microscopy image analysis of DU145 cells transduced with Ads carrying tumor
suppressor genes (p53, RB and p130) ± radiation from 72hrs. Apoptotic cells appear as floating
in the bright field microscopy image. Top row images are of control DU145 cells and the ones
that received radiation of 10Gy or 20Gy only. The second row images are DU145 cells that
received 50MOI adenoviral transduction of p53 alone and those combined with 10Gy and 20Gy
radiation. The third row images are of DU145 cells that received 50MOI adenoviral transduction
of pRB alone and those combined with 10Gy and 20Gy radiation. The fourth row images are of
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DU145 cells that received 50MOI of adenoviral transduction of p130 alone and those combined
with 10Gy and 20Gy radiation.

Figure 29b. Microscopy images of adenovirally transduced tumor suppressor genes (p53, RB
and p130) ± radiation from 24-72hrs. Top row images are of DU145 cells that received radiation
of 10Gy and 20Gy only at 24, 48, and 72 hours, respectively. The second row images are DU145
cells that received 50MOI of Ad.p53 combined with 10Gy and 20Gy radiation at 24, 48, and 72
hours, respectively. The third row images of DU145 cells that received 50MOI of Ad.pRB
combined with 10Gy and 20Gy radiation at 24, 48, and 72 hours, respectively. The bottom row
images are of DU145 cells that received 50MOI of Ad.p130 combined with 10Gy and 20Gy
radiation at 24, 48, and 72 hours, respectively.
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Transgene Expression of p53, pRb, and p130 in Irradiated DU145 Cells
Western blot studies were done to confirm the adenoviral transduction of DU145 cells by
adenoviruses carrying genes p53, pRb and p130. Normally, irradiation induced cell death results
in the accumulation of proteins p53 and hypo-phosphorylated pRb leading to G1 arrest. We
found that following x-ray irradiation there was no change in the expression of mutant p53 and
truncated pRb in the control DU145 cells regardless of the irradiation dose (Fig. 30). Mutant p53
and truncated pRb are stabilized and non-functional in DU145 cells leading resistance to
radiation-induced cell death [252, 254]. We also observed an accumulation of p130, which
occurred in a time dependent manner following x-ray irradiation, regardless of the irradiation
dose (Fig. 30). Cells transduced with adenoviral Ad.p53, Ad.RB, and Ad.p130 showed increased
expression of these functional recombinant proteins (Fig. 30). Higher expression levels of all of
the adenovirally transferred recombinant proteins were observed as the x-ray dose was increased
from 10Gy to 20Gy.
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Figure 30. Western Blot analysis of the cell lysates collected at 24, 48, 72 & 96 hours postadenoviral transduction. Treatments and time of collection after radiations are as labeled at the
top, protein detected are labeled on the right. Anti-beta-actin was used as a loading control. 50μg
of total lysates were run in SDS polyacrylamide gels.
Cell Cycle Analysis of DU145 Cells Following X-ray Irradiation and Gene Transduction
The replication status of DU145 cells following radiation therapy, adenoviral gene
transfer of p53, RB, or p130, or combined radiation and adenoviral gene transfer was computed
as the percentage of cells accumulated in the G1, S or G2 cell cycle phases by a propidium
iodide staining. The data was plotted on a linear diagram to show points in time where there was
accumulation or reduction of G1- and G2-phases at 24-96 hours of DU145 cells treated with the
various adenoviruses and x-ray irradiation (Fig. 31a-f). Control DU145 cells showed a small (811%) fraction of cells in S-phase (Table 4). The cells treated with Ad.p53, Ad.RB, or Ad.p130
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showed accumulation at the G1-phase with reduction in G2-phase of the cell cycle suggesting a
block of the G1/S phase transition (Fig. 31a, c and e). Notably, x-ray irradiated DU145 cells
showed a marked accumulation in the G2-phase with a reduction in the G1-phase of the cell
cycle suggesting a block at the G2/M transition (Fig. 31a-f). The combined treatment of Ad.p53
or Ad.RB transduction and x-ray irradiation showed a reduction of the number of cells in the G2phase with accumulation of cells in the G1-phase (Fig. 31a,b & c,d). However, combined
treatment of Ad.p130 transduction and x-ray irradiation showed a G2/M block (Fig. 31e-f),
suggesting that this cell cycle response was most likely due to the irradiation.

Table 4. The percentage of DU145 cells in G1, S and G2 cell cycle phase with its standard
deviation that received treatments of adenovirus, radiation and combined (radiation +
adenovirus) treatment as analyzed by flow cytometry at 24-96 hours.
G1 phase
S phase
G2 phase
(Mean ± SD)
(Mean ± SD)
(Mean ± SD)
Groups
24
48
72
96
24
48
72
96
24
48
72
96
hrs
hrs
hrs
hrs
hrs
hrs
hrs
hrs
hrs
hrs
hrs
hrs
Control 40 35.53 39.2 40.9 11.33 10
9
8.87 48.83 49.27 45.93 45.5
±
±
±
±
±
±
±
±
±
±
±
3
±
18.53 15.65 13.86 12.80 5.28 1.15 1.42 1.16 23.25 11.07 19.87
20.6
8
10Gy 70.87 62.3 51.67 40.53 15.63 14.03 19.83 24.17 13.93 23.9 29.4 34.9
Rad
±
±
±
±
±
±
±
±
±
±
±
7
2.63 1.51 4.29 0.76 1.45 2.20 2.55 1.05 1.67 2.52 0.96
±
1.7
20Gy 60.93 38.27 33.1 16.77 15.13 22.47 12.67 13.43 25.2 40.1 52.97 67.3
Rad
±
±
±
±
±
±
±
±
±
±
±
7
3.93 0.75 0.34 3.09 3.8 1.75 1.58 4.22 0.17 1.7 1.31
±
1.62
Ad.p53 27.33 36.93 49.37 55.8 8.07 10.06 16.87 6.16 65.1 53.63 34.33 36.2
±
±
±
±
±
±
±
±
±
±
±
7
4.98 1.59 3.42 2.17 2.89 1.26 3.35 2.39 3.82 1.66 1.53
±
3.42
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Ad.p53
+ 10Gy
Rad

6.07 9.47 14.1
27.2
36 48.83 59.47
±
±
±
±
±
±
±
0.15 1.94 2.36
1.61 1.08 3.27 2.35
Ad.p53
17.87 9.7 11.03
+ 20Gy 39.87 56.1 64.7 74.27
±
±
±
Rad
±
±
±
±
2.19 1.21 1.60
2.10 1.67 0.72 2.33
Ad.pR
11.33 8.3 7.43
B
19.9 30.87 37.33 44.1
±
±
±
±
±
±
±
3.76 3.65 0.59
3.74 4.27 2.2 2.36
Ad.pR
8.13 10.23 6.97
B+
23.23 31.1 38.77 51.93
±
±
±
10Gy
±
±
±
±
2.0 0.87 1.47
Rad
1.93 2.08 4.58 4.68
Ad.pR
11.4 10.53 13.87
B+
26.7 33.6 47.57 68.13
±
±
±
20Gy
±
±
±
±
5.38 3.89 0.64
Rad
2.08 2.07 2.42 2.87
Adp13 45.43 54.2 58.47 67.2 21.8 19.47 20.9
0
±
±
±
±
±
±
±
3.30 4.33 3.05 3.22 2.26 4.31 3.96
Adp13
20.47 19.2 13.23
0+
59.73 52.57 43.87 27.73
±
±
±
10Gy
±
±
±
±
1.50 1.35 3.21
Rad
1.65 3.13 0.93 7.70
Adp13
18.8 14.53 15.33
0+
57.9 52.47 34.27 18.73
±
±
±
20Gy
±
±
±
±
0.82 2.07 1.72
Rad
1.35 3.86 2.96 4.46
*Ad-adenovirus, *Rad- radiation, *SD- standard deviation
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13.07
±
67.13
2.15
±
1.53
10.77
±
42.83
1.27
±
3.5
12.6
±
69.03
1.4
±
1.80
11.33
±
68.9
2.35
±
1.83
6.93
±
61.63
3.27
±
2.83
17.47 32.9
±
±
2.40 3.99
15.17
±
19.27
7.41
±
1.65
10.07
±
24.5
4.79
±
0.79

27.1
53.33 32.63
7
±
±
±
3.19 3.86 1.46
15.2
34.83 24.7
7
±
±
±
0.91 1.97 3.09
42.9
60.97 55.37
7
±
±
±
2.18 1.96 3.72
58.77 54.4
±
±
1.69 3.27

36.4
±
2.0
24.9
54.9 38.53
3
±
±
±
1.68 2.61 3.95
26.23 20.47 15.3
±
±
±
1.60 0.67 3.54
27.8 42.23 56.7
±
±
±
2.41 1.70 1.15
33.33 51.57 70.5
±
±
±
5.76 1.53 1.06

Figure 31. The accumulation/reduction of cells in G1- and G2-phase of cell cycle from a
population of DU145 cells that received adenoviral p53 (panels a and b), RB (panels c and d)
or p130 (panels e and f) with or without radiation treatments. The days after radiation are
indicated on the ordinate. The percentage of cells in G1/G2 phase of cell cycle are indicated on
the abscissa. A best-fit line was drawn on data points collected over four days.
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External Beam Radiation Followed by Adenoviral p53, pRb, p130 Transduction Increased
the Apoptotic Rate of DU145 Cells In Vitro
Apoptotic cell death of Ad.p53, Ad.RB, or Ad.p130 transduced and irradiated DU145
cells was detected using a fluorescent-labeled Annexin-V antibody (Annexin-V-FITC) in
combination with propidium iodide (PI) by flow cytometry 24-96 hours after irradiation. We
observed that the apoptotic rate of DU145 cells transduced with control CMV non-coding
adenovirus (Ad.CMV) was comparable to the untreated control DU145 cells regardless of time
point (Fig. 32 & 33). Compared to the control, there was a significant (p<0.05) increase in cell
death for all treatments (Fig. 32 & Table 5). As radiation was increased from 10Gy
(14.23%±0.87) to 20Gy (24.67%±2.28) there was a ~10% increase in cell death at 96 hours. A
trend of increased cell death was also observed in all treated groups as time progressed (Fig. 33).
The highest percentage of cell death was observed at 96hrs following radiation for all treated
groups.
The percentage of cell death increased when adenoviral transduction of p53, RB or p130
was combined with x-ray irradiation in comparison to the control or to adenoviral transduced
groups regardless of the time point (Fig. 32 & 33). Compared to the 10 Gy irradiated cells there
was a significant (p<0.01) increase in cell death for p53 overexpressing cells (Fig. 32 & Table 5).
Compared to the 10 and 20 Gy irradiated cells there was a significant (p<0.01) increase in cell
death for pRb overexpressing cells (Fig. 32 & Table 5). The highest percentage (41.17%±1.46)
of cell death was observed at 96 hours for Ad.RB transduced DU145 cells in combination with xray irradiation (Fig. 32).
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Figure 32. Bar graph representation of apoptosis assay with Annexin-V and Propidium Iodide
staining of adenoviral infected tumor suppressor genes (p53, RB and p130) ± external beam
radiation at 96hrs analyzed on Accuri C6 flow cytometer. The percentages of dead cells are
indicated on the ordinate. The control and treatment groups are indicated on the abscissa. *
indicates statistical significance between control and 10-20 Gy irradiated cells. ** indicates
statistical significance between irradiated cells and cells that received combination of adenoviral
gene transfer and external beam radiation.
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adenoviral vectors and combination therapeutic groups (Ads and x-ray radiation).

cytometer. On the ordinate the percentages of dead cells are indicated. On the abscissa are indicated the different

transduced tumor suppressor genes (p53, pRB and p130) ± radiation from 24-72hrs analyzed on Accuri C6 flow

Figure 33. Graph representation of apoptosis assay by Annexin-V and Propidium Iodide staining of adenovirally

Table 5. Multiple comparison ANOVA (Analysis of Variance) significance table with a
Dunnett’s T3 test for Annexin-V assay experiment of DU145 cells following radiation and
adenoviral gene transfer for 96hrs time point. The statistical analysis was run using IBM SPSS
software.
(I) groups

(J) groups

DU145

CMV
Rad 10gy
Rad 20gy
Adp53
Adp53+ 10gy
Adp53+ 20gy
AdpRB
AdpRB+ 10gy
AdpRB+ 20gy
Adp130
Adp130+ 10gy
Adp130+ 20gy
Rad 10gy
Rad 20gy
Ad.p53
Ad.p53+ 10gy
Ad.p53+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Rad 20gy
Ad.p53
Ad.p53+ 10gy
Ad.p53+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy

CMV

Rad 10Gy

Mean
Std. Error
Difference (IJ)
-.43
.50
*
-11.73
.60
*
-22.17
1.36
-15.00*
1.02
*
-24.60
.96
*
-33.90
1.92
-18.13*
1.12
*
-25.93
.54
*
-38.67
.90
-9.43*
.94
*
-14.13
.98
*
-25.67
.87
*
-11.30
.63
-21.73*
1.37
-14.57*
1.04
*
-24.17
.98
-33.47*
1.93
-17.70*
1.14
*
-25.50
.58
-38.23*
.92
*
-9.00
.96
*
-13.70
1.0
*
-25.23
.90
-10.43
1.41
-3.27
1.09
*
-12.87
1.03
-22.17*
1.96
-6.40
1.19
*
-14.20
.67
-26.93*
.98
2.30
1.02
-2.40
1.05
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Sig.

1.0
.00
.02
.02
.00
.02
.02
.00
.00
.04
.02
.00
.00
.02
.02
.00
.02
.01
.00
.00
.04
.02
.00
.08
.49
.01
.04
.15
.00
.00
.74
.73

Rad 20Gy

Ad.p53

Ad.p53+10Gy

Ad.p53+20Gy

Ad.pRB

Ad.pRB+10Gy

Ad.pRB+20Gy

Ad.p130+ 20gy
Ad.p53
Ad.p53+ 10gy
Ad.p53+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.p53+ 10gy
Ad.p53+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.p53+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.pRB
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.pRB+ 10gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.pRB+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.p130
Ad.p130+ 10gy
Ad.p130+ 20gy

-13.93*
7.17
-2.43
-11.73
4.03
-3.77
-16.50*
12.73*
8.03
-3.50
-9.60*
-18.90*
-3.13
-10.93*
-23.67*
5.57
.87
-10.67*
-9.30
6.47
-1.33
-14.07*
15.17*
10.47*
-1.07
15.77
7.97
-4.77
24.47*
19.77*
8.23
-7.80
-20.53*
8.7
4.0
-7.53
-12.73*
16.5*
11.80*
.27
29.23*
24.53*
13.0*
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.95
1.63
1.60
2.31
1.70
1.39
1.56
1.59
1.61
1.55
1.32
2.12
1.44
1.06
1.28
1.31
1.33
1.26
2.10
1.40
1.00
1.23
1.26
1.28
1.21
2.18
1.94
2.07
2.09
2.11
2.06
1.16
1.37
1.39
1.42
1.35
.95
.99
1.02
.92
1.22
1.25
1.17

.01
.19
.96
.13
.69
.60
.02
.03
.14
.74
.03
.04
.77
.03
.00
.20
1.0
.02
.23
.16
.98
.01
.01
.02
1.0
.06
.33
.72
.02
.03
.30
.1
.00
.06
.52
.09
.01
.01
.02
1.0
.00
.00
.01

Ad.p130

Ad.p130+ 10gy
Ad.p130+ 20gy
Ad.p130+10Gy Ad.p130+ 20gy

-4.70
-16.23*
-11.53*

1.28
1.20
1.23

.29
.00
.01

Microbubble Assisted Adenoviral p53, pRb, and p130 Gene Transfer in Combination with
External Beam Radiation Enhanced Therapy of Radio-resistant DU145 Tumor Xenografts.
We have been focusing on developing a safe and effective means of gene delivery in vivo
to realize the therapeutic potential of the synergistic effects of tumor suppressor gene expression
and ionizing radiation to combat human malignancy, specifically prostate carcinoma. To follow
up on our previous studies on the use of microbubble assisted adenoviral gene transfer in radioresistant prostate cancer [53], we decided to compare the effects of microbubble assisted
adenoviral p53, RB, and p130 gene delivery combined with radiation therapy on xenografted
DU145 tumors in nude mice.
We have employed here a novel systemic delivery approach to target adenovirus (Ad)
release in a site-specific manner that consists of Ad incorporated in MBs combined with
diagnostic US [53, 214]. Proof-of-principle for this strategy comes from studies using Ad to
systemically deliver the GFP gene or a target gene (Mda-7/IL-24) in a tissue specific manner [53,
214].
For these current studies, we used DU145 human prostate carcinoma cells. The
therapeutic arm included three different non-replicating adenoviral constructs to deliver p53, RB,
and p130 that have been previously shown to increase radiation therapy response or to reduce
tumor growth in various tumor types [254, 258, 266, 267]. The control arms of the study
included Adenovirus expressing the green fluorescent protein (GFP) and the firefly luciferase
gene (LUC). To test the specificity of intravenous injection of Ads complexed MBs for gene
delivery in vivo we used the reporter firefly luciferase gene (LUC). We showed exclusive
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bioluminescence in the sonoporated tumor at 24hrs from MB-assisted gene delivery using whole
animal bioluminescence imaging (BLI) (Fig. 34), which was not extended to other districts of the
animal even after one week from LUC gene delivery.

Figure 34. Detection of MB-assisted Firefly Luciferase gene transfer through whole animal
imaging. Panel a) is the ultrasound image of a tumor xenograft. Panel b) is the image from a
mouse sonoporated on the tumor xenografted in the left flank showing specific luciferase
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luminescent signal at 24 hours from the treatment. Panel c) is the image from the same mouse as
in panel b showing specific luminescent signal at 1 week from the treatment.

To test this new therapeutic approach for targeted tumor delivery of p53, pRb and p130,
prostate tumor xenografts were established on both flanks of nude mice by injecting 4 x 106
DU145 cells in the subcutaneous region of each flank of the animals. DU145 tumor bearing nude
mice (n=5 each group) were then injected in their tail veins with 100 µL of US contrast agent
that was reconstituted with PBS or Ad.GFP as controls. Additional DU145 tumor control nude
mice (n=5 each group) were injected intratumorally (IT) with 100 µL of unprotected Ad.p53,
Ad.RB or Ad.p130. In the treatment arm tumor-bearing animals were injected in their tail vein
with 100 µL of US contrast agent (Targeson, San Diego, CA) that was reconstituted with
Ad.p53, Ad.RB or Ad.p130. Tumors implanted on the right-side, were sonoporated as previously
reported [53]. The treatment schedule is described in figure 4. In this study, gene transfer
treatments were started twelve weeks after the injection of the cell lines, when tumors reached an
approximate volume of 200-250 mm3. Mice were irradiated with 8Gy of x-ray irradiation from a
clinical linear particle accelerator (LINAC) on week 12. Three days after radiation therapy, mice
were injected once a week for four weeks (wks 13-16) and were again irradiated at week 16 (Fig.
35). Mice were then injected once a week for three additional weeks (wks 17-19) and were
sacrificed one week after the end of the treatments because the control tumors reached an
approximate volume of 1,000 mm3 (Fig. 35). Compared to untreated or to irradiated control,
tumors transduced with MB-assisted gene transfer using adenoviruses overexpressing p53, pRb,
and p130 in combination with radiation treatments showed marked reduction of tumor size
which was statistically significant (p<0.05) (Fig. 36). Tumors treated with ultrasound MB-
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assisted gene transfer of p53, RB, and p130 were smaller in size (Fig. 36) with an inhibition rate
of 91.24%, 92.27%, and 48.31% respectively, when compared to the final tumor volume of
control tumors (Table 6). Irradiated tumors were smaller in size than control tumors (Fig. 36)
with an inhibition rate of 21.98% (Table 6). B-mode US scanned images showed in figure 38
demonstrate tumor reduction in real time (Fig. 38) as the US images were recorded during the
course of the treatment. US scanned images for groups that were transduced with p53 or RB
showed a marked reduction in tumor growth, whereas tumors transduced with p130 exhibited a
plateaued growth (Fig. 38).
Compared to untreated or to irradiated control, intratumoral injections (IT) of Ad.p53 or
Ad.RB significantly reduced tumor size (p<0.05) with an inhibition rate of 81.29% and 85.99%,
respectively (Fig. 36 and Tables 6 and 7). Compared to radiation only groups, tumor treatment
with Ad.p53 (p=0.015) and Ad.pRB (p=0.014) significantly decreased tumor growth (Table 7).
The effect was further significantly enhanced (p<0.05) when gene transfer with Ad.p53 or Ad.RB
was combined with radiation showing a growth inhibition rate of 88.04% and 87.82% compared
to radiation control, respectively (Table 6 and 7). We also observed that when IT treatment of
Ad.p53 or Ad.RB was combined with radiation there was reduction in tumor growth (Fig. 36)
compared to gene transfer groups alone, although the difference was not statistically significant
(Table 7). Interestingly, the IT injection with Ad.p130 slowed the growth of the tumors with an
inhibition rate of 52.70%. However, IT injection of Ad.p130 combined with x-ray irradiation
improved its efficacy by only about 4% (Table 6).
The intravenous injection (IV) of MB complexed with Ad.p53 or Ad.RB did not result in
inhibition of tumor growth when no ultrasound was applied (Fig. 37). Only tumors on the flank
that received ultrasound (right flank) exhibited tumor growth reduction (Fig. 36 and 37). Tumors
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on the sonoporated flank (right side) that were transduced with Ad.p53 or Ad.RB (but not
irradiated) showed a growth inhibition rate of 91.24% and 92.27%, respectively. Tumors treated
with ultrasound MB-assisted gene transfer of Ad.p53 showed better (but not significant) growth
inhibition than IT Ad.p53 (p=0.363) or combined x-ray irradiation with IT Ad.p53 (p=0.65).
This trend was also observed in tumors treated with ultrasound MB-assisted gene transfer of
Ad.RB versus IT injections of Ad.RB (p=0.630) or combined x-ray irradiation with IT Ad.RB
(p=0.283) (Table 7). Tumors treated with x-ray irradiation combined with microbubble assisted
gene transfer of Ad.p130 resulted in 66.0% tumor reduction respect to the radiation control.
Notably, the greatest tumor reduction was observed in tumors that were treated with x-ray
irradiation combined with microbubble assisted gene transfer of Ad.p53 or Ad.RB with an
inhibition rate of 94.44% and 95.95%, respectively (Table 6) (p<0.05).

Table 6. Mean percentage inhibition rate and standard deviation of final tumor volume at week
19 compared against the control non-treated group.
Groups
Inhibition Rate (%)
Radiation (Control)
21.98
IT Ad.p53
81.29
IT Ad. p53 + Rad
88.05
IT Ad.pRB
85.99
IT Ad.pRB + Rad
87.82
IT Ad.p130
52.70
IT Ad.p130 + Rad
56.12
IV MB Ad.p53 US
91.24
IV MB Ad.p53 US + Rad
94.44
IV MB Ad.pRB US
92.27
IV MB Ad.pRB US + Rad
95.95
IV MB Ad.p130 US
48.31
IV MB Ad.p130 US + Rad
66.02
*SD-standard deviation *Rad-Radiation *% -Percentage
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SD
2.92
5.71
2.76
3.13
0.79
4.86
10.19
0.22
1.26
2.39
1.18
2.47
7.27

Figure 35. In vivo study timeline. Treatments are marked on the line from week 12 to week 19
(end of the study). Radiation followed by four gene transfer treatments is considered as a cycle.
In the in vivo study there were two treatment cycles.

Figure 36. Bar graph of DU145 tumor xenografts volumes (± SD) at week 19 after direct
intratumoral injection (IT) of Ad-GFP, Ad.p53,Ad.pRB, or Ad.p130 with and without radiation.
Mean tumor volume for intravenous (IV) injections of MBs complexed with Ad.p53, Ad.RB or
134

Ad.p130 of sonoporated tumors (right flank) with or without external beam x-ray radiation was
also plotted. The mean tumor volumes are indicated on the ordinate. The group is indicated on
the abscissa. The IT and IV treatments were compared against the non-treated control and
radiation control to determine the most effective treatment. * indicates statistical significance
between control and treated cells.

Figure 37. Bar graph representation of mean tumor volume for all groups (left and right flank
mean tumor volume) with standard deviation error bars. The tumor on the left flanks served as
internal controls to monitor any additional effect by the adenoviruses or MBs complexed with
viruses on distant untreated tumors. Only tumors on the right flanks were treated with adenoviral
vectors or UTMD of Ads/MBs regarding the sonoporated groups. On the ordinate the mean
tumor volumes are indicated. On the abscissa are indicated the different treatment groups.
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Table 7. Multiple comparisons ANOVA (Analysis of Variance) significance table with a post
hoc Dunnett’s T3 test for the in vivo experiment following radiation and adenoviral gene transfer
on the treated right tumors at week 19. The statistical analysis was run using IBM SPSS
software. Mean and standard deviation of final tumor volume obtained at week 19.
(I) Group

(J) Group

Control

Rad Control
IT Ad.p53
IT Ad.p53 + Rad
IT Ad.pRB
IT Ad.pRB + Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 +Rad
IV MB US Ad.pRB
IV MB US Ad.pRB +Rad
IV MB US Ad.p130
IV MB US Ad.p130 +Rad
IT Ad.p53
IT Ad.p53 + Rad
IT Ad.pRB
IT Ad.pRB + Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
IT Ad.p53 + Rad
IT Ad.pRB
IT Ad.pRB + Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53

Rad Control

IT Ad.p53
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Mean
Std. Error
Difference
(I-J)
242.11
70.51
*
894.55
64.95
*
966.22
60.59
941.38*
64.50
*
962.28
60.03
*
578.16
70.36
621.91*
70.97
*
999.64
59.77
*
1035.58
59.64
1012.58*
60.33
*
1052.10
59.72
530.80
62.32
*
727.83
65.38
652.44*
46.05
*
724.11
39.66
*
699.28
45.41
720.18*
38.80
336.05
53.40
*
379.80
54.20
757.53*
38.40
*
793.47
38.18
*
770.48
39.27
*
809.99
38.32
288.70
42.26

Sig.

.38
.02
.02
.01
.03
.04
.03
.03
.02
.02
.02
.07
.03
.01
.01
.00
.02
.06
.04
.02
.02
.01
.01
.08

485.73*

46.65

.01

71.67
46.84
67.74
-316.39
-272.64
105.09

28.63
36.18
27.43
45.81
46.74
26.85

.67
.99
.69
.06
.1
.36

IT Ad.p53 + Rad

IT Ad.pRB

IT Ad.pRB + Rad

IT Ad.p130

IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
IT Ad.pRB
IT Ad.pRB + Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
IT Ad.pRB + Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
IT Ad.p130
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
IT Ad.p130 + Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
IV MB US Ad.p130
IV MB US Ad.p130 +
Rad
137

141.03
118.04
157.55
-363.75*

26.55
28.08
26.74
32.13

.22
.29
.18
.01

-166.71

37.72

.18

-24.83
-3.93
-388.06
-344.31
33.42
69.36
46.37
85.88
-435.41*

27.59
14.30
39.37
40.46
13.16
12.52
15.52
12.93
22.01

1.0
1.0
.05
.07
.66
.16
.49
.09
.00

-238.38

29.58

.06

20.90
-363.22*
-319.48
58.26
94.20
71.20
110.72
-410.58*

26.34
45.16
46.11
25.74
25.42
27.02
25.63
31.21

1.0
.04
.06
.75
.40
.63
.31
.01

-213.55

36.94

.08

-384.13
-340.38
37.36
73.30
50.30
89.82*
-431.48*

38.51
39.62
10.30
9.47
13.18
10.01
20.43

.06
.08
.33
.05
.28
.02
.01

-234.45

28.42

.08

43.75
421.48
457.42*
434.42*
473.94*
-47.36

54.0
38.10
37.89
38.98
38.03
41.99

1.0
.05
.05
.04
.04
1.0

149.68

46.41

.43

IT Ad.p130 + Rad

IV MB US Ad.p53
377.73
39.22
.07
IV MB US Ad.p53 + Rad
413.67
39.01
.06
IV MB US Ad.pRB
390.68
40.07
.06
IV MB US Ad.pRB + Rad
430.19
39.15
.06
IV MB US Ad.p130
-91.11
43.01
.80
IV MB US Ad.p130 +
105.93
47.33
.76
Rad
IV MB US Ad.p53
IV MB US Ad.p53 + Rad
35.94
7.64
.17
IV MB US Ad.pRB
12.94
11.93
1.0
IV MB US Ad.pRB + Rad
52.46
8.29
.06
IV MB US Ad.p130
-468.84*
19.65
.01
IV MB US Ad.p130 +
-271.81
27.86
.06
Rad
IV MB US Ad.p53 +
IV MB US Ad.pRB
-23.0
11.22
.82
Rad
IV MB US Ad.pRB + Rad
16.52
7.24
.75
IV MB US Ad.p130
-504.78*
19.23
.01
IV MB US Ad.p130 +
-307.75
27.57
.05
Rad
IV MB US Ad.pRB
IV MB US Ad.pRB + Rad
39.52
11.68
.41
*
IV MB US Ad.p130
-481.78
21.30
.00
*
IV MB US Ad.p130 +
-284.75
29.05
.04
Rad
IV MB US Ad.pRB + IV MB US Ad.p130
-521.30*
19.50
.01
Rad
IV MB US Ad.p130 +
-324.27*
27.76
.04
Rad
IV MB US p130
IV MB US Ad.p130 +
197.03
32.98
.09
Rad
*IT – Intratumoral, *IV-Intravenous, *MB-Microbubble, *US-Ultrasound, *Ad-Adenovirus,
*Rad-Radiation.
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radiation at different times during treatment schedule.

MBs/US-guided Ad.p53, Ad.RB or Ad.p130 gene delivery and combination with

Figure 38. B-mode ultrasound (US) images of DU145 tumor xenografts treated with

Microbubble-Assisted p53, pRB, and p130 Gene Transfer Results in Enhanced Protein
Expression of Targeted Genes.
Protein expression of p53-, RB-, and p130-transduced genes in tumors that received US
and x-ray irradiation was analyzed by western blots (Fig. 39). There was no change in expression
of mutated p53 and pRb in all control tumors with either radiation or ultrasound (Fig. 39a). Only
endogenous expression of p130 was increased when the tumors were irradiated (Fig. 39 a, d).
Tumors that received direct intratumoral injection with Ad.p53, Ad.RB, or Ad.p130 showed
increased expression of the targeted tumor suppressor genes (Fig. 39a-d). Intravenous injection
of complexed MBs showed high expression of transduced p53, RB and p130 in tumors that were
sonoporated (Fig. 39a-d).

Figure 39. Western Blot analysis of the tumors collected at week 19 from in vivo study. L and R
indicate tumors implanted in the left and right flank, respectively. (Panel a) Control (not treated)
DU145 tumors and treated DU145 tumors, as labeled. PBS+MB = empty MBs; Rad = 8Gy
radiation; US = Ultrasound. (Panel b) Tumors untreated and treated with Ad.p53
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(Ad.p53+MBs), radiation and ultrasound, as labeled. (Panel c) Tumors untreated and treated
with Ad.pRB (Ad.pRB+MBs), radiation and ultrasound, as labeled (Panel d). Tumors untreated
and treated with Ad.p130 (Ad.p130+MBs), radiation and ultrasound, as labeled. Anti-beta-actin
was used as a loading control. 50μg of total cell lysates were run on SDS polyacrylamide gels.
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DISCUSSION
Primary prostate cancer (PC) can be tackled successfully in many cases with standard
treatments, such as radical prostatectomy, radiation therapy, and hormone therapy, offering longterm cancer-specific survival for most patients. While surgery and radiation therapy may have
similar outcomes for early-stage prostate cancer, radiation therapy is the primary option for
locally advanced prostate cancer. However, over one third of patients who are treated with
conventional curative therapy will progress to an androgen-independent (castration-resistant)
prostate cancer. Development of androgen-independent, radio-resistant prostate cancer and
metastatic progression are key concerns in the management of this disease [268, 269]. The
strategies used to tackle these issues are the accurate stratification of patients whose early
prostate cancer is likely to progress to hormone-refractory and metastatic disease, and of course
improvement and broadening of the available therapeutic choices. Prostate cancer is regarded as
relatively resistant to radiation [257]. Consistent with this notion, androgen-independent DU145
human prostate cancer cells manifest resistance to radiation-induced apoptotic death [254, 255].
Previous studies using UV- [254] and γ-radiation [270] have been shown to cause a
G2/M cell cycle-phase block in DU145 cells at 24hrs. In our study, ionizing radiation of 10Gy
and 20Gy also resulted in G2/M cell cycle-phase block with an increasing number of DU145
cells accumulated in the G2-phase of the cell cycle when assayed from 24 to 96hrs.
Interestingly, we observed little apoptotic cell death in the DU145 cells at 24hrs for both 10Gy
and 20Gy external beam radiation which could be explained by the fact that DU145 cells
undergo DNA fragmentation as early as 4hrs after irradiation while end-stage DNA
fragmentation does not peak until 24-36hrs [249]. Additionally, Bromfield et al. demonstrated
with flow cytometry assays that greater than 70% of DU145 cells were non-proliferating
following irradiation [251], which provided us with a rationale for investigating modalities to
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increase the sensitivity of prostate cancer to radiation-induced DNA damage using gene transfer
of key cell-cycle regulators.
The p53, RB and p130 gene products are key factors that participate in cell-cycle arrest,
apoptosis and cellular senescence. PCs manifest frequent mutations in tumor suppressor genes
such as p53 and RB [271], and we have demonstrated in the past an inverse association between
histological grading in aggressive tumor types of prostate cancer [272] and p130 expression.
Additionally, p130 has been mapped to the human chromosome 16q12.2, an area in which
deletions have been found in several human neoplasias including breast, ovarian, hepatic, and
prostatic cancers [273].
Our model system, DU145 cells, a human prostate cancer cell line, has a mutant
nonfunctional temperature sensitive p53, and expresses a truncated pRb protein [254]; however
the functional status of p130 is undetermined in DU145 prostate cancer cells. P53 and pRb
overexpression have been shown to play a central role following radiation in PC cell lines [274]
[256] while RB loss has been linked to radiation resistance in DU145 cells [256].
We decided to compare and contrast the ability of p53, RB and p130 to radio-sensitize
prostate cancer cells in vitro and to investigate their efficacy in reducing tumor size following
targeted gene transfer using a microbubble-assisted gene transfer method that we have perfected
in our laboratory [53, 214, 218]. This strategy allows for systemic targeted delivery to prostate
cancer xenografts of therapeutic adenovirus carrying therapeutic genes.
As expected, DU145 cells transduced with adenovirus carrying wt-p53 showed a shift
from the G2/M to the G1-phase of the cell cycle regardless of the radiation dose, as previously
demonstrated [255]. Apoptosis was observed for p53 groups treated with or without radiation.
Overexpression of p53 in DU145 cells restored irradiation-induced senescence by forming the
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characteristic heterochromatin structure called senescence-associated heterochromatic foci
(SAHFs) [275]. SAHFs could account for the relatively low amount of apoptosis at 24 hrs. The
downstream effectors such as Bax [251] or p21Waf1 that are attenuated/absent in DU145 [276]
would hamper the cells from undergoing apoptosis. Additionally, the mutant p53 described in the
DU145 cells has been shown to suppress the ability of wt-p53 to induce cell cycle arrest by
exerting a dominant negative effect on the DNA binding activity of wt-53 and to reduce the
trans-activation of target genes [277]. Even by lowering the temperature to 32ᴼC from 37ᴼC and
activating the temperature sensitive nonfunctional p53 in DU145 cells, Bajgelman and Stauss
were unable to trans-activate p21Waf1 [252]. However, we observed that adenoviral
overexpression of wt-p53 restored the sensitivity of the DU145 cells to ionizing radiation
indicating that gene transfer of wild-type copies of the p53 gene and its overexpression in the
targeted cells could be a viable therapeutic option for radio-resistant PCs.
Proteins of the retinoblastoma family (pRb, p107 and p130) are known to exert control
over the entry into S-phase of the cell cycle [278]. Gamma (γ) and ultraviolet (UV) radiation are
known to be ineffective on pRb deficient cells. After DNA damage by γ-radiation, pRb is
hypophosphorylated and induces growth arrest by blocking cell-cycle progression at the G1/S
phase [279]. G1-phase blockage has been previously observed when cells were transduced with
pRb in the presence or absence of radiation [254]. Some reports indicate that apoptosis of cells
which are deficient in pRb protein is inhibited after restoring wt-pRb [280]. In our study, we
observed that by restoring a wild-type RB in DU145 cells, which have a truncated pRb, we were
able to facilitate apoptosis similarly to when we restored wt-p53. The highest apoptotic response
was observed in pRb transduced DU145 cells which received 20Gy irradiation. Interestingly, our
study showed increased expression of pRb protein when Adenoviral gene transfer treatment was
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combined with radiation therapy. Similar results have been shown for pRb negative and positive
esophageal squamous cell carcinoma (ESCC) treated with a combination of adenoviral gene
delivery of RB94, a truncated more active RB gene product, and radiation therapy [267].
Hypophosporylated p130 complexes with E2F transcription factors and has been
associated with control over the G0/G1 phase of the cell cycle [278]. In our study we observed
that overexpressed p130 in prostatic DU145 cells led to DNA accumulation at G0/G1 of the cell
cycle. Interestingly, irradiated or combined irradiated and Ad.p130 gene transfer groups showed
accumulation of cells in the G2 cell cycle phase suggesting a block at the G2/M transition. In
several cell lines, the overexpression of p130 has been shown to result in binding to cyclins A
and B promoter regions, regulating the expression of S- and G2-phase transitions, and
dominating the p53-p21 DNA damage response pathway leading to senescence [281].
Our in vitro study confirmed an increase in expression of endogenous or transduced p130
after exposure to genotoxic stress such as radiation, as previously observed [275, 282].
Adenoviral overexpression of p130 increased the percentage of apoptotic cells after ionizing
radiation, but to a lower extent than in groups transduced with p53 or RB.
It has been shown in the prostatic cancer cell lines C4-2 and LNCap, that ionizing
radiation exposure results in up-regulation of the transcription factor E2F4 which has been
shown to complex with p130 and to co-localize in the nucleus regardless of androgen sensitivity,
resulting in tumor growth suppression and G2 arrest [282]. The authors demonstrated that the
formation of the E2F4/p130 complex is specifically regulated by IR in prostate cancer cells and
suggested that the interaction between p130 and its natural partner CDK2 is also affected by IR,
which may be a result of the increased levels of E2F4 associated with p130, leading to a decrease
in p130 phosphorylation and decreased cell viability. The inhibition of E2F4 by siRNA in
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prostate C4-2 cells results in apoptosis and increased sensitivity to radiation [282], thus
suggesting a partial explanation of the lack of apoptosis and radiation resistance of the DU145
cells following overexpression of p130. Additionally, p130 induces accumulation of proapoptotic p73, a p53-related gene that alternatively splices and mediates radiation-induced
apoptosis independent of p53 by interacting with c-Abl tyrosine kinase in glioblastoma cells
indicating that p130 radiosensitization could be cell type specific [258].
Adenoviral gene transfer is limited by the ability of Adenovirus serotype 5 (Ad5) to
transduce target cells and the inability to deliver it intravenously without causing liver
inflammatory damage or elimination by the immune system [202]. Patients exposed to
adenoviruses tend to develop neutralizing and anti-adenovirus antibodies [283, 284]. Another
limitation of using Adenoviruses for gene transfer techniques in cancer is that the efficiency of
these viruses to transfer genetic materials to cancer cells is dependent upon the availability of
Coxsackie adenovirus receptor (CAR) on the surface of the targeted cells, which facilitates
adenoviral entry. These difficulties in the use of Adenoviruses for cancer gene therapy have
limited their use to direct injections to the tumoral mass, which resulted in partially transduced
tumors [218, 285].
To circumvent the difficulties caused by the use of adenoviruses as vectors for gene
transfer we used ultrasound contrast agents (microbubbles) to provide protection to the virus
from the immune system as well as to increase target organ specificity, allowing intravenous
injection and less aggressive viral administration [214]. Microbubbles (MBs) can be injected into
peripheral veins, as these robust bubbles can re-circulate through the systemic circulation
numerous times within the bloodstream [219]. Cavitation also improves the efficiency of viral
infection by creating small shockwaves that increase cellular permeability [220]. Phase I to III
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clinical trials have demonstrated that MBs are safe and well tolerated even at higher doses [286].
Previous studies of our lab demonstrated that MB complexes with Ad.GFP (Green
Fluorescent Protein) were able to express GFP specifically localized to sonoporated tumors [53].
Our western blot studies on harvested tumors showed high levels of transgene expression at the
tumor site by more efficient GFP gene transfer into the target cells [53].
In earlier studies, therapy resistant prostate cancer cell lines containing wt-p53, mutated
p53 or p53 null were radio-sensitized by adenoviral mediated p53 gene transfer [274, 287]. As
expected, in our in vitro study the DU145 cells transduced with p53 were radio-sensitized to
ionizing radiation resulting in higher apoptotic rates than either irradiation group or adenoviralp53 transduced groups. Additionally, reduction of tumor volumes by ultrasound mediated
microbubble destruction of wt-p53 or wt-pRb resulted in increased ablation of the tumors when
compared to intra-tumoral injections. Ad.p130 intra-tumoral injection in mice showed slower
growth rate than the untreated control or irradiated groups. Interestingly, Ultrasound targeted
microbubble destruction (UTMD) of Ad.p130 MB complexes resulted in slower tumor growth,
but no tumor reduction was observed (Fig. 36).
Clinical studies for combinational therapy of p53 and RB gene transfer and ionizing
radiation in lung [266], hepatocellular [288], and esophageal carcinomas [267] have been
successful in eliciting partial and complete remission of tumors. Our study demonstrated that
combination therapy of radiation and intratumoral injections of Ad.p53, Ad.RB or Ad.p130
caused an enhanced effect in comparison to adenoviral intratumoral injections (IT) or radiation
treatment alone. Currently, phase-I clinical studies of combination therapy with IT adenoviral
p53 gene delivery for prostate cancer are underway at M.D. Anderson Cancer Center, Texas and
UCLA School of Medicine, California to test its efficacy [289]. Interestingly, we observed more
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profound response in reducing tumor growth of treated tumors by combining the ultrasoundtargeted destruction of Ad.p53 or Ad.RB MB/complexes with ionizing radiation. As
demonstrated by western blot analysis, tumor volume reduction in these samples was associated
with overexpression of the p53 or RB genes (Fig. 39). UTMD of Ad.p130 combined with
radiation resulted instead in a relatively plateaued tumor growth curve, which was comparable to
the initial volume of tumors at the beginning of the treatment schedule. Thus p130, in a
comparative gene transfer study with other known cell cycle regulating proteins such as pRb and
p53, caused a “tumorstatic” effect that was not significantly enhanced by radiation therapy. On
the other hand, we showed that the highest decrease in tumor growth was observed when p53
and RB genes were transferred by ultrasound-targeted destruction of Adenoviral-MB/complexes
in combination with ionizing radiation.
An open question is: What effect would the pooled transfer of the cell cycle regulating
genes p53, pRb and p130 with or without ionizing radiation have on tumor growth? It is possible
that combined gene transfer of multiple cell cycle regulatory proteins could result in further
tumor growth suppression. In fact, tumors are made of a heterogeneous population of cells that
may contain a variety of genetic dysfunctions and/or changes. Thus exploring the effects of
pooled transfer of therapeutic genes is needed in order to increase their antitumoral activity while
possibly decreasing the number of injections needed to realize their radiosensitizing ability.
Altogether, these findings highlight the translational therapeutic potential of this novel imageguided gene transfer technology in combination with external beam radiation for prostate cancer
patients with therapy resistant disease.
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CHAPTER VI : CONCLUSION AND FUTURE DIRECTIONS
In Chapter 1, we reviewed current literature on prostate cancer (PC) and highlighted
some of the therapeutic options in treating PC. We also reviewed some of the potentials and
barriers to gene therapy with viral vectors. We chose to study metastatic PC because there are no
successful treatment modalities available for the disease while treatment options for stage T1/T2
have decent 5 year survival rates.
In Chapter 2 we described the ultrasound targeted destruction of microbubbles as a gene
delivery system. We reviewed current literature on the different types of available MBs that are
currently used. We also described the behavior of the MBs when exposed to US and the
biological changes that are associated with their interactions. Chapter 2 clearly shows that
together MB and US become a reliable systemic drug delivery system.
In Chapter 3, we explored human DU145 and murine TRAMP-C2 PC cells as potential
animal models for testing the UTMD drug delivery system. Infection studies were carried out to
establish whether human non-replicative viruses (Ad.GFP and Ad.mda-7/IL-24) and replicativecompetent virus (CTV.mda-7) could be used to determine a therapeutic response in cancer cells.
We clearly observed that Ad.GFP and Ad.mda-7/IL-24 could infect and transfer their transgene
in both PC cells, although only CTV.mda-7 could be replicated in DU145 cells. UTMD gene
delivery system was also tested in an in vitro setting showing an increased enhancement of
Ad.GFP transgene expression. This clearly showed that US with MBs caused pore formation on
the plasma membrane thereby increasing the permeability of the membrane to allow increased
Ad uptake. Thus, animal studies on xenografted DU145 PC studies in immune-compromised
nude mice and syngeneic model of TRAMP-C2 PC injected in immune-competent mice become
attractive to test the UTMD gene delivery system.
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In Chapter 4, we described our studies of the UTMD gene delivery system for Ad.GFP,
Ad.mda-7 and CTV.mda-7 in a xenograted DU145 PC model with tumors on both flanks of nude
mice. Targeson MBs/Ads complexes were injected into the tail vein while only the tumor on the
right flank was sonoporated. The study was designed to define an improved therapeutic approach
for delivering Ad.mda-7, which will permit systemic delivery and targeted tumor release by US
specifically and effectively in the primary tumor. This treatment resulted in a dramatic reduction
in the size of not only the treated tumor on the right flank, but also of the non-treated tumor on
the left flank due to mda-7 bystander effect [53]. US-guided focused release of entrapped
materials from the MBs will increase the delivery specificity and therapeutic efficiency of
Ad.mda-7 towards PC xenografts. Our findings in combination with the positive results of
Phase-I Clinical trial with Ad.mda-7 [211] suggest that this cytokine has considerable potential
as a gene therapy for cancer.
In Chapter 5, we described the combined therapy approach of using radiation and UTMD
for the delivery of Ad.p53, Ad.RB and Ad.p130 in a xenografted DU145 PC model with tumors
on both flanks of nude mice. Similar to the previous animal study, Targeson MBs/Ads
complexes were injected into the tail vein while only the tumor on the right flank was
sonoporated. We demonstrated that combined radiation and UTMD gene therapy enhanced the
therapeutic benefit of tumor suppressor genes in radiation resistant PC. There was no bystander
activity that was observed in this study as tumor suppressor genes such as p53, pRb and p130 are
not secreted proteins. The increased expression of p53, Rb and p130 further proved that UTMD
targets only the tumor that is sonoporated making it a specific gene delivery therapy system.
In addition to the experiments that were performed, we propose to further develop the
UTMD system using immune-competent animals to facilitate its translation into a clinically
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feasible technology for the effective delivery of therapeutic genes to treat human PC. Our data
shows that murine TRAMP-C2 PC cells are efficiently infected by non-replicative Ad.GFP and
Ad.mda-7/IL-24 using the MB/Adenoviral system cavitated by US, which results in the
expression of the transduced genes. Additionally, mda-7/IL-24 acts as a pro-apoptotic gene
resulting in the increased cell death of PC cells. Thus we believe that MBs will effectively shield
the Ads from immune surveillance in immune-competent mice, and target the delivery of
Ad.GFP & Ad.mda-7 specifically to PCs. These studies would further establish the efficiency
and specificity of gene delivery in primary advanced prostate cancer by using an innovative
system consisting of ultrasound contrast agents, viral vectors and ultrasound waves.
In conclusion, our present body of work supports the hypothesis that the UTMD systemic
gene delivery system we have developed is a promising therapeutic approach for PC that
deserves further investigation in immune competent organisms to warrant its future translation
from bench to bedside.
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